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SUMMARY
The studies presented in this thesis were designed to evalulate the 
mechanism of action of the lipolytic effects of growth hormone in both sheep and 
rats. The initial study was carried out with virgin rats and involved manipulating 
levels of endogenous growth hormone using a specific antiserum to growth 
hormone (anti-rGH). The results showed that lowering levels of endogenous 
growth hormone resulted in an increase in the inhibition of isoprenaline-stimulated 
lipolysis, of isolated adipocytes, by submaximal concentrations of both PIA and 
PGE|. There was also an increase in the amount of the inhibitory G-protein Gj2 
and these effects were reversed upon replacement of growth hormone. Therefore 
growth hormone in vivo, specifically suppresses the expression of ot-Gj2, in rat 
adipocytes leading to decreased sensitivity to anti-lipolytic agonists.
Further studies carried out with lactating and litter removed rats, again 
involving manipulation of endogenous growth hormone. Chronic treatment of 
lactating rats with growth hormone had no effect on maximum response or 
sensitivity to PIA, however, a diminished ability of antilipolytic agents after growth 
hormone treatment was seen in rats in which lactation was prematurely terminated 
but did not appear to involve a change in either adenosine receptor number or the 
amount of G-l plus Gj2. Therefore, it would appear that Gj in lactating rats in 
response to growth hormone is subject to covalent modification.
That the Gj-mediated antilipolytic system is a major target of growth 
hormone action was investigated further by treating sheep with recombinant bovine 
growth hormone (Monsanto) at 10 mg per day for 7 days in vivo. Treatment of 
sheep with the hormone decreased the maximum inhibition of isoprenaline- 
stimulated lipolysis. This effect of growth hormone was not accompanied by any 
discernable change in the number of adenosine receptors or amounts of the various 
isoforms of Gj. Therefore these studies also suggested that a decrease in Gj activity 
was occuring.
Further investigations were carried out using sheep adipose tissue in vitro. 
Sheep adipose tissue explants were preincubated in culture for 24 hours with no 
hormones and then growth hormone was added for the next 24 hours. As for the 
in vivo experiments, growth hormone treatment resulted in a decreased maximum 
response to PIA. Again there was no change in either adenosine receptor number 
or amounts of Gj. Further experiments were carried using this tissue culture system 
using a range of inhibitors to elucidate the mechanism of growth hormone action. 
As aGj2 can be phosphorylated by at least two kinases the effect of protein kinase 
and phosphatase inhibitors were tested in the tissue culture system. Addition of 
H7, a protein serine kinase inhibitor, diminished the effects of growth hormone 
while the protein-serine phosphatase inhibitor, okadaic acid mimicked the effect of 
growth hormone, and therefore suggested that the effect of growth hormone 
involves protein serine phosphorylation. Further experiments with the phorbol 
ester PMA suggested involvement of protein kinase C isoforms that can be down- 
regulated by PMA in growth hormone actions, but use of D609, a 
phosphatidylcholine phospholipase C inhibitor suggested that diacylglycerol 
production via this pathway is not involved.
In time course experiments the maximum effect of growth hormone was 
reached after 24 hours demonstating that growth hormone is not simply activating a 
phosphorylation cascade. These results were supported by data from experiments 
with actinomycin D, an inhibitor of gene transcription, which was shown to knock 
out the effects of growth hormone.
More detailed studies were carried out to elucidate the nature of the altered 
activity of Gj. To do this ADP-ribosylation experiments were carried out with 
adipocyte membranes using Pertussis toxin and PIA to determine if growth 
hormone altered the ability of the adenosine receptor to cause dissociation of Gj. 
The results obtained show that growth hormone treatment does not affect receptor 
coupling to Gj. Gj activity was further assessed in adipocyte membranes using the 
diterpene forskolin or isoprenaline to activate adenylate cyclase, and p[NH]ppG or
PIA to inhibit this activation through a Gj-mediated response. The results from 
these experiments indicated that functional Gj was detected in membranes from 
control sheep adipose tissue but not in growth hormone treated tissue, indicating 
that the attenuation of the antilipolytic effect of adenosine may thus be due to 
changes in the interaction of Gj with adenylate cyclase.
Thus growth hormone decreases signalling through Gj by at least two 
mechanisms, altering both the amount of one isoform of this key protein and also 
the activity of the protein. Effects of growth hormone on the system vary with 
physiological state and are species specific.
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CHAPTER ONE 
INTRODUCTION
1.1 General Introduction
In recent years considerable interest has been expressed in reducing adiposity 
in domestic animals by the use of recombinant growth hormone (Boyd and 
Bauman, 1989; Bauman, 1992; Steele and Evock-Clover, 1993), and it has been 
shown that chronic administration of growth hormone decreases adiposity in farm 
animals (Boyd and Bauman, 1989; Hart and Johnsson, 1986). Other studies using 
transgenic animals expressing alien growth hormone genes have shown that pigs 
with rat growth hormone (Ebert et al, 1988) or bovine growth hormone (Wieghart 
etal, 1988), exhibited reduced adiposity.
Research into the control of milk production during recent times has focused 
principally upon the nutritional requirements and the central role that the endocrine 
system plays in stimulating milk yield. In the course of these studies it became 
apparent that, at least in rumimants, growth hormone is capable of inducing 
increases in milk yield of up to 50% (see Bauman and Vernon, 1993). Bovine 
growth hormone significantly enhances milk production of lactating cows at least in 
part by coordinating tissue nutrient utilisation to preferentially divert nutrients away 
from tissues such as adipose tissue to the mammary glands (Bauman and Vernon, 
1993). Such chronic regulation of metabolism is known as homeorhesis, and 
homeorhetic controls shift nutrient partitioning by altering tissue response to acute, 
homeostatic signals such as insulin and the catecholamines epinephrine and 
norepinephrine and through tissue specific changes in gene expression (Bauman and 
Currie, 1980).
Resolution of the control processes of the signal transduction in adipocytes 
may provide novel means for manipulating both milk production and the degree of 
adiposity in animals and may also provide means for selective manipulation of the 
amounts of fat in different parts of the body.
Although adipose tissue is a major target of growth hormone, the 
mechanisms by which this hormone achieves its effects in adipose tissue are still not
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fully understood. However, there is a growing body of evidence to suggest that the 
hormone acts both directly to alter the amount of key metabolic enzymes and in 
addition alters the ability of the adipocyte to respond to acutely acting metabolic 
hormones. These aspects, in particular effect on the lipolytic system, are 
considered in more detail below.
1.2 Adipose tissue
The major form of adipose tissue in adult animals is white adipose tissue. 
White adipose tissue is located at various sites throughout the body, for example: 
within the abdomen, omental, perirenal, under the skin (subcutaneous), within the 
musculature. In some animals adipose tissue can constitute as much as 50% of the 
body weight and in some grotesquely obese humans can be even higher (Flint and 
Vernon, 1993). In all mammals including marsupials the distribution of fat depots 
is essentially the same, and the average cell size, which varies from depot to depot, 
shows the same pattern of variation amongst different species (Pond and 
Mattacks,1985).
Adipose tissue comprises of adipocytes and a number of other cells. The 
adipocytes constitute approximately 25% of the cell population, but due to the 
enormous size of the adipocytes when bloated with fat actually contributes about 
90% of the mass of adipose tissue in adult animals. The other cells are usually 
referred to as the stromovascular fraction and consist of adipocyte precursor cells 
at different stages of development, endothelial cells, mast cells and blood cells (Flint 
and Vernon, 1993).
While the major role of white adipose tissue is an energy store, the individual 
depots develop at different rates and different times (Flint and Vernon, 1993). This 
has led to numerous hypotheses as to its possible functions other than that of an 
enery store. The role of insulation has been considered as an important role,
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especially for subcutaneous fat. While it is plausible that the function of 
subcutaneous adipose tissue is for insulation this is not always the case as in most 
land animals and ducks this fat is the first to be utilised in conditions of poor 
nutirition (see Vernon and Flint, 1993). Therefore the accumulation of large 
amounts of subcutaneous adipose tissue seen in artic animals may be for the 
physical reasons that really large amounts of fat can only be stored in the adominal 
cavity and under the skin. It has also been considered that the presence of adipose 
tissue around vital organs serves as protection. However, it has been suggested 
that cardiac and some intermuscular adipose tissue depots may play a critical, 
localized role in providing fatty acids as a fuel source for adjacent muscle fibres 
(Marchington et al, 1989). A role for adipose tissue for buoyancy in fish has been 
demonstrated in many species and studies described by Howell (1930) revealed a 
'lipid circulation system' with ducts and vessels that may allow rapid movement of 
lipids to aid in buoyancy.
Distinct adipose tissue depots play an important role in secondary sexual 
characteristics in some species. The mammary gland develops in a bed of adipose 
tissue (Sheffield, 1988) and produces such paracrine factors as prostaglandins and 
insulin-like growth factor that promote mammary growth (Levine and Stockdale, 
1984). Adipose tissue is also required for the normal function of menstrual/estrous 
cycles and makes a major contribution to oestrogen production in postmenopausal 
women (Cleland et al, 1983).
Adipose tissue may also be important for the immune system as it has been 
shown to secrete adipsin, a serine protease (Cook et al., 1987), which is a member 
of the alternative complement pathway, (Rosen etal., 1989).
The second form of adipose tissue is brown adipose tissue; it is more 
prevalent in young animals and has an important role in heat production by 
nonshivering thermogenesis. It is typically found in a small number of defined 
depots (Himms-Hagen et al, 1972), has dense blood and nerve supplies (Fawcett,
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1952; Ballard, 1974) and large numbers of mitochondria and the protein thermogin 
(Cannon et al, 1982). These and other differences found between white and brown 
adipose tissue indicate the major functional distinction between these tissues. 
However, all following information will focus on white adipose tissue.
1.2.1 Adipose tissue development
The growth of tissues involves an increase in cell number and cell size. In 
adipose tissue increased cell size is primarily due to lipid accumulation. Studies 
using 3T3-Llcells have led to a model of adipocyte development (Green, 1978; 
Green et al, 1985), which propose, the existence of pluripotent mesenchymal cells, 
which can differentiate into the precursors of adipocytes (adipoblasts) and also 
chondrocytes and myocytes (Sager and Kovac, 1982; Grigoradis et al, 1988). 
Adipoblasts are thought to be small, undifferentiated cells with little or no lipogenic 
activity and lacking lipid droplets, and are thought to proliferate and differentiate 
under multihormonal control into preadipocytes. Preadipocytes contain both 
lipogenic and lipolytic enzymes and accummulate fat as a number of small droplets 
that eventually fuse to form one single, large droplet, which occupies the centre of 
the cell surrounded by a thin film of cytoplasm.
It is now generally accepted that mature, lipid-filled adipocytes do not divide, 
and there is evidence for loss of actin filaments and other components required for 
mitosis during preadipocytes differentiation (Roncari, 1984), however, mitosis has 
been described in vitro in mature adipocytes, which lose their lipid and 
dedifferentiate (Sugihara et al, 1986, 1987). During later life increases in fat cell 
number are thought to be due to the proliferation and differentiation of precursor 
cells or to the accummulation of lipid in differentiated cells devoid of lipid.
Cell lines and primary cultures have been used for studying the development 
of the adipocyte and its endocrine control, however, these approaches are not
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without problems. The requirement for serum in the medium bathing the cells in 
early studies made it difficult to investigate the importance of particular exogenous 
agents with confidence. There is still a requirement for serum in certain systems, 
but an increasing number of techniques involve serum-free cultures.
In vitro studies have shown differences in growth rate of stromovascular 
fractions derived from different adipose tissue depots. For example perirenal rat 
adipocytes have a higher mitotic rate than epididymal adipocytes (Djian et al, 1983; 
Kirkland et al, 1990), while in sheep, adipocytes from channel (lumbar) fat showed 
greater replication rates than several other types of adipocytes (Cryer and Cryer, 
1989), whereas subcutaneous and popliteal preadipocytes showed a greater 
tendency to differentiate than omental preadipocytes (Adams et al, 1996). In broiler 
chickens precursor cell proliferation was much more rapid in vitro than that of 
precursors from (leaner) layer strain chickens, a difference that can be sustained 
through several passages (Donnelly et al, 1989). In vivo studies involving 
transplantation of adipose tissue between lean and obese mice suggest that lipid 
accummulating adipocytes is entirely dependent on cellular enviroment rather than 
any intrinsic factor (Ashwell et al, 1977; Ashwell and Meade, 1979). Therefore 
both intrinsic and enviromental factors influence the rate of adipose tissue 
formation, with their relative importance depending on situation. These site- 
specific differences then, offer considerable opportunities to manipulate the 
amounts of individual adipose tissue depots.
1.2.2 Adipose tissue metabolism
Food energy in animals is stored primarily as triacylglycerols in lipid storage 
droplets of adipocytes. Lipolysis is the process that liberates fatty acids and 
glycerol from stored lipid, while esterification, is the priniciple pathway involved in 
the synthesis of triacylglycerol, and the relative rates of the two processes 
determine if there is a net loss or accumulation of lipid (see figure 1.1).
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Figure 1.1 Pathways for synthesis and hydrolysis of triacylglycerol
ADIPOCYTE
Triacylglycerol
Glycerol 3- 
phosphate
GlycerolFatty acids
Glucose Acetate
\1/VLDLr-^  Fatty acids
BLOOD
Adipose tissue synthesizes triacylglycerol using glycerol-3-phosphate which 
is derived from glucose and fatty acids which may be synthesised de novo in 
adipocytes or derived from plasma lipoproteins by the action of lipoprotein lipase. 
Adipose tissue has little or no glycerol kinase activity and so cannot re-use glycerol 
released by lipolysis as a precursor (Vernon, 1980). The enzyme lipoprotein lipase 
is secreted by adipocytes and serves to hydrolyse plasma triacylglycerols prior to 
uptake into the adipocyte. This enzyme is transported to the endothelial cells lining 
the capillaries and attaches to the outer surface of the plasma membrane facing the 
lumen of the capillary. The greater the amount of fat in the diet the greater is the 
importance of lipoprotein lipase, but even in ruminants which normally consume 
relatively low amounts of fat, lipoprotein lipase activity may supply in excess of 
fifty percent of fatty acids deposited (Vernon, 1980). Transport into the cell of the 
resulting fatty acids and monoglycerols is thought to be facilitated by a fatty acid 
translocase located in the plasma membrane (Scow and Blanchette-Mackie, 1985). 
Monoacylglycerols taken up by the cell are hydrolysed to fatty acid and glycerol.
1.2.2.1 Lipogenesis
Lipogenesis (fatty acid synthesis) requires a source of cytosolic acetyl CoA 
and NADPH. The most important precursors of acetyl CoA are acetate, glucose 
and possibly lactate but it can also be produced from a number of amino acids. The 
significance of these precursors varies from species to species and with age within a 
species (see Vernon. 1980, 1986). While glucose and lactate are most important in 
non-ruminants and may make a more substantial contribution in the foetal animal, 
for adult ruminants acetate is the most important precursor (Vernon, 1986).
The NADPH required for lipogenesis can be derived from three systems; 
glucose-6-phosphate and 6-phosphogluconate dehydrogenases, malic enzyme and 
NADP-isocitrate dehydrogenase. Their relative importance varies with species with 
isocitrate dehydrogenase being of special importance in ruminants (Vernon, 1980).
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As cytosolic acetyl CoA and NADPH may be used for syntheses other than 
lipogenesis, the most important control point of lipogenesis is thought to be at 
acetyl CoA carboxylase which catalyses the conversion of acetyl CoA to malonyl 
CoA (Vernon, 1992). The enzyme exists in active and inactive states where 
phosphorylation of key serine residues results in inactivation (Hardie, 1989).
1.2.2.2 Lipolysis
A central feature of the metabolism of white adipose tissue is lipolysis, 
brought about by the action of hormone-sensitive lipase which is under complex 
acute and chronic endocrine control (Vernon, 1992).
Triacylglycerols are triesters of glycerol with three long chain carboxylic 
acids, thus hydrolysis of fat yields glycerol and three fatty acids. Some of the fatty 
acids released from ester linkage are re-esterified and so retained in the cell. As 
adipocytes are deficient in the the glycerol kinase free glycerol produced by 
lipolysis cannot be phosphorylated and used for reesterification and so is released 
from the cell, thus providing a useful measure of lipolysis (Margolis and Vaughan, 
1962).
1.2.2.3 The lipolytic pathway
Adipocytes possess both 0 C2  and (3-adrenergic-receptors (Vernon and Sasaki, 
1991). Catecholamines acting via P-adrenergic receptors are stimulators of 
lipolysis, details of which are outlined in figure 1.2. These, and glucagon, utilise the 
same pathway to cause triacylglycerol mobilisation. Binding of catecholamines to 
the p-adrenergic receptor in the plasma membrane causes it to interact with the 
heterotrimeric GTP-binding protein G§ which then binds GTP and dissociates to 
yield free, GTP-bound activated Gg-a  subunit and a py subunit. The a-subunit 
interacts with, and subsequently activates adenylate cyclase (AC). All of these
7
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steps occur at the level of the plasma membrane. AC then catalyses the synthesis of 
cyclic AMP (cAMP) from ATP, which is released into the cytosol where it causes 
the dissociation and activation of cAMP-dependent Kinase (A-kinase). cAMP 
concentration is modulated by the activities of several cAMP phosphodiesterase 
enzymes which degrade cAMP to AMP (Beavo, 1995; Bolger, 1994). In addition, 
insulin, activates cyclic AMP-phosphodiesterase activity and decreases cAMP 
concentration (Conti et al, 1991; Morganiello, 1995). Therefore the cAMP 
concentration and hence the activation status of A-kinase will not only depend on 
the strengths of the various signalling through G§, but also that through cAMP 
phosphodiesterase activity. A-kinase has a pivotal role, integrating a variety of 
signals into one, inhibiting lipogenesis and promoting lipolysis by phosphorylating 
specific serine residues of hormone-sensitive lipase causing its activation and 
thereby increases the rate of lipoysis (Vernon, 1992). Studies have suggested that 
phosphorylation of hormone-sensitive lipase results in a translocation of the lipase 
to its substrate at the surface of the lipid storage droplet (Egan et al, 1992). 
Perilipin is a protein located on the surface of the fat droplet and is phosphorylated 
by A-kinase, and studies suggest that perilipin is a 'docking protein1 for hormone 
sensitive lipase (Londos et al, 1990; Greenberg et al, 1991). Triacylglycerols are 
hydrolysed by the action of hormone sensitive lipase that cleaves two molecules of 
fatty acids. The resulting monoacylglycerol is hydrolysed to glycerol and fatty acid 
by monoacylglycerol lipase (Vernon, 1992). The cleavage of the first fatty acid 
moiety by hormone sensitive lipase is thought to be the rate-limiting step, while the 
monoacylglycerol lipase is very active and monoacylglycerol is normally present in 
very low amounts in the tissue (Vernon, 1992).
Essentially all the glycerol and some fatty acids produced are released from 
the cell, whereas some fatty acid is re-esterified. Esterification and lipolysis occur 
simultaneously and continuously giving a constant turnover of triacylglycerol, and 
the relative rates of the two processes determine if there is a net loss or 
accumulation of lipid (Vernon, 1992).
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Other hormones and some locally produced factors bind to receptors linked 
to isoforms of another heterotrimeric GTP-binding protein termed Gj. An occupied 
receptor interacts with the Gj a-subunit, causing it to bind GTP. The G-protein 
then undergoes a conformational change, leading to the dissociation of the Py 
complex and the release of the GTP-bound a-subunit which interacts with and 
inhibits adenylate cyclase activitity, thereby reducing cAMP formation.
Adenosine (Vernon et al, 1991) and prostaglandin E (PGE) (Reichelson, 1992) 
which are produced in adipose tissue, act through their own receptors to inhibit 
lipolysis while catecholamines, by acting through the a2-receptor can also inhibit 
lipolysis by this mechanism. Hence lipolysis in the adipocyte is under complex, 
acute control, (Rodbell, 1980). That is the activity of hormone sensitive lipase at 
any moment is determined by the balance struck between stimulatory and inhibitory 
agonists.
The involvement of a G-protein in transmembrane signaling was first 
suggested by the requirement for GTP for hormonal activation of adenylyl cyclase 
(Rodbell et al, 1971a). At the same time it was found that GTP interfered with 
detection of the hormone glucagon binding to receptors responsible for regulation 
of adenylyl cyclase activity (Rodbell et al, 1971b). It was subsequently found that 
the effect of guanine nucleotides on receptor binding was specific for agonists and 
that their affinity for the receptor was reduced (Maguire et al, 1976). Further 
experiments with turkey erythrocyte membranes involving catecholamine- 
stimulated GTPase activity (Cassel and Sellinger, 1976, 1977), showed that G- 
protein-linked systems are activated on binding of GTP; hydrolysis of GTP initiates 
or is responsible for deactivation and dissociation of GDP is linked with the rate- 
limiting step and is controlled by the receptor. G-proteins and their receptors are 
considered in more detail in section 1.4.
9
1.2.3 Hormonal regulation of lipolysis
As described above, the hydrolysis of triacylglycerol by hormone sensitive 
lipase is under complex acute and chronic endocrine control. In mammals 
including ruminants (see Vernon, 1980) catecholamines are potent stimulators of 
lipolysis whereas glucagon has only a small affect; in poultry the converse is seen 
with glucagon being the major lipolytic hormone (Butterwith, 1988). Insulin is the 
major anabolic hormone of the body (Vernon and Flint, 1989) promoting lipid 
synthesis and inhibiting lipolysis in adipose tissue, and appears to decrease lipolysis 
by both cyclic AMP-dependent and independent mechanisms, the former probably 
involving activation of cyclic AMP phosphodiesterase and the later activation of a 
phosphatase and dephosphorylation of hormone sensitive lipase (Stralfors and 
Honnor, 1989). In contrast to insulin, IGF-I and IGF-II have been claimed to have 
acute lipolytic effects in sheep adipose tissue (Lewis et al, 1988), although these 
results have not been found to be reproducable (Houseknecht et al, 1996).
Studies with rats have shown that glucocorticoids increase p-receptor 
number but decrease maximum adenylate cyclase activity (Giudicelli et al, 1989; 
Ros et al, 1989). These results were supported by studies of that showed 
prolonged incubation of sheep adipose tissue with the glucocorticoid analogue, 
dexamethasone, increased response and sensitivity to isoprenaline and decreased 
maximum adenylate cyclase activity (Finley et al, 1990). Prolonged exposure to 
dexamethasone also increases response to a2-adrenergic agents and to adenosine in 
sheep adipose tissue (Vernon et al, 1991b). Conversely, studies with rat adipose 
tissue have shown that adrenalectomy increases response to adenosine (Saggerson, 
1980; DeMazancourt et al, 1989). Hypothyroidism in rats has been shown to 
decrease the response to P-agonists and increase the response to adenosine and 
prostaglandin E2  (Malbon et al, 1988; Vernon et al, 1991a). These effects were 
not due to receptor level changes, but the effects of adenosine and prostaglandin E2  
were found to involve an increase in Gj activity (Malbon et al, 1988, Milligan and
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Saggerson, 1990). Conversely hyperthyroidism in rats increased the response to 
(3-agonists and, due to a decrease in adenosine receptor number, decreased the 
response to adenosine (Malbon et al, 1988).
Insulin has a chronic as well as an acute effect on lipolysis (Vernon, 1992). 
Studies have shown that diabetes appears to decrease sensitivity to adenosine 
(Saggerson, 1989; Green and Johnson, 1991), possibly due to a change in Gj 
activity (Strassheim et al, 1990; Green and Johnson ,1991). Diabetes also appears 
to cause a decrease in maximum adenylate cyclase acivity in the rat (Lacasa et al, 
1983; Strassheim et al, 1990).
1.2.4 Effects of lacatation on adipose tissue in sheep
A change in physiological state may alter a number of components of systems 
transmitting stimulatory and inhibitory signals. For lipolysis such changes could 
adjust the range of operational cyclic AMP concentrations within the cell and hence 
the strength of signal transmitted to A-kinase. Lactation provides an example of 
such a state.
The cycle of pregnancy and lactation causes profound changes in adipocyte 
metabolism. While lipid is usually accumulated during pregnancy, onset of lactation 
in ruminants results in a substantial transient loss of lipid from adipocytes as extra 
nutrients are needed to meet the requirements for milk production, which is 
replenished during the declining phase of lactation (Vernon and Flint, 1984; Vernon 
and Finley, 1988).
One complication is that the lipolytic response varies with fat-cell size 
(Vernon and Finley, 1985) and season, (Larsen et al, 1985) and these have to be 
taken into account when comparing responsiveness in situations that lead to 
substantial changes in fat cell size, such as lactation, (Vernon and Flint, 1984).
Studies with the p-agonist, isoprenaline have shown evidence for an increase 
in maximum response and sensitivity to catecholamines during late pregnancy and
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early lactation in sheep (Guesnet et al, 1987; Iliou and Demarne, 1987). In these 
studies mean cell volume did not change during lactation, indicating that changes in 
response and sensitivity were not due to a change in cell size. Studies with 
subcutaneous adipose tissue from lactating sheep showed both an increase in the 
response to noradrenaline, which has both 0- and a2-adrenergic effects, and an 
increase in response to isoprenaline (Vernon and Finley, 1985; Vernon et al, 1995). 
These results showed that the enhanced response was due to an increased P- 
adrenergic response with no apparent in the a2-adrenergic response. It has also 
been shown that no change in the response to the a2-adrenergic agents with 
lactation occured in cattle (Smith and McNamara, 1989). While studies showed 
that lactation increased both the maximum response and the sensitivity to P- 
agonists in sheep omental and subcutaneous adipose tissue, paradoxically it has 
also been shown that there was a concomitant increase in response to adenosine 
(Vernon et al, 1995). Lactation thus results in both the adrenergic p-adrenergic 
and adenosine signal transduction systems of adipocytes becoming more responsive 
to agonists. Why lactation should enhance the response to antilipolytic factors is 
unclear. However, the paradox remains that lactation alters the responsiveness of 
both the stimulatory and inhibitory arms of the adrenergic-adenosine signal 
transduction system.
The studies, previously mentioned, (Vernon et al, 1995) also revealed that 
while an increase in P-receptor numbers in omental tissue was observed, this was 
not the case for subcutaneous tissue. In contrast, there was an increase in total 
adenylate cyclase activity in subcutaneous but not omental adipose tissue, while for 
both tissues the amounts of Gsa-subunits were increased during lactation. The 
differences in signal thus seem to due to adaptations at the plasma membrane as 
activities of both PDE and A-kinase were unchanged by lactation. The increased 
response of omental and subcutaneous adipose tissue to adenosine may be due to 
an increase in the amounts of Gj a-subunits (Vernon et al, 1995).
12
1.2.5 Effect of lactation on adipose tissue in rats
There is some lipid accumulation in adipose tissue during pregnancy in rats, 
but much of this is lost around parturituion with some further loss during lactation 
(Vernon and Flint, 1984). Lipid lost during lactation is replaced on removal of 
young, so reproductively active female animals undergo cycles of lipid loss and 
accumulation (Johnson, 1973).
In contrast to sheep, no change in response to (3-agonists was observed 
during lactation in the rat indicating a variation between species. However, the 
response of adipocytes to the anti-lipolytic effect of adenosine was again 
paradoxically, increased despite the increased mobilisation of fat reserves during 
lactation (Vernon et al, 1983). Further studies have shown an increase in 13- 
receptor number and decreased cAMP phosphodiesterase activity during lactation 
but there is also a decrease in maximum adenylyl cyclase activity and activation of 
A-Kinase was unaltered (Vernon et al, 1993). Therefore lactation induced changes 
in some individual components of the P-adrenergic signal-transduction system 
which apparently cancelled each other out, so that there was no overall change in 
response or sensitivity to the signal.
Litter-removal from lactating rats decreased the response to p-agonists 
(Vernon et al, 1987; 1993; Ros et al, 1992). Ros et al (1992) suggested that this 
was due to a decrease in p-receptor number and amount of G§. These results were 
refuted by Vernon et al. (1993), who showed that the fall in P-receptor number 
acted to restore the receptor numbers to levels found in virgin rats; more 
importantly, they showed that activation of protein kinase A was unimpaired and 
that the diminished response was due to a failure of hormone sensitive lipase to 
translocate to the fat droplet or in response to catecholamines.
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1.3 Growth hormone
Growth hormone (GH) is secreted by acidophil cells of anterior pituitary 
gland and this secretion is mainly controlled by hypothalamic GH-releasing 
hormone which stimulates release, and somatostatin, which inhibits release (Page et 
al, 1989). GH is a single chain peptide hormone of 191 (Wallis, 1989) amino acids 
that is secreted in a pulsatile, circadian pattern that occurs about seven or eight 
times a day, usually associated with exercise, the onset of sleep or in response to 
falling plasma glucose levels about an hour after meals (Rawlings and Mason,
1989). GH promotes protein synthesis in muscle tissue and in conjunction with 
insulin stimulates amino acid uptake by muscle cells (Pell, 1989).
1.3.1 Growth hormone and lipid metabolism
The relationship between growth hormone and the metabolism of lipids was 
first investigated by Lee and Shaeffer in the 1930s when they showed that a 
decrease in total body fat occurred when rats were given prolonged treatment of 
pituitary extracts, while still observing an overall increase in body size (Lee and 
Shaeffer, 1934). Further experiments were carried out to isolate the factor 
responsible for the decrease in body fat and this resulted in the isolation and 
purification of growth hormone (Li et al, 1945). Other studies have also established 
that prolonged treatment of rats with preparations rich in growth hormone 
decreased the amount of body fat (Goodman and Schwartz, 1974; Rao and 
Ramachandran, 1977), while the availability of recombinant growth hormone has 
shown similar effects in ruminants (see section 1.1). For some tissues, for example 
the mammary gland, it would appear that the effects of growth hormone are 
mediated by IGF-I (Bauman and Vernon, 1993). However, the presence of growth 
hormone receptors and the absence of IGF-I receptors in rat and human adipocytes 
suggests that the mode of growth hormone on the adipocyte is direct. Further
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evidence for this comes from studies such as those of Schoenle et al (1983) who 
found that effects of hypophysectomy in rats on glucose metabolism of adipose 
tissue could be prevented by infusion of growth hormone but not IGF-I for IGF-II. 
The effects of growth hormone on adipose tissue metabolism can also be observed 
with the addition of growth hormone to in vitro chronic cultures of adipose tissue 
(Vernon and Flint, 1989; Bauman and Vernon, 1993), providing further evidence 
for direct effects of growth hormone on adipocytes.
1.3.1.1 Effect of growth hormone on lipolysis
The role of growth hormone in the regulation of lipolysis is not fully 
understood but although it is still controversial, it appears that the hormone does 
not have direct lipolytic effects (Vernon and Flint, 1989). Several lines of evidence 
suggest that growth hormone probably exerts its effects indirectly by altering the 
ability of lipolytic and also antilipolytic factors to alter the rate of lipolysis. Chronic 
treatment of steers (Peters, 1986) or lactating cows (McCutcheon and Bauman, 
1986; Sechen et al, 1990; Houseknecht et al, 1985) increased the lipolytic response 
to catecholamines in vivo (assessed from changes in plasma fatty acid and glycerol 
concentrations). Chronic treatment with growth hormone in vivo had no effect on 
sensitivity to catecholamines (Sechen et al, 1990). Studies in vitro involving 
maintenance of sheep adipose tissue in culture for 48 hours in the presence of 
growth hormone also increased the response and sensitivity to the P-agonist, 
isoprenaline, and increased ligand binding to the P-adrenergic receptor (Watt et al,
1991). Further evidence suggesting that growth hormone enhances signal 
transduction by increasing the number of P-adrenergic receptors was seen in studies 
by Vernon et al, (1993) and Watt et al, 1990, who showed that varying serum 
growth hormone in rats in vivo altered the ligand binding to the p-receptor of 
adipocytes. Additional evidence comes from studies with lactating rats (see section 
1.3.2).
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In contrast to the above, chronic treatment with growth hormone in vivo had 
no effect on lipolytic response to catecholamines in vitro in bovine adipose tissue 
(Peters, 1986; Lanna et al, 1992). This raised the possibility that some effects of 
growth hormone may be on the antilipolytic system. Treatment of lactating rats 
after litter removal with growth hormone reduced response to adenosine in 
adipocytes in vitro (Vernon et al, 1987) while tissue culture of sheep adipose tissue 
with growth hormone for 48 hours decreased the response to both adenosine (PIA) 
and a2-agonists (Vernon et al, 1991b). Thus growth hormone appears able to 
modulate signalling through both the lipoytic and antilipolytic systems.
1.3.1.2 Effect of growth hormone on lipogenesis
Growth hormone affects carbohydrate and fat metabolism in adipocytes: it 
acts chronically to antagonise the insulin-mediated cellular uptake of glucose and 
stimulates lipolysis (Vernon and Flint, 1989). The insulin-antagonistic effects of 
GH may also be important in the development of insulin resistance which is 
associated with obesity and diabetes mellitus (Fowelin et al, 1991). Growth 
hormone alters the activities of enzymes involved in lipid metabolism in adipocytes. 
Studies with intact rats showed that chronic elevation of growth hormone 
decreased rates of glucose oxidation and fatty acid synthesis in adipose tissue 
(Davidson, 1987; Goodman and Schwartz, 1974) while in intact growing pigs, 
growth hormone treatment reduced the rate of lipogenesis and the activity of 
several lipogenic enzymes (Magri et al, 1987). Decreases in acetyl CoA 
carboxylase and fatty acid synthase activities occur following chronic treatment of 
adipocytes or adipose tissue with growth hormone (Dietz and Schwartz, 1991; 
Bauman and Vernon, 1993; Vernon et al, 1993). Chronic growth hormone has 
also been found to decrease the expression of the GLUT1 glucose transporter in 
both rat adipocytes and 3T3-F442A adipocytes (Kilgour et al, 1993; KuTai et al,
1990). Growth hormone is a powerful insulin antagonist and inhibits the activation
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of acetyl CoA carboxylase by insulin, possibly by inhibiting the synthesis of a 
protein required for mediation of the insulin-induced activation of the enzyme 
(Vernon et al, 1991a).
Time-course experiments of growth hormone effects on adipose tissue in rats 
has shown that abstinence from growth hormone for a few hours, in vivo or in 
vitro, or more results in a transient stimulation of lipogenesis and inhibition of 
lipolysis (Goodman, 1993). As these effects are only seen in cells previously 
deprived of growth hormone for several hours the physiological relevance of the 
findings is doubtful, except perhaps in young male rats in which growth hormone 
secretion is highly pulsatile (Vernon and Flint, 1989). This insulin-like effect is 
short lived, after which inhibition of glucose utilisation and enhanced lipolysis 
typical of the chronic effects of growth hormone are seen, however the 
development of these chronic effects are prevented by the addition of actinomycin 
D, an inhibitor of gene transcription (Goodman et al, 1987; Goodman, 1993). 
Studies with sheep adipose tissue showed that the full chronic effects of growth 
hormone on lipogenesis were seen after 12 hours following a 3-4 hour lag phase. 
This lag-phase was extended when insulin was present (Borland et al, 1994).
Polyamines have been implicated in the insulin-like antilipolytic effect of 
growth hormone on lipolysis in chicken adipose tissue (Campbell and Scanes, 
1988). The effects of polyamines include a role in gene transcription (Scalabrino et 
al, 1991; Sjoholm, 1993), activation of a number of protein kinases and 
phosphatases (Morgan, 1990) and enhancing hormone binding to plasma membrane 
receptors (Pedersen et al, 1989). Exposure of sheep adipose tissue to growth 
hormone also increases the activity of S-adenosyl methionine decarboxylase, an 
enzyme of polyamine metabolism (Snoswell and Vernon, 1990). Studies carried 
out by Borland et al, (1994) showed that the inhibition of lipogenesis is sheep 
adipose tissue by growth hormone required polyamines. Further studies using 
actinomycin D, an inhibitor of gene transcription, implicated a protein with a half
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life of less than three hours in the inhibition of lipogenesis by growth hormone 
(Borland et al, 1994). As the effect of actinomycin was not overcome by adding 
spermidine to cultures, it would appear that this putative protein is not ornithine 
decarboxylase (Borland et al, 1994). Very recent studies (Vernon, 1996) using the 
inhibitors H7, staurosporine and okadaic acid indicate a role for both protein serine 
phosphorylation and dephosphorylation in the inhibition of lipogenesis by growth 
hormone.
1.3.2 Growth hormone and lipid metabolism at lactation
Serum growth hormone is increased during lactation in ruminants but not in 
rats (Vernon, 1989). While it has not been proven directly, it would seem probable 
that this increase in serum growth hormone contributes to the enhanced response 
and sensitivity to catecholamines and the increased number of P-adrenergic 
receptors of adipocytes in lactating ruminants. The elevated levels of serum growth 
hormone are not sufficient to achieve a maximum effect, in lactating cows at least, 
as treatment with growth hormone enhances response, but not sensitivity to 
catecholamines (Sechen et al, 1990; Houseknecht et al, 1995). Elevated serum 
growth hormone is also thought to contribute to the decreased adipocyte 
lipogenesis in lactating ruminants (Vernon, 1988; Bauman and Vernon, 1993).
The role of growth hormone in lactating rats is less clear. The lack of 
increase in lipolytic response to catecholamines is consistent with lack of an 
increase in the serum growth hormone concentration. However, in rats, 
replenishment of lipid reserves following litter removal is associated with a 
decreased ability of catecholamines to stimulate lipolysis and an increase in lipid 
synthesis. The diminished response to catecholamines can be mimicked in lactating 
rats by treatment with a specific antiserum to rat growth hormone (Vernon et al, 
1987). Similarly, the decrease in response at litter removal can be prevented with 
treatment of growth hormone. Serum growth hormone concentrations are very
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variable due to pulsatile secretion, however, serum IGF-I which provides an 
indirect assessment of serum growth hormone rose on litter removal (Vernon et al,
1993), suggesting that the changes in the lipolytic system were not due to fall in 
serum growth hormone; it is possible that the sensitivity or response of the cells to 
growth hormone is decreased. This study also showed that growth hormone 
altered several components of the adrenergic signal transduction system in these 
animals, increasing the number of p-receptors and hormone-sensitive lipase activity 
and decreasing cAMP phosphodiesterase activity. The key effect of growth 
hormone was, however, on the association of hormone-sensitive lipase with the 
lipid droplet following catecholamine stimulation.
While in ruminants at least, changes in serum growth hormone may contribute 
to changes in lipogenesis and lipolytic response to catecholamines during lactation, 
the increased response to adenosine in adipocytes during lactation must be due to 
some other factor.
1.3.3 Growth hormone and differentiation
During differentiation, preadipocytes progressively accumulate lipid and 
acquire sensitivity to agents which regulate lipid metabolism. GH promotes the 
differentiation of adipocyte precursor cells (preadipocytes) into mature adipoctyes 
Evidence for this comes primarily from studies using preadipocyte cell lines such as 
3T3-F442A and Ob 1771 which both exihibit GH-dependent differentiation 
(Zezulak and Green, 1986; Grimaldi et al, 1984). It appears that GH can increase 
the transcription of IGF-1 (Doglio et al, 1987) and primes cells to respond to the 
mitogenic effects of IGF-1 and other agents which then stimulate a limited clonal 
expansion of the young adipocytes prior to terminal differentiation (Zezulak and 
Green, 1986).
GH has also been shown to influence the expression of other proteins 
involved in adipocyte differentiation. In 3T3-F422A cells GH alters the expression
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of various cytoskeletal proteins (Guller et al, 1992) which could explain the 
morphological changes seen in the initial stages of differentiation. GH also 
increases transcription of early response genes c-fos and c-jun in preadipocytes 
(Doglio et al, 1987; Gurland et al, 1990), the increase in expression of these 
transcription factors may regulate the expression of further genes involoved in the 
differentiation process.
While many of the recent advances in understanding growth hormone 
signallling systems have been derived using growth hormone-sensitive preadipocyte 
cell lines, where growth hormone responses are studied in isolation after the 
removal of other serum components, cellular responses to growth hormone in vivo 
occur against a background of effects elicited by other hormones and growth 
factors. Therefore more challenging work on signalling on primary cultures of 
growth hormone-sensitive cells and in vivo is also necessary to confirm cell line- 
derived data.
1.3.4 The Growth hormone receptor
Growth hormone exerts direct effects on adipose tissue by interacting with 
receptors which have been demonstrated to be present on adipocytes of rats (Fagin 
et al, 1980) and man (DiGirolamo et al, 1986). The growth hormone receptor has 
been cloned from several species including man (Leung et al, 1987), rat (Mathews 
et al, 1989), mouse (Smith et al, 1989), cow (Hauser et al, 1990) and sheep 
(Adams et al, 1990). It is characterised as a single peptide of between 630 and 650 
amino acids (Waters et al, 1990) comprising an N-terminal signal sequence 
followed by an extracellular hormone-binding domain, a single hydrophobic 
membrane spanning region and a large intracellular domain. The number of 
receptors varies with depot, sex and age, (Vernon and Flint, 1989). The growth 
hormone receptor possesses several structural features which classifies it as a
20
member of the cytokine or haematopoeitin receptor superfamily. This group also 
includes receptors for prolactin, erythropoeitin and several interleukins (2,3,4,6,7) 
(Bazan, 1989).
Due to alternative splicing there are short and long forms of the growth 
hormone receptor: the short form is a binding protein that ciculates in the blood and 
interacts with growth hormone (Kelly et al, 1994). A recent study indicated that 
rat adipocytes express both the full length receptor and a short form which remains 
tethered to the external membrane face (Goodman et al, 1994). The pool of 
growth hormone receptors on the adipocyte cell surface is made up of about 20% 
of the short form compared to 80% of the long form. They have different turnover 
rates and appear to be independently regulated. Immunoneutralisation of the short 
form decreased the magnitude of the effect of growth hormone on glucose 
metabolism, suggesting that the short form may mediate some of the responses to 
growth hormone (Goodman et al, 1994).
Studies by de Vos et al (1992) and Cunningham et al (1991) demonstrated 
that one molecule of human growth hormone (hGH) binds two molecules of the 
solubilised extracellular domain of the receptor. Thus there appears to be two 
distinct receptor binding sites on hGH. The formation of the growth 
hormone/receptor complex occurs sequentially, the receptor binding first to the 
higher affinity site 1 on growth hormone then to site 2. Studies suggest that 
dimerization of receptor is a necessary prerequisite for the formation of an active 
signal-transducing complex (Fuh et al, 1992). Since receptor oligomerisation has 
been shown to be important in signalling by other growth factors, eg. insulin, EGF 
and PDGF (Ullrich and Schlessinger, 1990), it seems likely that it will play some 
key role in growth hormone signallling.
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1.3.5 JAK2 and growth hormone signalling
Several distinct signalling pathways which link the cell surface growth 
hormone receptors to effects on the nucleus have been tentatively identified 
(Anderson, 1994; Carter-Su et al, 1996). Although the growth hormone receptor 
possesses no intrinsic tyrosyl kinase activity itself agonist binding results indicated 
the rapid tyrosyl phosphorylation of a number of intracellular proteins (Anderson et 
al, 1990; Wang et al, 1993). Tyrosyl phosphorylation is initiated by the ability of 
the receptor to sequester the tyrosyl kinase JAK2 (Argetsinger et al, 1993). This 
kinase was initially shown in 3T3-F442A cells to be able to associate with the 
occupied growth hormone receptor resulting in activation of JAK2 kinase and 
tyrosyl phosphorylation of the growth hormone receptor (Argetsinger et al, 1993). 
JAK2 is a member of the Janus tyrosine kinase family that also includes JAK1, 
TyK2 and JAK3. All these proteins share the unusual feature of having two kinase­
like domains (see Ihle et al, 1994). Studies using mutated growth hormone 
receptor (GHR) have been carried out to determine which region of the GHR 
associates with JAK2 and to examine whether activation of JAK2 is the only 
requirement for biological responses to growth hormone (Vanderkuur et al, 1994). 
These studies showed that the proline-rich Box 1 motif of the cytoplasmic domain, 
is primarily required for association of JAK2 with GHR and GH-dependent 
activation of JAK2. However, the N-terminal quarter of the cytoplasmic domain of 
the GHR appears to augment the interaction with JAK2. Although the sites of 
tyrosyl phosphorylation of the GHR have not been unequivocally identified, 
mutational studies suggest (Vanderkuur et al, 1994) that one or more of the tyrosyl 
residues present in the N-terminal half of the cytoplasmic domain of GHR are 
phosphorylated by JAK2.
It is now apparent that members of the Janus tyrosyl kinase family serve as 
receptor associated kinases for the multiple members of the cytokine/haemopoietin 
receptor family. In addition to the growth hormone receptor, JAK2 has been
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shown to associate with the erythropoietin receptor (Witthuhn et al, 1993), IL-3 
receptor (Silvennoinen et al, 1993) and prolactin receptor (Lebrun et al, 1994).
1.3.6 Growth hormone and signal transduction via STATS
Signal transducers and activators of transcription (STATs) participate in 
growth hormone signalling between the receptor and the nucleus (Darnell et al,
1994). ST AT proteins contain both SH2 and SH3 (Src homology) domains (Fu, 
1992; Schindler et al, 1992a; 1992b; Shuai et al, 1992) a specific region within 
target effector molecules that have considerable sequence similarity to the non- 
catalytic region of the src family of protein tyrosine kinases (Pawson and Gish,
1992). A large number of signalling molecules have been shown to contain SH2 
domains which bind directly to tyrosine-phosphorylated receptors (see Malarkey et 
al, 1995).
Growth hormone has been shown to induce tyrosyl phosphorylation and 
nuclear accummulation of several STAT or STAT-related proteins: STATl/p91; 
STAT3/APRF (acute-phase response factor; and/or STAT5/MGF (mammary gland 
factor) (see Carter-Su et al, 1996). STAT1 is a subunit of the ISGF3 complex 
which comprises of a 48-kDa DNA-binding component, and 84/91-kDa protein and 
a 113-kDa protein, termed p48, p84, p91 and pi 13 respectively, and these protein 
subunits of ISGF3 are localised in the cytoplasm of unstimulated cells. Formation 
of the complex and its migration to the nucleus requires tyrosine phosphorylation of 
p91/84 and pi 13 and it is hypothesised that this tyrosine phosphorylation is 
mediated by a JAK (Meyer et al, 1994). Following phosphorylation, STAT1 and 
STAT3 migrate to the nucleus and interact with the sis-inducible element (SIE). 
The c-fos promoter possesses a SIE, and these STATs probably contribute to GH- 
induced c-fos expression although growth hormone probably also regulates the 
SRE (serum response element) in the c-fos promoter via the MAP kinase pathway
23
(see below). STAT5 binds to the growth hormone response element in the serum 
protease inhibitor gene (see Carter-Su et al, 1996).
1.3.7 Growth hormone signal transduction via MAP kinases
The second receptor-nucleus pathway involves the mitogen-activated protein 
(MAP) kinases. MAP kinase was first identified as a serine/threonine-directed 
kinase that utilised microtubule-associated protein 2 as a substrate following 
stimulation of adipocytes with insulin (Ray and Sturgill, 1987). MAP kinases are 
expressed in all cells and can be activated by hormones, growth factors, 
neurotransmitters and other cell stimuli (Anderson, 1992b). The activation of MAP 
kinase requires phosphorylation upon both tyrosine and threonine residues 
(Anderson et al, 1990; Gomez and Cohen, 1991) by dual specificity MAP kinase 
kinases or MEKs (Nakielny et al, 1992; Crews and Erikson, 1992).
Activation of MAP kinases can result in their translocation to the nucleus 
where they phosphorylate several transcription factors including the p62 ternary 
complex factor which participates in formation of the serum response element 
binding complex (Treisman, 1995). Growth hormone has been shown to activate 
two MAP kinases, namely the p42 and p44 isoforms (Anderson, 1992b; Winston 
and Bertics, 1992; Campbell et al, 1992) in 3T3-F442A preadipocytes. 
Administation of growth hormone to hypophysectomised rats induces the 
translocation of p42 and p44, and other tyrosine phosphorylated proteins, to the 
nucleus in hepatocytes (Gronowski and Rotwein, 1994). Growth hormone has also 
been shown to phosphorylate and activate the S6 kinase p90rs^ which can also 
translocate to the nucleus (Chen et al, 1992) and has been shown to phosphorylate 
and activate several transcription factors (Blenis, 1993). This S6 kinase lies 
downstream of the p42 and p44 MAP kinases, and some studies suggest a role for 
protein kinase C (PKC) in the growth hormone-dependent activation of MAP 
kinases and p90rsk (Anderson, 1992a). Growth hormone also phosphorylates and
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Figure 1.3 Summary of Growth hormone signalling pathways
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activates the S6 ribosomal kinase p7 0 ^ K  in 3T3-F442A cells (Anderson, 1993) 
which is involved in the regulation of translation via phosphorylation of the S6 
ribosomal proteins; activation of p70 is via a MAP kinase independent 
pathway.
Therefore, the GH signalling pathway, a summary of which is outlined in 
Figure 1.3, apparently includes the involvement of activation of JAK2, a non 
receptor tyrosine kinase. The subsequent phosphorylated GHR and JAK2 serve as 
docking sites for SH2 domain-signalling molecules (Carter-Su et al, 1996) and 
includes the activation of MAP kinase, which are known to phosphorylate 
transcription factors, and STATs which, when combined with an active sis- 
inducible factor, are able to activate transcription by direct interaction with 
response elements on target DNA (Larner et a/, 1993, Sadowski et al 1993 and 
Shuai etal, 1993).
1.4 Guanine nucleotide binding Proteins
1.4.1 Identification of the stimulatory G-protein Gs
The identification of G§ was achieved by reconstitution with eye- S49 cells
(Bourne et al, 1975) which are deficient in this G-protein. This provided the first
assay and purification of G§, yielding a heterotrimer of a,P,y subunits. Subsequent
to this the isolation of certain exotoxins from cultures of both vibrio cholerae and
Bordetella pertussis aided the identification of the stimulatory and inhibitory G-
proteins, termed G§ and Gj respectively. Gill and Meren demonstrated that the
cholera toxin activation of adenylyl cyclase in pigeon erythrocytes correlated with
37the radiolabelling of a 42kDa polypeptide, in the presence of [ PJ-NAD+ (Gill and 
Merren, 1978). The presumed reaction of cholera toxin was an ADP-ribosylation 
similar to that already detailed for the action of diphtheria toxin on a protein 
component required for protein synthesis (Collier, 1975). ADP-ribosylation by
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cholera toxin, of a key arginine residue (R201/202 or R187/188, depending upon 
which of the four splice variants is referred to) in its a-subunit leads to the loss of 
GTPase activity and concomitant activation of adenylate cylase (Gilman, 1987; 
Birmbauer et al, 1990; Kaziro et al, 1991; Bray et al, 1986). Mutation of this 
arginine residue in Gga  (Freissmuth & Gilman, 1989), as seen with the gsp 
oncogene (Landis et al, 1989), also leads to the constitutive activation of adenylate 
cyclase. Cholera toxin requires the presence of a protein co-factor termed ADP- 
ribosylation factor (ARF) which is itself able to bind GTP (Kahn and Gilman, 1984) 
in order to catalyse the ADP-ribosylation of Gg. The effect of cholera toxin was 
similar to that obtained by non-hydrolysable analogues of GTP, thus allowing the 
identification of Gga  both a substrate for cholera toxin catalysed ADP-ribosylation 
and a protein capable of binding and hydrolysing guanine nucleotides.
1.4.2 Identification of the inhibitory G-protein Gj
Pertussis toxin, which is also termed islet activating protein (IAP), was shown 
to produce alterations in receptor mediated control of cyclic AMP production 
(Katada and Ui, 1981). Initial experiments in rat C6 glioma cells treated with 
pertussis toxin showed and increase in GTP activation of adenylyl cyclase, 
concomitant with the transfer of [^P]-ADP-ribose from [^P]NAD+ to a 41kDa 
membrane associated polypeptide (Katada and Ui, 1982). The release of tonic 
inhibition of adenylyl cyclase activity paralled by the modification of the 41kDa 
protein thus identified this protein as the previously unidentified inhibitory G- 
protein of the adenylyl cyclase cascade (Gj).
Pertussis toxin functions in a similar manner to cholera toxin in that it is an 
ADP-ribosyl transferase however, in this instance it catalyses the transfer of ADP- 
ribose from NAD+ onto a C-terminal cysteine on the G-protein a-subunit. The 
functional effects of pertussis toxin catalysed ADP-ribosylation of Gja is to prevent 
productive coupling between the receptor and the G-protein, thus receptor
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mediated inhibition of adenylyl cyclase is attenuated after pretreatment with 
pertussis toxin (Katada & Ui, 1979; Burns et al, 1983). This led to the over- 
simplistic hypothesis that any event which was attenuated by prior treatment with 
pertussis toxin was taken as indicative of a role for Gj in mediating the response.
1.4.3 Stimulatory G-proteins
At least four forms of G§a  exist, which are obtained from alternative splicing 
of a transcript from a single gene (Bray et al, 1986; Kozasa et at, 1988). These 
have been grouped into two subtypes which are termed long (46-kDa) and short 
(44-kDa) Gsa. The cDNAs that encode two of the forms of Gga  have been 
isolated from a bovine adrenal cDNA library and are identical except for a sequence 
of 46 nucleotides in which the shorter form of Gga  contains alterations in 4 
nucleotides and a deletion of 42 others (Robishaw et al, 1986). Whereas at least 
two forms of G§ are expressed in most tissues, their relative amounts usually vary 
(Mumby et al, 1986). Although Gs was originally identified as the G-protein
required for receptor mediated stimulation of adenylyl cyclase, the protein has also
. . . . 0 +been shown to couple to the activation of the dihydropyndine-sensitive Ca
channels (Yatani et al, 1987), the inhibition of the calcium pump in liver membranes
(Jouneauz et al, 1993) and the inhibition of Na+ channels in cardiac myocytes
(Schubert et al, 1989). G§a  has also been shown to mediate epidermal growth
factor-elicited stimulation of rat cardiac adenylyl cyclase (Nair et al, 1990). A
protein with 88% amino acid homology to Gsa  has been cloned from olfactory
epithelia and termed GQjp Its sole location is in the olfactory neuroepithelia where
it is responsible for olfactant regulation of adenylyl cyclase (Jones and Reed, 1987;
Bruch, 1990).
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1.4.4 Inhibitory G-proteins
Gjot. Three genes encode the family of G-proteins, known as Gjl, G{2 and 
Gp (Kaziro,1990; Jones and Reed, 1987). In addition to the three forms of GjOt 
mentioned, other G-protein a-subunits have been termed Gj-like due to their 
degree of amino acid homology with these proteins. However, it is not certain as 
to whether all or just certain of these species can inhibit adenylate cyclase under 
physiological conditions (Raymond et al, 1994; Houslay, 1991a). Recently cDNAs 
encoding persistently activated Gja were expressed in several cell systems, where 
inhibition of some subtypes of adenylyl cyclase by all three G^a subunits was shown 
to occur (Wong et al, 1991; Lowdnes et al, 1991; Hermout et al 1991; Wong et al, 
1992; Taussig et al, 1993), indicating a possibe direct role for all three Gj forms in 
the inhibition of adenylyl cyclase. These conclusions were based upon inferences 
made by studying cAMP metabolism in intact transfected cells rather than any 
direct measure of adenylate cyclase activity. However, the overexpression of 
mutant G-proteins might attenuate adenylate cyclase functioning in a manner which 
does not necessarily reflect that seen in vivo. For example such a strategy showed 
that mutant Gza  inhibited forskolin-stimulated cAMP activity (Wong et al, 1992). 
This result was surprising as G-protein controlled inhibitory regulation of adenylate 
cyclase in native systems had uniformly been shown to be blocked by pertussis 
toxin, whereas Gz is insensitive to the action of this toxin (Gilman, 1987; Birnbauer 
et al, 1990; Kaziro et al ,1991; Bray et al, 1986; Freissmuth and Gilman, 1989). 
However, studies using a variety of approaches suggest that at least G-2a can 
mediate such an inhibitory action in cells which have not been transfected with Gia- 
subunits (Bushfield et al, 1990; Mckenzie and Milligan, 1990; Simonds et al, 1989; 
Watkins et al, 1992; Goetzel et al, 1994; Carter and Medrihadsky, 1993; Raymond 
et al, 1993; Milligan et al, 1991).
Activation of protein kinase C causes the phosphorylation of the a-subunit of 
Gj2 (Pyne et al, 1989; Rothenberg et al, 1988). Phosphorylation of G-2a in
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hepatocytes (Houslay, 1991b; Morris et al, 1994) and other cells (Katada et al,
1985; Watanabe et al, 1988; Daniel-Issakani et al, 1989; Strassheim and Malbon,
1994; Yatomi et al, 1992) appears to cause loss of GTP-dependent inhibition of
adenylate cyclase. This effect, however, may be a cell-specific phenomenon, as it is
not observed in all cell tyes. It has been suggested that hepatocyte Gj2 is controlled
by a futile cycle of phosphorylation and dephosphorylation involving protein kinase
C and protein phosphatase activity (Houslay, 1991b; Bushfield et al, 1991). Thus
either stimulation of protein kinase C or inhibition of protein phosphatase activity
may inhibit the functioning of Gj2. Phosphorylation of Gj2a also occurs at a
207second site, suggested to be ser (A-site), which results upon elevation of cAMP 
levels (Morris et al, 1994).
G^a. At least two forms of transducin occur, transducin 1 ( Gt l) and 
transducin 2 (Gt2), which are encoded by seperate genes, and are found in rod and 
cone cells respectively (Lerea et al, 1986) and have an approximate 80% homology 
with the Gi-like proteins. They serve to couple rod and cone opsins to cGMP 
phospodiesterases. A novel transducin-like G-protein (Gg) has recently been 
identified from taste tissue (McLaughlin et al, 1992). Due to sequence homology 
in those regions of the G-protein a-subunit known to interact with receptors and 
effectors, it is known that a cGMP phosphodiesterase is involved in its means of 
signal transduction.
Gq. Studies using purified preparations of pertussis toxin substrates from 
bovine brain (Sternweis and Robishaw, 1984; Milligan and Klee, 1985; Neer et al, 
1984) in conjunction with the purification of rat brian substrates (Katada et al, 
1986), led to the identification of the 39 kDa G-protein a-subunit termed GQ for 
other (Nukada et al, 1986; Itoh et al, 1986). cDNA clones of GQa  have been 
isolated from bovine retina (Van Meurs et al, 1987), rat C6BU1 glioma cells (Itoh 
et al, 1986) and rat olfactory epithelium (Jones and Reed, 1987). Additional GQa
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isoforms have also been identified (Goldsmith et al, 1988; Kobayashi et al, 1989) 
immunologically (Goldsmith et al, 1988) and biochemically (Inanobe et al, 1990; 
Hsu et al, 1990). While the function of GQ remains unresolved, early evidence
exists to suggests that this G-protein may be involved in the regulation of receptor-
• • • 9+mediated inhibition of voltage operated Ca channels (Hescheler et al, 1987;
Harris-Warrick et al, 1988; Ewald et al, 1988). More recent studies demonstrate a
role for GQ in coupling to somatostatin receptors (Law et al, 1991, 1993) and the
aip-adrenergic receptor (Blizter et al, 1993) which serve to inhibit adenylyl cyclase
and stimulate phospholipase C activity respectively.
Gza  Gxa cDNA was isolated from rat brain and was identical to one 
isolated from human retina (Fong et al, 1988). This protein is pertussis toxin 
insensitive and exhibits a remarkably slow rate of guanine nucleotide exchange and 
a very slow intrinsic GTPase activity when compared to GjOC. The biochemical 
properties of Gza appear, therefore, to differ from thoses of GjOt, although as yet 
the physiological significance of this remains undetermined.
1.4.5 G-protein linked receptors
Receptors span the cell membrane and have at their externally facing side a 
site specific for a particular hormone, growth factor, neurotransmitter, antigen or 
other ligand. Binding to the receptor generates a signal within the cell itself. Cell 
surface receptors can be divided into two classes, one of which possesses the 
machinery for the generation of an intracellular signal, while the second is reliant 
upon interaction with other plasma membrane proteins to elicit a signal.
For the second group of receptors mentioned, G-proteins function as 
intermediaries in transmembrane signalling (Houslay, 1992). The receptors that 
participate in such reactions are many and one of best charactized is the P- 
adrenergic receptor which has for example the agonist adrenaline and the more
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selective agent isoproterenol (Gilman, 1987). Isolation, purification, molecular 
cloning and sequencing of the P-adrenoreceptor, (Dixon et al., 1986) allowed 
models to be formulated regarding the disposition of the receptor in the plasma 
membrane. Subsequent cloning of other G-protein linked receptors identified a 
similar seven-membered hydrophobic transmembrane helices and because of this, 
such receptors were given the mnemonic 'R7G receptor1 (Strosberg, 1991).
R7G receptors are formed from a single peptide chain of about 400 to 600 
amino acids in length (Fraser, 1991; Raymond et al, 1990; Strosberg, 1991). 
Characteristic features are seven stretches of 22-28, essentially hydrophobic, amino 
acids that are thought to form distinct transmembrane domains as deduced from the 
electron microscopy imaging studies of bacteriorhodopsin (Henderson and Unwin, 
1975). Bacteriorhodopsin, like the visual photoprotein rhodopsin, exerts its 
physiological effect by binding to the G-protein transducin causing it to bind GTP 
and dissociate (Hingorani and Ho, 1990). Once bound the GTP-Ta causes the 
activation of its specific effector/signal generator, a cyclic GMP phosphodiesterase. 
Therefore the R7G receptors are thought to consist of seven interacting 
transmembrane cylinders with loops of hydrophilic residues extending out into the 
extracellular space at the N-terminus and between cylinders 2/3, 4/5 and 6/7. The 
C-terminus of the protein and the cytosolic loops formed between the cylinders 
1/2, 3/4 and 5/6 are at the cytosolic space. Greatest homology is seen within the 
seven individual transmembrane domains and this has been useful in cloning other 
members of this family.
1.4.6 The GTPase cycle
Using the available data on the efects of cholera toxin and non-hydrolysable 
GTP analogues on G§, together with the ability to measure hormonal stimulation of
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high affinity GTPase activity, Cassel and Selinger (1977) were able to propose a 
cyclical model to account for G-protein function which is still applicable.
Binding of a ligand to its receptor causes the a-subunit to lose its GDP and 
bind GTP in a Mg dependent manner. Agonists act to reduce the concentration
9 _ i _
of Mg required for activation, for example glucagon lowers the magnesium 
concentration required for GTPyS activation of Gsa from 25mM to lOuM. As the 
intracellular Mg is estimated to be of the order of 2mM it can then be utilised 
(Iyengar and Birnbaumer, 1982). The binding of GTP reduces the affinity of the 
receptor for agonist, resulting in a dissociation of the receptor-G-protein complex 
and a magnesium dependent dissociation of the a-subunit from the py (Maguire et 
al, 1976). The Ga-GTP is now in an 'active' conformation suitable for specific 
interaction with an effector protein. On completion of effector activation, GTP is 
hydrolysed to GDP by the intrinsic GTPase of the a-subunit (Rodbell, 1980). The
now inactive Ga-GDP can reassociate with its Py subunits. This system is cyclical
9+and dependent on ligand binding, GTP and Mg (Ransas et al, 1992).
1.4.7 Covalent modification of G-Proteins
G-proteins can be covalently modified in several ways. These modifications 
are believed to be potentially important in regulating the function and cellular 
targetting of the G-protein.
1.4.7.1 Lipid modification
The association of G-proteins with cellular membranes is crucial in ensuring 
efficient signal transduction for essentially all these molecules (Helper & Gilman, 
1992; Bourne et al 1991). Three general types of lipids can be found covalently 
linked to G-protein. The first is a saturated 16-carbon fatty acyl group, palmitoyl 
which was detected on products of the RAS proto-oncogenes (Chen et al, 1985).
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Palmitoylation of proteins is a post-translational event, generally occurring through 
labile thioester bonds to cysteine residues (Schmidt, 1989). The lability of this 
bond is thought to be a critical facet of palmitoylation; it is the only one of the three 
major types of lipid modifications that is reversible. The second is a 14-carbon 
myristoyl group (Gordon et al 1991). Analysis of G-a and GQa  subunit 
polypeptides by both chemical and metabolic labellling techniques initially revealed 
the presence of myristic acid on the proteins (Buss et al, 1987). Subsequent studies 
confirmed that the G ial, Gj0t2, Gja3, GQa  and Gza  subtypes were all myristolated 
at conserved amino terminal residues, (Mumby et al, 1990; Jones et al, 1990). 
Indeed, mutagenesis of this glycine residue produced proteins which did not
'i
incorporate [ H]myristate and did not become associated with cellular membranes. 
The third lipid type involves the 15- or 20-carbon unsaturated isoprenoid lipids to 
cysteine residues at or near the carboxyl terminus (Clarke, 1992). Ras proteins, 
which are monomeric 'mini' G-proteins are prenylated and the modification is 
required for oncogenic forms of these proteins to transform cells (Hancock et al, 
1989; Casey et al, 1989). The y-subunits of all heterotrimeric G-proteins are also 
prenylated, this is believed to promote a means of anchoring the py complexes to 
the plasma membranes (Clarke, 1992; Casey et al, 1989). These lipid 
modifications influence interactions between the proteins or between each protein 
and the plasma membrane.
1.4.7.2 ADP ribosylation
Pertussis toxin and cholera toxin catalysed mono ADP-ribosylation of G- 
protein a-subunits has been well characterised (sections 1.4.1, 1.4.2). However it 
is still uncertain if endogenous ADP-ribosylation occurs under normal cellular 
physiological conditions and thus promotes cellular control. Both arginine (Moss 
and Vaughn, 1988; Inageda and Tanuma, 1991) and cysteine specific (Tanuma et 
al, 1987; Tanuma et al 1988) mono-(ADP-ribosyl) transferases have been idenified
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in several cell types. Enzymes that catalyse the removal of ADP-ribose from ADP- 
ribosylated arginine residues have also been identified (Moss et al, 1992), 
suggesting that ADP-ribosylation may be a reversible physiological event (Moss et 
al, 1985).
1.4.7.3 Phosphorylation
Phosphorylation of G-proteins is the least well defined of the covalent 
modifications. The G-protein a-subunits contain consensus sites for 
phosphorylation by a number of protein kinases and thus may be subject to 
regulation by hormones that do not interfere directly with a certain G-protein-linked 
pathway (Spiegel et al, 1992). It was shown by Jakobs and co-workers that a 
purified preparation of brain Gj, consisting of multiple forms, could be 
phosphorylated by PKC, suggesting that this may provide a basis for an alteration in 
G- functioning (Katada et al, 1985). This suggests that phosphorylation might 
stabilise the inactive GDP-bound form of Gj and would be consistent with the 
hypothesis that phorbol esters serve to attenuate the rate of activation of Gj (Bell 
and Brunton, 1986). This is also consistent with the observation that the ability of 
pertussis toxin to mediate ADP-ribosylation of Gja, which can only occur on the 
intact GDP-bound holomeric form of this G-protein, was considerably greater in 
cells treated with phorbol ester for 15 minutes (Choi and Toscano, 1988). 
Furthermore in several cell systems (Daniel-Issakani and Spiegel, 1989; Gordelatze 
et al, 1989), and hepatocytes (Houslay, 1991) it has been demonstrated that PKC 
is able to phosphorylate Gj2a, which leads to increased cAMP synthesis. The 
phosphorylation of the a-subunit of this G-protein is thought to occur on se r^ ^  
(C-site) (Morris et al, 1994). Studies with recombinant G-proteins have shown 
that the a-subunit of Gz is stoichiometrically phosphorylated by partially purified 
PKC on a serine residue near the N-terminal, whereas recombinant G jla, Gj2a 
and Gj3a were not labelled under the same conditions (Lounsbury et al, 1991).
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Studies have also shown that G-proteins of the Gj family are phosphorylated by 
insulin and EGF-elicited tyrosine kinases (Cerione, 1991) when the G-protein is in 
its holomeric, GDP-bound state.
Evidence that the a-subunits of G§ can be phosphorylated on serine residues 
by protein kinase C (Pyne et al, 1992) and protein kinase A (Pyne et al, 1992b) has 
also been reported.
Although is has been demonstrated that the a-subunit of certain G-proteins 
can be phosphorylated in vitro, a link with physiological events has yet to be 
conclusively demonstrated and the biological implications of such G-protein 
phoshphorylation remain unclear. However phosphorylation of G-proteins may 
provide the basis for 'cross-talk' between distinct signalling systems.
1.4.8 G-protein interaction with Adenylyl cyclase
Adenylyl cyclase catalyses the conversion of intracellular ATP to cAMP, 
increasing the intracellular levels of cAMP. It was only recently that detailed 
molecular information about the adenylyl cyclase enzyme has been acquired, 
following the cloning of several isoforms of the enzyme. Most adenylyl cyclases 
are membrane-associated although certain bacterial enzymes (and perhaps one form 
in mammalian sperm [Rojas et al, 1993]) are cytosolic.
The cloning of the first adenylyl cyclase revealed a large complex structure 
(Krupinski et al, 1989). This and all subsequently cloned adenylyl cyclases 
comprise 1,080 - 1,248 amino acid polypeptides. These membrane associated 
adenylyl cyclases have short cytoplasmic N- and C-terminal regions and two 40kDa 
cytoplasmic domains (Cl and C2) punctuated by two intensley hydrophobic 
stretches (Ml and M2), each of which are hypothesised to contain six 
transmembrane helices (figure 1.4). The two cytosolic regions include putative 
ATP-binding domains, which are homologous to each other (Krupinski et al, 1989)
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Figure 1.4 Structure of adenylate cyclase isoforms
M. M.
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Figure 1.4 represents the structure of the eukaryotic adenylate cyclases (adapted from 
Tang and Gilman, 1992 [Cell 70, 869-872]).
and between different adenylyl cyclases (50-92%) (Tang and Gilman, 1992; 
Iyengar, 1993). Accumulating data indicate that non-overlapping regions exist on 
these enzymes, which allow separate interaction with Gga, G^a and Py subunits of 
G-proteins, although the precise domains have not yet been defined, (Taussig et al, 
1993; Taussig et al, 1994). cDNAs encoding numerous adenylyl cyclases of this 
type have now been cloned, 6  of which are from mammalian sources:
Type I from brain (Krupinski et al, 1989)
Type II from brain and lung (Feinstein et al, 1991)
Type III from olfactory specific neurons (Bakalyar and Reed, 1990)
Type IV from peripheral tissue and Brain (Gao and Gilman, 1991)
Type V from dog heart (Ishikawa et al, 1992) and rat liver and kidney 
(Premont et al, 1992)
Type VI from dog heart (Katsushika et al, 1992), rat heart, liver and kidney 
(Premont et al, 1992), Mouse S49 lymphoma cell (Premont et al, 1992b) and 
mouse hamster hybrid NCB-20 cells (Yoshimura and Cooper, 1992).
In addition, a cDNA from mouse S49 lymphoma cells that encodes a portion 
of an adenylyl cyclase related to the type II enzyme has been idendified and named 
the type VII enzyme (Kruprinski et al, 1992). Also a cDNA has been isolated from 
a human brain lilbrary that appears to partially encode a distinct species of adenylyl 
cyclase (Parma et al, 1991) and corresponding rat cDNA sequences have also been 
obtained for this form (Kruprinski et al, 1992) and have been termed type VIII.
All the mammalian adenylyl cyclase enzymes are activated by G§a. For a 
long time it was thought that inhibition of adenylyl cyclase could not be obtained 
with activated a-subunits of inhibitory G-proteins and a mechanism of hormonal 
inhibition was proposed, whereby py dimers generated by the inhibitory receptor 
quenched the activity of Gga. Inhibition was thus proposed to come about by 
removal of the stimulatory signal. However, the finding that cyc-S49 lymphoma 
cells which lacked a functional G§a  and still exhibited normal inhibitory regulation 
of adenylyl cyclase argued against this as the sole mechanism of inhibition (Katada
36
et al, 1984). It was later shown that antibodies specific to Gj2a suppressed 
receptor mediated inhibition of adenylyl cyclase in NG108-15 cells (McKenzie et al, 
1988).
The emerging picture of adenylyl cyclase regulation is extremely complex. 
In peripheral tissues such as fat, liver and heart, adenylyl cyclase subtypes are 
insensitive to Py subunits and a  subunits probably mediate hormonal effects, 
whereas in the central nervous system as well as in some endocrine, exocrine and 
epithelial cells signalling by a  and Py subunits may occur (Birnbauer, 1992).
1.5 Aims
Growth hormone has long been regarded as a lipolytic hormone however, the 
mechanism whereby it facilitates lipolysis is not fully explained. Treatment of cattle 
with growth hormone makes adipose tissue more susceptible to the lipolytic effects 
of catecholamines in vivo (Sechen et al, 1990) and in some circumstances, for 
example litter removal from lactating rats, growth hormone treatment renders 
adipocytes more responsive to catecholamines in vitro due to changes in the 
amount or activity of components of the P-adrenergic signal transduction system 
(Vernon et al, 1993). As well as acutely acting lipolytic agents, lipolysis is subject 
to acute control by antilipolytic agents, for example adenosine and prostaglandins.
Preliminary studies suggested that this antilipolytic system is chronically 
regulated by growth hormone, hence the objective of this study was to characterise 
the effects o f growth hormone on this antilipolytic system, with emphasis on 
determining at a molecular level the mechanism whereby growth hormone exerts its 
effects.
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CHAPTER TWO 
MATERIALS AND METHODS
2.1 Materials
Bovine growth hormone was a generous gift given by Monsanto Europe, 
B-1150, Brussels, Belgium, and was used in some studies, while ovine growth 
hormone NIADDK-oGH-13 (National Institute of Arthritis, Diabetes, Digestive 
and Kidney diseases, Bethesda, MD, USA) was used in some studies. All radio 
chemicals were purchased from Amersham International, pic (Buckinghamshire, 
UK) except [ P]NAD which was purchased from ICN Biochemicals Ltd. (Thame, 
Oxon, UK). All other reagents were obtained from Sigma Chemical Company 
(Poole, Dorset, UK), Gibco BRL (Renfrewshire, Scotland) or BDH (Poole, Dorset, 
UK) unless otherwise stated.
2.2 Animals
2.2.1 Sheep
Sheep were all Finn x Dorset Horn cross-breds. The animals were given 
hay and water ad libitium plus 400 g/day of a cereal mix for at least 4 weeks before 
slaughter. Both wether lambs (6-9 months old) and 3-4 year old ewes were used . 
Sheep were anaesthetised with an intrajugular injection of 20-30 ml of Sagatal 
(May & Baker, Dagenham, Essex, UK), given by Dr R.G. Vernon. The animals 
were exsanguinated when unconcious and samples of adipose tissue were removed 
asceptically and placed in isotonic saline at about 37°C and taken to the laboratory 
as quickly as possible (less than 5 minutes).
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2.2.2 Rats
Female Wistar rats from A.Tuck and Son (Rayleigh, Essex, U.K.) were 
given Labsure irradiated CRM diet (Labsure, Poole, Dorset, U.K.) and water ad 
libitum. Virgin rats used in studies described in chapter 3 weighed about 170 g; 
lactating rats used in studies described in chapter 4 weighed about 250 g while 
control, virgin rats used in chapter 4 were the same age as the lactating rats and 
weighed about 200 g. To minimise stress, animals were accustomed to handling 
before the commencement of experimentation. Injections were administered twice 
daily, at 09.00 and 17.00 h, for 2 days. On day 3 Rats were anaesthetised by an 
intraperitoneal injection of Sagatal (see Vernon et al, 1993) and adipose tissue 
taken and transported to the laboratory in isotonic saline at 37°C. Following fat 
removal the rats were killed by exanguination.
2.3 Methods
2.3.1 Preparation of sheep adipocyte membranes
Subcutaneous or omental adipose tissue was removed and transported to 
the laboratory in 0.9% (w/v) saline at 37°C as described in section 2 .2 .1 . 
Adipocytes were prepared by collagenase digestion using the method of Rodbell 
(1964). Adipose tissue (approximately 20 g) was minced in a petri-dish containing 
medium 199 (containing Earle's salts, L-glutamine, 25 mM-Hepes [4-{2- 
hydroxyethyl}-l-piperazine-ethansulphonic acid] (pH7.3) supplemented with 2mM 
acetate (final concentration 2.6 mM) and antibiotics (Penicillin G 60 |J,g/ml; 
Streptomycin sulphate 100 jig/ml; neomycin sulphate 10 pg/ml); (this is referred to 
as Medium 199), and then transferred to flasks containing 15 ml of Krebs Ringer
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bicarbonate buffer containing 1.2 mM CaC^, 120 mM NaCl, 5 mM KC1, 1.5 mM 
KH2 PO4  and 25 mM NaHCC^, supplemented with 25 mM Hepes (pH 7.4), 2 mM 
Na acetate, 0.3 mg/ml D-glucose, 1 mg/ml collagenase (type II, cat. no. 6885, 
Sigma) and 30 mg/ml BSA (dialysed and fatty acid free). The tissue was then 
digested for 45 minutes - 1 hour at 37°C in a shaking water bath. The digest was 
then passed through a plastic strainer, and the floating adipoctes washed three times 
with 30 mis of Krebs- Ringer bicarbonate containing 900 mg BSA.
Upon removal of Krebs buffer, adipocytes were lysed by addition of 15 ml 
of extraction buffer [10 mM Tris-HCL (pH 7.4), 20 mM EDTA, 0.2 M sucrose 
containing 1 pg/ml leupeptin, 0.3 mg/ml benzamidine-HCL and 100 pM phenyl- 
methylsulphonylfluoride (PMSF)] at 37°C. The suspension was vortexed for 2 
minutes, transferred to warmed 50 ml plastic (polypropylene) centrifuge tubes and 
centrifuged at 2800 rpm for 5 minutes at 22°C to minimize trapping of membranes 
within the lipid layer. The tubes were then put on ice until the fat solidified, and the 
infranatant removed and diluted to 50 ml with ice-cold 10 mM Tris/HCl pH 7.4, 
containing 90 mM NaCl and centrifuged at 32,000 rpm at 4°C for 1 hour in a 
Sorvall RC5B (SS34 rotor). The resulting membrane pellet was resuspended in 50 
mM Tris/HCl pH 7.4, containing 1 0  mM MgC^, 1 pg/ml leupeptin and 100 pM 
PMSF and then rapidly frozen to -80°C and stored in liquid nitrogen.
2.3.2 Preparation of rat adipocyte membranes
Rat adipose tissue was removed and transported to the laboratory in 0.9% 
saline at 37°C. Adipose tissue was minced in 30 mm petri-dishes and transferred to 
flasks containing Medium 199 supplemented with antibiotics (as described in 
section 2.3.1). After a 1 hour incubation at 37°C the resulting adipocytes were 
passed through a plastic strainer and washed once in medium 199 at 37°C, after
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which they were washed a further three times in TES buffer (Tris 20 mM, EDTA 
1 mM, sucrose 0.255 mM) at room temperature. Membranes were then prepared 
(Strassheim et al, 1990). The adipocytes were transferred to a 5 ml homogeniser 
where the cells were ruptured, placed in centrifuge tubes and spun at 2 , 0 0 0  rpm 
(1500 g) for ten minutes to separate the fat, the infranatant was then transferred to 
fresh tubes and spun for a further 2 0  minutes at 19,000 rpm (15,000 g). Once the 
supernatant had been discarded the pellet was resuspended in 3 ml of ice cold TES 
buffer and the tubes centrifuged at 19,000 rpm (15,000 g) for 2 0  minutes, and the 
resulting pellet was then resuspended in 1 mM Tris/ 1 mM EDTA pH 7.4 and 
frozen rapidly to -80°C and stored in liquid nitrogen.
2.3.3 Tissue Culture
Pieces of sheep adipose tissue (approximately 20 mg) were cut with 
sterilised scissors and then used immediately for the isolation of adipocytes or 
maintained in tissue culture. Tissue pieces of about 20 mg (total weight about 100 
mg) were maintained in culture at 37°C under air/CC^ (19:1, v/v) in 2  ml of 
Medium 199 containing Earle's salts, L-glutamine and 25mM Hepes (pH 7.3) and 
supplemented with 2 mM acetate (pH 7.3) and antibiotics (Penicillin G, 60 p.g/ml; 
streptomycin sulphate, 100 fig/ml; neomycin sulphate 10 ng/ml) for 24 hours 
(Wastie et al 1995). The tissue was then transferred to fresh medium 199 for a 
further 24 hours containing hormones and other additions as described in the results 
chapters. Following this second period of culture the adipose tissue pieces were 
used for membrane preparations or in lipolysis studies.
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2.3.4 Sheep Lipolysis Assay
Adipose tissue was prepared (as described above) and the rate of lipolysis 
was measured as glycerol release during a 3 hour incubation period at 37°C in 
Krebs -Ringer bicarbonate buffer (see section 2.3.1) supplemented with 25 mM 
Hepes (pH 7.3), 2 mM Na-acetate, 0.3 mg/ml D-glucose and 30 mg/ml BSA 
(dialysed and fatty acid free) as described by Vernon & Finley, (1985). The 
incubation medium was supplemented with hormones and other agents as indicated 
in the results chapters. Following incubation, 1 ml of the medium was taken and 
deproteinised by adding 300 pi of 45% (w/v) perchloric acid and following a 15 
minute centrifugation (2500 rpm), 800 pi of the resulting supernatant was 
neutralised with 85 pi KOH (5M) and 170 pi saturated KHCO3 . Following a 
further 15 minute centrifugation (2500 rpm), 800 pi of each sample supernatant 
was transferred to fresh LP3 tubes and stored at -20°C prior to the determination 
of glycerol levels.
2.3.5 Rat Lipolysis assay
Immediately after killing, parametrial adipose tissue was removed and 
adipocytes were prepared (Aitchison et al, 1982). The parametrial pads were 
removed and placed in Medium 199 with 1 mg/ml collagenase and 30 mg/ml BSA 
and adipocytes prepared as described section 2.3.2.
The resulting adipocytes (final cell number 1 0  ^ cells/ml) were incubated in
2.5 ml Medium 199 plus additions that will be detailed in the results chapters. 
Adipocytes were incubated for 60 min at 37°C. The reaction was terminated by 
addition of 0.3 ml of 45% (w/v) HCIO4  followed by deproteinisation and 
neutralisation as described in the sheep lipolysis section above.
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2.3.6 Glycerol assay
Glycerol contcentration was measured as described previously (Aitchison et 
al., 1982). Samples prepared in the lipolysis assay outlined above were used to 
determine glycerol levels. Samples were defrosted and centrifuged at 2500 rpm for 
15 minutes, following which 30 pi of each sample was placed in duplicate into a 96 
well plate with 200 pi of assay mix containing: 13.5 ml of 0.25 M triethanol 
ammonium chloride buffer pH 7.5, 2.5 ml of 2 mg/ml NAD, 2.7 ml of 5 mg/ml 
ATP, 250 pi of 1 M MgCl2, 1 2  pi Triton X-100 ( 1 0 %), 215 pi of 1 mg/ml 
diaphorase, 20 pi of 10 mg/ml Glycerol-3-phosphate dehydrogenase (G-3-PDH),
2.5 mg/ml [3-{4,5dimethylthiosal-2-yl}-2,5-diphenyl-tetrazoliumbromide] (MTT) 
and 810 pi distilled H2 0. The assay mix was prepared in a light-protected bottle 
containing a magnetic flea and was stirred at 4°C. Glycerol levels were 
determined by adding 50 pi of glycerol kinase (4 units/ml) and the plates were 
incubated at room temperature in the dark for 45 minutes. Following incubation the 
plate was read at 600nm on a Titertek plate reader. Glycerol levels were calculated 
from a glycerol standard curve that was measured on each 96-well plate over a 
concentration range of 2 -2 0 nm.
2.3.7 Ligand binding assays
'i
Binding of 1-[propyl-2,3-[ H]dihydroalprenolol (specific radioactivity 61 
3Ci/mmol), [O-methyl- H]raulwolscine (specific radioactivity 6 6  Ci/mmol) and
f \  ^(-)N -R-[G-H jphenylisopropyladenosine (specific radioactivity 36 Ci/mmol) to 
sheep (Watt et al, 1991), and rat adipocyte membranes was performed in 50 mM- 
Tris/HCl (pH 7.4)/ 10 mM MgCl2  at 37°C in a final volume of 200 pi containing 
20-200 pg of membrane protein and the appropriate radioligand prepared in 1 mM
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ascorbic acid to a final concentration of 20 nM (sheep membranes only) or up to
100 mM (rat membranes), (Malbon et al., 1978). 13 ml tubes were placed in a
water bath and 40 pi of buffer was added to each tube, followed by 40 pi of
labelled ligand. 40 pi of appropriate ligand (isoprenaline, yohimbine and PIA, in
1 mM ascorbic acid were used to assess P-adrenergic receptors, a2-receptors and
adenosine receptors respectively) or 40 pi 1 mM ascorbic acid (control) was then
added to the tubes and the reaction was initiated by addition of membrane
suspensions. Incubations were stopped after 10 mins by addition of 5 ml of ice-
cold incubation buffer. The contents of each assay tube were then rapidly filtered
under vacuum through Whatman GF/C filter discs (2.5cm diameter). The filters
were then washed with 2 x 5 ml of ice-cold incubation buffer and dried under
vacuum. Filters were then placed in 10 ml of Opti-Fluor scintillant and counted for
a radioactivity on an LKB 1215 Rackbeta liquid-scintillation counter. Assays were
performed in duplicate. Non-specific binding was determined by incubating
corresponding tubes with 100 pM -(-)isoprenaline, 100 pM-yohimbine or 100 pM-
N 6 -phenylisopropyladenosine to measure p-, a2- and adenosine receptor ligand
binding respectively. Specific binding of radioligands was defined as the total 
3 3[ H]ligand bound minus [ H]ligand bound in the presence of 100 pM competing 
ligand.
'i
For binding studies using [ HJphenylisopropyladenosine, plasma 
membranes (20-100 pg) were first resuspended in incubation buffer (50 nM- 
Tris/HCl, pH 7.4 and 1 mM MgC^) and incubated with adenosine deaminase 
(1 pg/ml) for 1 0  min at 30°C, final volume of asay mix was 70 pi (Trost and 
Schwabe, 1981). Adenosine deaminase treated plasma membranes were used 
immediately to assay adenosine-receptor binding. 20 nM ligand was sufficient to 
saturate the binding capacity of sheep fat-cell membranes whereas 100 nM ligand 
was required to saturate the binding capacity of rat-cell membranes.
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2.3.8 Protein determination
Protein was measured by the method of Bradford (1976) using the Bio-rad 
protein assay (Cat. No. 500-0006). BSA (fraction V) was used as a protein 
standard (1-5 pg standard curve). Assays were performed in 96-well microtitre 
plates and the sample volume was 50 pi. The protein standard was prepared in 
distilled T^O at a concentration of 0 . 1  mg/ml and was arranged in the first two 
lanes of each plate, with each point in triplicate. When both the standard curve and 
samples had been added, 240 pi of diluted Bio-rad protein reagent was added to 
each well. The concentrate was diluted in the ratio 1 part concentrate : 4 parts 
H 2 O. The plate was then left for 5 minutes before being read using a Titertek 
Multiskan at 620nm.
2.3.9 Preparation of bovine serum albumin
All bovine serum albumin used was fraction V, essentially fatty acid free, 
from Sigma chemical Company, Poole, Dorset, and was dialysed prior to use as 
described (Hanson & Ballard, 1968). A 10% solution of the albumin was dialysed 
over 3 days against 0.9% NaCl at 4°C. The 0.9% NaCl was changed 5 times over 
the three days. The albumin was finally dialysed for at least 6  hours against distilled 
water to remove NaCl. The dialysed solution was lyophilised and the dry powder 
stored at 4°C until required.
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2.3.10 Determination of adipocyte volume and number of adipocytes
per gram tissue
Cells were prepared and washed as described earlier (2.3.2) and samples (5 
pi) of the cell suspension were transferred to a warm haemocytometer and the 
diameter of 100 cells was measured using a Projectina microscope at 145 x 
magnification. The mean cell volume was then calculated as described by 
Girolamo et al (1971). An estimate of the number of cells per gram tissue was 
obtained by dividing the total lipid content of the tissue by the mean cell volume x 
density of lipid (where density of lipid was taken to be 1.1). For rat adipose tissue, 
the total lipid content was taken to be equal to the diy weight of the tissue. The 
means of determining the lipid content for sheep adipose tissue is described below 
in section 2.3.11.
2.3.11 Determination of lipid content of sheep adipose tissue
Adipose tissue pieces (prepared as described in section 2.3.3) were weighed 
and added to 30 ml centrifuge tubes containing two drops of 1 M HC1 in 8  ml 
CHC^/MeOH and shaken. The tubes were then left at room temperature for two 
hours. After this time 4 ml of CHCI3  was added to each tubes, the tubes were 
shaken and then left overnight at room temperature. 3 ml of 0 .8 8 % KC1 was then 
added to the tubes, the tubes were shaken and centrifuged at 2500 rpm for 15 
minutes and the two phases allowed to seperate. The upper phase was then 
removed and the lower phase was taken to dryness using a rotary evaporator. The 
remaining lipid was then dissolved in 2-3 ml of chloroform, filtered into a weighed 
scintillation vial and the chloroform was removed with air whilst the vial was on a
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heating block at 65°C. The vials containing the lipid were then left to cool and 
weighed.
2.3.12 Insulin Radioimmunoassay
The insulin RIA assay was used to determine levels on endogenous insulin 
in rat experiments following manipulation of growth homone levels. The buffer 
used in the assay comprised 0.05 M Na2 PC> 4  pH7.4, 0.15 M NaCl, 0.05% (w/v) 
sodium azide and 0.5% (w/v) BSA. The insulin standard, natural porcine insulin 
was dissolved in 10 mM HC1, diluted in RIA buffer and batched in 100 pi aliquots 
( 1 0  pg/ml) in eppendorf tubes and stored at -20°C. The first antibody, anti-bovine 
insulin antiserum, was raised in guinea pigs by D.J. Flint, Hannah Research Institue, 
and used at a final dilution in the assay at 1:20000. The second antibody was 
prepared in 140 mg ethylene diaminetetra-acetic acid (EDTA) (BDH Ltd., 
Glasgow, UK) in 15 ml RIA buffer (adjusted to pH 7.4 after adding EDTA), then 5 
pi normal guinea pig serum and 125 pi anti-guinea pig precipitating serum (Scottish 
Antibody Production Unit, Glasgow, UK) and 15 ml of 16% (w/v) polyethylene 
glycol 6000 grade (PEG) (FSA Laboratory Supplies, Loughborough, Leics. UK). 
The insulin assay was based on a method described by Vernon, Clegg and Flint 
(1981). Insulin standards ranged from 0.16 to 5 ng/ml. A volume of 100 pi was 
taken, in duplicate, for standards and samples and this was added to 1 0 0  pi of anti- 
bovine insulin antiserum to give a final antiserum dilution of 1 :2 0 0 0 0 . 1 0 0  pi of 
buffer and 1 0 0  pi antiserum was added to the zero tubes, whereas non-specific 
binding tubes received only 2 0 0  pi of buffer. After a 24 incubation at 4°C,  ^^ 1 -  
insulin was added to all tubes (100 pi: 10000 cpm). The tubes were incubated for 
24 hours at 4°C, following which 300 pi of second antibody was added and the 
tubes were incubated for a further 4 hours at room temperature. After this time the
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tubes were centrifuged at 3000 rpm for 30 minutes and the supernatant was
I O C
decanted. The protein precipitate, containing antibody-bound lz,JI-insulin, was 
counted on a gamma counter (Cobra Auto-gamma, Packard, Pangbourne, Berks. 
UK). The concentration of insulin in the samples was determined by interpolation 
from a standard curve.
2.3.13 1GF-I Radioimmunoassay
Determination of endogenous levels of rat IGF-I was achieved using IGF-I
RIA. The RIA buffer used for the assay consisted: 0.05 M Na2 PC>4 , 0 . 15 M NaCl,
0.1 mg/ml thimersal and 0.5% (w/v) BSA. The IGF-I standard (Bachem) was
dissovled in acid ethanol (250 mM HC1 in ethanol) and then diluted in RIA buffer,
batched in 1 0 0  pi aliquots (0.01 pg/pl) in ependorf tubes and stored at -20°C. The
first antibody anti-IGF-I (NIDDK and NHPP, University of Maryland School of
Medicine, USA) was stored at a dilution of 1:10, which when diluted 1 : 2 0 0  gave a
final dilution in the assay of 1:2 0 0 0 0 . The second antibody, anti-rabbit precipitating
serum (SAPU, Carluke, UK) was prepared in 140 mg EDTA in 15 ml of RIA
buffer (adjusted to pH 7.4 after adding EDTA), then 60 pi normal rabbit serum
(SAPU) and 900 pi anti-rabbit precipitating serum and 15 ml of 16% (w/v)
polyethylene glycol (PEG). IGF-I standards ranged from 0.3 to 10 ng/ml. A
volume of 1 0 0  pi was taken, in duplicate, for standards and samples and 1 0 0  pi of
anti-IGF-I was added to give a final antiserum dilution of 1:2000. 100 pi of buffer
and 1 0 0  pi antiserum was added to zero tubes, whereas non-specific binding tubes
received only 2 0 0  pi of buffer, the tubes were then vortexed and incubated at room
195temperature overnight. Following this, 100 pi I-IGF-I was added to all tubes 
( 1 0 0  pi : 2 0 , 0 0 0  cpm), the tubes were then vortexed and incubated at room 
temperature overnight. 300 pi of second antibody was then added, the tubes were
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vortexed, incubated for 4 hours at room temperature, centrifuged for 30 minutes at
3,000 rpm and the supernatant removed. The protein precipitate, containing 
195antibody bound I-IGF-I, was counted on a gamma counter (Cobra Auto­
gamma, Packard, Berks, UK). The concentration of IGF-I in the samples was 
determined by interpolation from a standard curve.
2.3.14 Standard size Polyacrylamide Gels
12% SDS/polyacrylamide gels were used to resolve proteins of both rat and 
sheep adipocyte membranes, prepared as described earlier. For 20 cm gels, 30 ml 
of a 12% separating gel containing: 10.08 ml distilled F^O, 7.5 ml Tris-HCl 
(1.5M) pH 8 .8 , 10 ml acrylamide (30%), 0.3 ml SDS (sodiumdodecylsulphate) 
( 1 0 %), 0 . 1  ml ammonium persulphate ( 1 0 %) and 2 0  p.1 tetramethylethylenediamine 
(TEMED) was cast and left to set at room temperature for about 1 hour. To 
prevent the gel drying out a thin layer of saturated butanol was added to the top of 
the gel. Once the gel was set the butanol was poured off and the gel washed 3 
times with distilled water, a 5% stacking gel comprising: 5.7 ml deionised ^ O ,
2.5 ml Tris/HCl (0.5M) pH 6.7, 1.6ml 30% acrylamide, 0.1 ml SDS (10%), 0.1 ml 
ammonium persulphate and 7.5 pil TEMED was poured, and the well-forming comb 
was carefully inserted avoiding air bubbles. Once the stacking gel had set after 
about 30 minutes, the comb was removed, the wells washed with distilled H2 O and 
the gel assembled ready for sample loading and running. The plates were then 
secured to the cooling system of the tank and tank buffer containing: 14.4 g/1 
glycine, 1 . 0  g/1 SDS and 3.0 g/1 Tris, poured into the top tank, and the main tank . 
The wells were loaded with sample using a blunt-ended Hamilton syringe, and the 
tank was placed on a stirrer the water cooling system was set in operation. As a 
means of protein size and identification a Bio-Rad (Bio-Rad Laboratories, Watford,
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Herts, UK) standard (broad range; 7,200 to 208,000 daltons) was run on each gel. 
The gels were then run at 30-40 milliamps constant current per gel for 3-4 hours.
2.3.15 Mini-gels
7.5 cm-length mini-gels in a Bio-rad mini-gel tank were used for the 
detection of Gj. 3.5 ml of seperating gel, prepared as described above were used 
with 1.5 ml of stacking gel and gels were run in about 500 ml of tank buffer at 
about 25 milliamps for approximately 1 hour. Instead of using a water cooling 
system to keep the gels from heating the tank buffer was cooled to 4°C, this was 
sufficient due to short gel- running time.
2.3.16 Western Blotting
Western blotting was performed essentially as described previously 
(Mitchell et al, 1989; Strassheim et al, 1990, 1991). While gels were running (see 
above), transfer buffer was prepared with 86.4 g glycine, 18 g Tris in 4.8 1 of 
deionised H2 O and placed in the cold room at 4°C and just prior to use 1.2 1 of 
methanol was added. Transferring of proteins from the gel to nitrocellulose paper 
was performed using a Transfer elecrophoretic transfer unit. The system was 
assembled by placing one half of a cassette in a tray containing cold transfer buffer, 
followed by a sponge, a piece of blotting paper and then the piece of nitrocellulose 
paper. The gel was then placed on top of the nitrocellulose paper and particular 
attention was paid to the removal of all air bubbles so as to ensure the transferring 
of all proteins from the gel. A further piece of blotting paper followed by another 
sponge was then overlaid and the second half of the cassette was then secured and
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the entire unit was placed in the tank containg cold transfer buffer, and the transfer
of the proteins was carried out overnight at a constant current of 130 mamps.
Following the transfer of the proteins, the nitrocellulose paper was placed in
100 ml of 2.5% Marvel blocking buffer: 2.5 g Marvel, 5 ml 1M Tris (pH 7.5), 0.9g
NaCl, O.lg azide, 100 pi Tween and 95 ml deionised H2 O. The nitrocellulose was
then left in the blocking buffer overnight at room temperature.
The blocking buffer was removed the following day and the nitrocellulose
was placed in a buffer containing the first antibody, which had been prepared in 1 %
marvel buffer: 1 g Marvel, 5 ml 1M Tris (pH 7.5), 0.9 g NaCl, 0.1 g azide, 100 pi
Tween and 95 ml deionised H2 O, on a shaker at room temperature for 4 hours.
After this 4 hour incubation the antibody was poured off and the nitrocellulose was
vigorously washed 4 times in 1% marvel solution (as above), and each wash
consisted of 5 minutes of shaking. Detection of the proteins for analysis was 
195carried out using the I - labelled protein A in 1% Marvel . The nitrocellulose
was incubated for 1.5 hours on a shaking table at room temperature, following 
175which the I was removed and the blot washed 4 times in 1% and 10 times in 
Tris buffered saline ( 2.42 g/1 Tris, 9.0 g/1 NaCl, pH 7.4). The blot was then dried 
overnight and autoradiographed at -80°C. Quantification of reactive proteins was 
achieved by y-radiation counting of excised bands or by densitometric scanning 
using a Bio-Rad 620 densitometer.
2.3.17 ADP ribosylation
Pertussis toxin ADP ribosylation of the inhibitory G-proteins in sheep 
adipocyte membranes was carried out using 70 pi of pertussis toxin 0.1 pg/ul was 
activated by incubating with 7 pi of 5 mM dithiothreitol (DTT) and 7 pi of 1 mM 
ATP for 60 minutes at room temperature. After this time the activated toxin was
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placed on ice until used. The reaction mix (per tube): 25 pi 1M NaPO^ buffer pH 
7.0, 10 pi 150 mM thymidine (made fresh in H2 O), 2 pi 50 mM ATP and 2 pi 50 
mM GTP was prepared and stored on ice prior to use. 39 pi of reaction mix was 
then added to each labelled ependorf tube with 25 pi membranes prepared as 
detailed in section 2.3.1 with 31 pi of activated pertussis toxin mix. The reaction 
was started upon addition of 7 pi [^P]NAD (5 pi unlabelled 100 pM NAD plus 2 
pi 1.4 pCi/ul NAD) and incubated in a water bath for 2 hours at 37°C. The 
reaction was halted by addition of 1 ml ice cold 50 mM Tris (containing the 
protease inhibitors PMSF 100 pM and leupeptin 1 pg/ml). The samples were then 
centrifuged at 14,000 rpm at 4°C for five minutes, the supernatant discarded and 
50 pi of lx sample buffer (0.06 M Tris, 0.06 M P-mercaptoethanol, 2% (w/v) SDS, 
10% glycerol and 0.02% (w/v) phenol red) was added, mixed and boiled for 5 
minutes. The samples were then run on a 1 0 % gel as described in section 2.3.11, 
the gel was then dried on a X gel drier following which autoradiography was 
performed overnight at -80°C.
In experiments where PIA was employed, H2 O was omitted from the 
reaction mix and PIA was added to give final concentrations of 1 - 1000 nM.
2.3.18 Adenylate Cyclase Assay
To determine levels of adenylate cyclase in adipocyte membranes the 
method of Houslay et al (1976) was used with modifications (Strassheim et al, 
1990). Sheep adipocyte membranes were prepared as described in section 2.3.1, 
with the exception that isolated adipocytes were suspended in 0.25 M sucrose, 
10 mM Tris/HCl and 3mM ATP (Strassheim et al, 1990). A stock incubation 
medium: 25 mM Triethanolamine, 5 mM MgSO^, 10 mM theophylline, 1 mM 
EDTA and 1 mM DTT was made as a 4x concentration solution and stored at
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room temperature. This stock was then be diluted 1:2 with distilled H2 O for use in 
an assay where it occupied 50% of the volume, giving a correct final concentration. 
The ATP regeneration system for the assay was prepared in 2x concentration 
incubation medium plus 1.5 mM ATP, 7.4 mg/ml creatine phosphate (Boehringer),
0.2 mg/ml creatine kinase (Boehringer) and 0.8 mg/ml BSA. To 1.5 ml eppendorf
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tubes (on ice), 50 pi regeneration system, 10 pi 10 M GTP and 10 pi other 
agents (see chapter 6 ) or 10 pi incubation medium, was added. Finally, while the 
tubes were still on ice, 30 pi of membranes at 2 pg/pl protein concentration or 30 
pi of H 2 O (control) was added and the tubes were quickly vortexed and 
immediately transferred to a water bath at 30°C for 10 minutes. At the end of the 
incubation time the reaction was stopped by placing the tubes in a boiling water 
bath for 3-4 minutes. The tubes were then cooled and centrifuged at 14,000g for 5 
minutes to precipitate the protein and the supernatant was removed and used for 
cAMP determination.
In experiments where PIA was employed, theophylline was omitted from 
the assays and the non-methylxanthine cAMP phosphodiesterase inhibitor Ro-07- 
2956 was added at 0.1 mM, together with 1 unit of adenosine deaminase/ml.
2.3.19 cAMP Binding Assay
The determination of cAMP binding was carried out as described by 
Whetton et al (1983). An assay buffer was prepared: 50 mM Tris/HCl and 4 mM 
EDTA, pH 7.4 and stored at 4°C. 10 mg of the binding protein, protein kinase 
cAMP was added to a solution of 25 ml assay buffer and 125 mg BSA, stirred and
1.1 ml aliquots were snap frozen and stored at -20°C. cAMP to be used for 
standards was stored at -20oC in 1.1 ml, aliquots at 3.2 pM. At the time of 
experimentation the aliquot was diluted 1:10 to give 320 nM cAMP which is
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equivalent to 16 pmol/50 pi, and from this concentration a serial dilution was 
carried out. [3H]cAMP was diluted in assay buffer at 2 pi 0.5 pCi/ml in 4 ml assay 
buffer and was stored on ice prior to use. The charcoal suspension used to stop the 
reaction was prepared approximately 30 minutes before use and comprised 520 mg 
activated charcoal in 20 ml assay buffer containing 400 mg BSA. The suspension 
was kept stirring on ice prior to the assay.
For the assay of cAMP binding, eppendorf tubes were placed on ice. To the 
tubes, 50 pi of membrane/ 50 pi cAMP standard, 50 pi [3H]cAMP and 80 pi assay 
buffer, were added. The reaction was started upon addition of 20 pi of binding 
protein, the tubes were vortexed and incubated in the cold room at 4°C on ice for 4 
hours. The reaction was stopped upon the addition of 100 pi of charcoal 
suspension. The samples containing the charcoal suspension must sit on ice for at 
least 90 seconds. Following this the tubes were spun at 14,000 g for 5 minutes and 
then 400 pi of supernatant (without disturbing charcoal sediment in tube) was 
removed and placed in a scintillation vial with 4 ml of Opti-fluor scintillant and 
counted for radioactivity on an LKB 1215 Rackbeta liquid-scintillation counter.
Statistics
Statistical significance of results was assessed by analysis of variance or 
Student's t-test for either paired or unpaired observations as appropriate. Unless 
otherwise stated, the results are given as means either ± SED (standard error of 
difference) or ±  SEM.
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CHAPTER THREE
STUDIES ON THE LIPOLYTIC ACTION OF 
GROWTH HORMONE IN RAT ADIPOSE TISSUE
3.1 Introduction
In several species, including the rat, growth hormone has been shown to 
decrease adiposity through changes in the rate of both lipid synthesis and also 
lipolysis (Goodman et al, 1988; Vernon and Flint, 1989; Cuneo et al, 1992; Flint 
and Gardner, 1993). Recent studies suggest that growth hormone effects on 
lipolysis are indirect and are achieved by altering the maximal response or 
sensitivity of adipocytes to acutely acting lipolytic or antilipolytic agents.
Adipocyte lipolysis is under acute regulatory control from both stimulatory 
and inhibitory agonists. The rate limiting enzyme, hormone-sensitive lipase can be 
phosphorylated and activated by cyclic-AMP-dependent kinase. Therefore 
changes in adenylate cyclase (AC) activity, which modulate cAMP levels, are 
intimately connected with the control of lipolysis (Belfrage, 1985).
AC activity can be regulated by both stimulatory and inhibitory receptors 
which exert their actions through the heterotrimeric G-proteins, G§ and Gj 
respectively. Changes in the expression of adipocyte Gj and G§ have been shown 
to occur in a number of animal models of pathophysiological states, such as 
chemically induced hypothyroidism (Milligan and Saggerson, 1990), genetic 
obesity (Strassheim et al, 1991; Begin-Heick, 1992) and insulin resistance 
(Strassheim et al, 1990, 1991; Saggerson et al, 1991; Begin-Heick, 1991), and 
also in obese humans (Ohiosalo and Milligan, 1989; Milligan and Saggerson, 
1990; Strassheim et al, 1991, Begin-Heick, 1992).
This prompted the following investigations into whether growth hormone 
can influence the regulation of lipolysis by altering the expression of Gj and Gs in 
rat adipocytes, and how this may correlate with the functioning of inhibitory 
receptors.
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3.2 Experimental Procedure
Virgin female Wistar rats (200-25Og) were handled and injections given as 
described previously in materials and methods (section 2.2). The rats received the 
following injections twice daily at 09:00 and 17:00 h: y-globulin fraction of
antiserum to rat growth hormone (anti-rGH; 150mg/injection, equivalent to 4.5 ml 
of serum), either alone or in combination with ovine growth hormone (NIADDK- 
oGH-13), 0.5 mg per injection. Control animals received carrier solutions (Madon 
et al, 1986). On day 3, between 10.00 and 11.00 h, rats were anaesthestized by 
injection of 0.5ml of Sagatal (May and Baker, Dagenham, Essex, UK), as 
previously described (Vernon et al, 1993).
Immediately after the induction of anaesthesia, samples of blood and 
parametrial adipose tissue were taken, after which rats were killed by 
exsanguination. There were ten rats in each treatment group; five were used for 
measurement of lipolysis (section 2.3.5) and five for preparation of membranes 
(section 2.3.2) to be used in receptor binding assays and western blotting for 
analysis of G-proteins.
Analysis of results
Statistical significance was assessed by analysis of variance. Unless other­
wise stated, the results are given as means either ± S.E.D (standard error of 
difference) or ± SEM.
56
3.3 Results
3.3.1 Changes in rat growth rate
The effectiveness of treatments in changing serum GH concentration was 
assessed by measuring changes in growth rate. The rats were weighed at 10.00 
hours before the injection regime commenced and then subsequently each day at 
this time over the following 48 hours. The body weight of the control group did 
not change over the 48h period of treatment (-1.22 ± 1.7g) whereas a significant 
decrease (P < 0.05) was observed with the group treated with anti-rGH (-4.5 ± 
1.7g) (Fig. 3.1). In contrast, the group receiving ovine growth hormone along 
with the anti-rGH increased body weight by 7.3 ±  1.7g (Fig. 3.1). All the values 
are mean ±  SED for 11 observations. While confirming the actions of the anti- 
rGH, these results suggest that the animals injected with oGH were receiving 
slightly higher than normal levels of GH.
3.3.2 Serum IGF-1
Effectiveness of the anti-rGH, and also of injections of oGH, were 
checked by assaying for serum IGF-1. Treatment of rats with anti-rGH alone 
significantly (P< 0.001) decreased the serum IGF-1 concentration, as compared 
with that in control animals, and concurrent injection of oGH prevented this 
decrease. Serum IGF-1 levels were 496 ng/ml for control animals, 233 ng/ml for 
anti-rGH-treated animals and 644ng/ml for anti-rGH + oGH-treated animals (SED 
= 51, n = 1 1  in each case).
3.3.3 Lipolytic response to PIA and PGEj
In the lipolysis assays the maximal stimulation of lipolysis was achieved, as 
reported previously by Vernon et al (1987), by including 0.8p.g/ml adenosine
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deaminase and 100 nM isoprenaline in the incubations. Lipolysis was then
f sinhibited in a dose-response manner using the adenosine analogue N -phenyl- 
isopropyladenosine (PIA) or prostaglandin Ej ( PGEj).
Treatment of rats with anti-rGH, either with or without oGH, had no effect 
either on basal lipolysis or on the stimulation of lipolysis by isoprenaline (Fig. 3.2). 
Basal glycerol release, measured in the presence of adenosine deaminase, was
/T
0.5 ±0.1  pmol/min per 10 cells, and 100 nM isoprenaline increased (P < 0.001) 
the level of glycerol release to 5.4 ± 0.1 pmol/min per 10^ cells (results are means 
±  S.E.M. of 15 observations ie. for all rats).
Lowering of serum GH levels by injecting rats with anti-rGH resulted in a 
significant increase (P< 0.05) in the inhibition of lipolysis induced by both 3nM and 
lOnM PIA (Fig. 3.3). This effect was prevented by concurrent injections with 
oGH. In contrast, anti-rGH had no significant effect on the inhibition of lipolysis 
by lOOnM PIA (Fig. 3.3).
Treatment with anti-rGH also significantly increased (P < 0.02) the 
inhibition of lipolysis observed with lOOnM PGE| (Fig. 3.4, Table 3.1). As 
described above, this effect was prevented by concurrent treatment with oGH. At 
levels of lpM  PGEj the apparent increase in the inhibition of lipolysis in animals 
treated with anti-rGH was not statistically significant.
These results show that GH supresses the anti-lipolytic effects of both PIA 
and PG E|, by decreasing the sensitivity of adipocytes to sub-maximal 
concentrations of these agents. However, GH appears to have little effect on the 
response of lipolysis to maximally effective concentrations of either PIA or PGEj.
3.3.4 Ligand binding to adenosine receptors
Measurement of ligand binding was performed on adipocyte membranes to 
determine if the differences in sensitivity to PIA was attributable to a change in 
receptor number. Initially receptor-binding studies were carried out using a single
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maximum concentration of [HJ-PIA at 20nM, based on the previous studies with 
sheep adipocyte membranes. The amount of [HJ-PIA bound to the membranes 
was 83.0 fmol/mg protein in the control animals, 96.7 fmol/mg protein in the anti- 
rGH treated rats and 71.0 fmol/mg protein in the anti-rGH + oGH-treated rats. 
The results are means of 5 observations where the S.E.D. was 15.5 fmol/mg 
protein, therefore indicating no significant effect of treatments.
A subsequent experiment was carried out using a range of [H J-PIA  
(Fig. 3.5, Table 3.2) and showed that maximal binding was achieved at 
concentrations of about lOOnM [HJ-PIA. No significant effect of manipulation of 
serum GH levels was observed with any concentrations of [ HJ-PIA used. These 
results suggest that the changes in sensitivity are due to a post-receptor change; 
this might be expected as sensitivity to both adenosine (PIA) and prostaglandin is 
affected.
3.3.5 Immunoblotting of a-subunits of Gjl, Gj2, Gj3 and Gs
Having determined GH has no effect on receptor number, experiments 
were carried out to look at the levels of the G-proteins as the next protein in the 
lipolytic cascade. To ascertain changes in the levels of a-subunits of individual G- 
proteins in adipocyte membranes anti-peptide antisera were used.
Rat adipocytes express three forms of Gj (Gjl, Gj2 and Gj3), which are 
distinct gene products (Milligan, 1988; Mitchell et al, 1989). They also express 
two forms of G§ (42 kDa and 45 kDa), derived by alternative splicing (Robishaw 
et al, 1986; Strassheim et al, 1990, 1991). Injection of rats with anti-rGH had no 
effect on the expression of the a-subunit of Gj3 or on the 45 kDa and 42 kDa 
a-subunit forms of G§, and this was also the case in those animals treated with 
anti-rGH + oGH (Fig. 3.6, Table 3.3). The similarity in size of the a-subunits of 
Gjl (a-G jl; 41 kDa) and Gj2 (a-G|2; 40 kDa) did not permit their separation 
under the electrophoresis conditions used. The antiserum used , SGI, recognises
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both a-Gj 1 and a-Gj2 and therefore detected only one immunoreactive band which 
presumably represents both of these a-subunits. Injection of rats with anti-rGH 
resulted in a 3 + 0.27 increase (P< 0.001; mean ±  S.E.M. for 5 observations) in the 
amount of a-Gjl plus a-Gj2, as detected by antiserum SGI, in adipocyte 
membranes (Fig. 3.6, Table 1). This increase was prevented by concurrent 
administration of oGH. Immunoblotting with 11C, which recognises only a-G jl, 
showed that anti-rGH had no effect on the amount of this a-subunit (Fig. 3.6, 
Table 1).
From these results it can be concluded that the increase in intensity of the 
immunoreactive band, revealed by antiserum SGI, after injection of rats with 
anti-rGH, can be attributed entirely to an increase in a-Gj2. This suggests that the 
increase in Gj2, elicited by depletion of endogenous rat GH, must be over 3-fold. 
These results then demonstrate that GH specifically and profoundly suppresses the 
amount of a-Gj2 in adipocyte membranes.
3.4 Discussion
Growth hormone has long been regarded as a lipolytic hormone, but the 
mechanism whereby it increases lipid mobilisation in fat cells has been a subject of 
considerable controversy. There is now growing support for the theory that GH 
alters the responsiveness of fat cells to acutely-acting lipolytic agents, and that this 
indirect effect may be the major mechanism whereby GH enhances lipolysis.
Measurement of serum GH itself is problematic, as the hormone is secreted 
in a highly pulsatile manner (Jannson et al, 1985) and the anti-rat GH serum 
interferes with the radioimmunoassay. In this study, the changes measured in 
growth rate and serum IGF1 indicate that significant changes in serum GH were 
being achieved, as found in previous studies using this antiserum and GH-therapy 
regime (Flint and Gardner, 1993; Vernon et al, 1993).
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This study provides further evidence for GH modulating lipolysis by 
altering the ability of acutely acting factors to influence the process, and suggests 
that a major efect of GH is on the anti-lipolytic signalling system which operates 
via Gp In this study using non-lactating virgin rats, GH treatment failed to alter 
the maximum response to p-agonists. This is in accordance with other studies that 
have shown that GH treatment failed to increase the response to P-agonists in 
lactating rats (Vernon et al, 1991) and cows (Lanna et al, 1992). These results 
may therefore imply that the only effect on the system as a whole is on the anti­
lipolytic signalling system. However, GH has been shown to affect the response to 
P-agonists in other states: both litter-removal form lactating rats (Vernon et al, 
1991, 1993) or cessation of lactation by removal of both serum prolactin and GH 
(Barber et al, 1992) leads to a substantial fall in the response to p-agonists which is 
prevented by concurrent treatment with GH (but not prolactin).
In the present study show that the predominant effect of GH is on the 
sensitivity to anti-lipolytic agents which act via G-. However various observations 
suggest that GH can have a spectrum of effcts on the Gs-Gj-based signalling 
systems which regulate lipolysis. In lactating rats in which lactation was abruptly 
and completely curtailed either by litter removal (Vernon et al, 1987) or by 
endocrine manipulation (Barber et al 1992), GH markedly suppressed maximum 
response to PIA (sensitivity was not measured). In contrast, by giving GH 
injections or injections to anti-rGH, and thereby varying serum GH, showed that 
the effect on response to maximal concentrations of PIA in normally lactating rats 
(Vernon et al, 1987) and lactating cows (Lanna et al, 1992), was only small. 
However in lactating cows, as in this study, GH increased sensitivity to sub- 
maximal concentrations of PIA.
The possibility that varying GH serum may affect receptor number was 
investigated by looking at the effect of adenosine binding using [ HJ-PIA. These 
studies show that GH has no affect on adenosine binding, therefore indicating no 
change in the number or affinity of adenosine receptors.
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The results from the lipolysis experiments using PIA and PGEj showed 
that manipulation of endogenous GH levels revealed a decrease in sensitivity to 
both agonists (Figs. 3.3 and 3.4). PIA and PGEj couple to distinct receptors, 
therefore the results suggest that GH modifies a post-receptor step, common to 
both agents. As both receptors presumably exert inhibitory action on adenylate 
cyclase by coupling to the inhibitory G-protein, Gj, it was thought that changes in 
this protein might account for the changes in anti-lipolytic effects.
An examination of the amounts of the various G-proteins of adipocyte 
membranes were determined by immunoblotting following separation by SDS gel 
electrophoresis, using antisera which are specific for the various isoforms of Gs 
and Gp except for Gj2 where the antisera used recognised both Gjl and Gj2. The 
immunological analysis of the adipocyte membranes revealed that treatment of 
animals with anti-rGH enhanced, by more than 3-fold, the amount of a-Gj2, but 
had little effect on the amounts of a-Gjl, a-Gj3 and oc-G§. Prevention of the 
levels of a-Gj2 were achieved upon administration of oGH, a treatment which in 
itself did not alter the levels of the other G-proteins. Therefore the observation 
that GH down-regulates the levels of a-Gj2 in adipocyte membranes provides an 
explanation for the decreased sensitivity to the anti-lipolytic agonists, PIA and 
PGEj, seen in adipocyte membranes.
Therefore GH appears to affect a specific form of Gj, that being Gj2, of the 
G-protein family. Various investigations have suggested that Gj2 is responsible for 
the inhibition of adenylate cyclase in physiological systems. Studies carried out by 
McKenzie and Milligan (1990) showed that the 8 -opoid receptor of mouse 
neuroblastoma x rat glioma hybrid cells (NG108-15) interacts directly and 
specifically with Gj2 to cause inhibition of adenylate cyclase. Other studies with 
platelet membranes identified Gj2 as the dominant mediator of cyclase inhibition 
(Simonds et al, 1989). Thus the data obtained in this study imply that both the 
adenosine and PGEj receptors exert inhibitory effects by coupling to Gj2, although 
it cannot be ruled out that they may also react with Gjl and/or Gj3.
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The similar maximal degree of inhibition of lipolysis by PIA and PGEj, 
achieved in adipocytes from control and GH- deficient rats (Fig. 2 and Fig. 3) 
could be explained if the receptors for these agonists couple to a pool of Gj2 
which, in itself, is of sufficient size, in both groups of animals to achieve maximal 
inhibition of lipolysis.
The use of anti-rGH to deplete GH levels would seem a more reliable 
indicator of events when looking at the GH-deficient state of the animal. Previous 
studies by Goodman et al (1988) looked at levels of G-proteins in 
hypophysectomized rats and found increased intensity of a 40 kDa band labelled by 
pertussis toxin-catalysed ADP-ribosylation. The 40 kDa band in this case could 
have represented the a-subunits of Gjl, Gj2 , Gj3 and Go, all of which are 
expressed in rat adipocytes and exhibit similar molecular sizes of about 40 kDa 
(Milligan, 1988; Mitchell et al, 1989). While these results may indicate a 
supression of inhibitory G-protein levels by GH, the number of endocrine 
deficiences induced by hypophysectomy makes a precise interpretation of the 
results difficult. Further problems arise when trying to resolve ribosylated forms of 
G-/Gq on gels and the fact that changes in dissociation of G-protein subunits can 
alter their ability to be ADP-ribosylated by pertussis toxin. Therefore the use of 
anti-rGH to deplete GH specifically and oGH to replace it is a simpler and more 
reliable way of looking at GH effects, and suggests that GH deficiency is a 
principal cause in the changes seen in G-protein expression.
In conclusion, these studies have demonstrated that GH, in vivo, 
specifically suppresses the levels of a-Gj2 in rat adipocytes and this leads to an 
attenuated response to the anti-lipolytic agents PIA and PGEj. This will 
contribute to the ability of GH to decrease body fat mass. Other studies have 
shown that in several animal models of genetically acquired obesity (Strassheim 
et al, 1991; Begin-Heick, 1992) and in obese humans (Ohisalo and Milligan, 1989) 
the levels of Gj and Gs in adipocytes are lowered. The results from this study 
would then also indicate that G-protein expression in adipocytes are important in
63
determining fat mass, and that modulation of these proteins can lead to profound 
changes in body fat composition.
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C h an g e  in r a t  weight resul t ing f rom  e a c h  t r e a t m e n t
1 0  -i
Contro l  ArGH ArGH + GH
Figure  3.1 Rats  w e re  in jec ted  tw ice  daily fo r  2 days  with
with e i the r  saline (contro ls) ,  anti r a t  GH (ArGH) or  anti  r a t  
GH + ovine GH (ArGH + GH). C h a n g e s  in body  weigh t  o v e r  
th e  48h  per iod  of t r e a t m e n t  w e r e  m e a s u r e d .  Resu l t s  a r e  the  
m ean s  + SED of 11 o b se rv a t io n s .
Basal and maximally-stimulated lipolysis of rat adipocytes
8  -I
maximal
control ArGH ArGH + GH
Figure 3.2 Adipocytes were prepared from ra ts  t re a te d  as 
decsribed in legend to Fig 3.1. Glycerol re lease  was m easured, 
in the presence  of 0.8 ug/mi adenosine deaminase and for 
maximal conditions, plus 100 nM isoprenaline. Results a re  the 
means + SEM of 5 observations.
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Figure 3.3 Adipocytes were p repared  from ra ts  t r e a te d  as 
in Fig 3.1. Glycerol re lease  was m easured, in the p re se n c e  of 
0.8 ug/ml adenosine deaminase, 100 nM isoprenaline and the 
indicated concentration  of PIA, as described  in the experimental 
section. Results a re  the means of 5 observations, and the  SED 
for comparing values at the same PIA concentra tion  is 10.15.
Effect of PGE1 on Isoprenaline-stimulated lipolysis 
following manipulation of GH levels in vivo in virgin ra ts
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Figure 3.4 Adipocytes were prepared from ra ts  t re a te d  as described 
in legend to Fig 3.1. Glycerol release  was meaured, in the p resence  
of 0.8 ug/ml adenosine deaminase.100 nM isoprenaline and the indicated 
concentration of PGE1, as described in the experimental section. 
Results are means of 5 observations and the SED for comparing values 
at the same PGE1 concentration is 7.3.
Table 3.1 Effect of varying serum GH in vivo on inhibition of isoprenaline- 
stimulated lipolysis by PGEj in vitro
Adipocytes were prepared from rats injected with anti-rGH, with or without oGH, or 
carrier solutions. Glycerol release was measured, in the presence of indicated 
concentrations of PGEj as described in the legend to Fig. 3.4. Results are the means 
of 5 observations and the SED for comparing values is 7.3; a and b indicate that the 
value is significantly different from the appropriate value for rats which received 
carrier solutions (P < 0.02) or anti-rGH (P <0.01) respectively.
Glycerol release (% inhibition)
Injection PGEj^ concentration 100 nM 1000 nM
Carrier solutions 50.6 70.4
Anti-rGH 70.4a 78.8
Anti-rGH, oGH 40.0b 64.0
E ffe c t  of varying GH c o n c e n t ra t io n  on th e  ability 
of a d ip o cy te  m em branes  to  bind 3 H-P1A
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Figure 3.5 Rats  w e re  in jec ted  tw ice  daily fo r  2 day s  as  d e s c r ib e d  
in legend  to  Fig 3.1, a f t e r  which they  w e re  killed, a d ip o c y te  m e m b ra n e s  
p r e p a r e d  and the  ability of m em branes  to  bind c o n c e n t ra t io n s  of PHIPIA 
w as a s s e s s e d .  Each value is the  m ean of 3 s e p e r a t e  o b s e rv a t io n s .  SED 
ra n g e  from  5.2 fo r  1 m M 3 H-PIA to  5 0  fo r  100  nM °H -P IA .
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Figure 3.6 Im m unoblotting of G-protein a-subunits in adipocyte m em branes
(a) Detection of a-Gil with antiserum I1C (10 ^ g  per track), (b) Detection of a-G il plus a-Gi2 
with antiserum SGI (2.5 /ug per track), (c) Detection of a a-Gi3 (10 per track). (d)Detection 
of the 42 kDa and 45 kDa forms of a-Gs with antiserum CS1 (30 iug  per track). Adipocyte 
membranes were prepared from rats injected with (1) carrier solutions, (2) anti-rGH plus oGH 
or (3) anti-rGH alone. Immunoblotting was performed as described in the material and methods 
section. Data shown are typical of experiments done five times using membranes from different 
rats.
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CHAPTER FOUR
STUDIES ON THE LIPOLYTIC ACTION OF GROWTH 
HORMONE IN LACTATING RAT ADIPOSE TISSUE
4.1 Introduction
Lactation usually results in a partial depletion of the lipid reserves of white 
adipose tissue, which are susequently restored on removal of the litter or during 
natural weaning (Vernon and Flint, 1984). The restoration of lipid reserves in the 
rat after litter removal is of interest because it is associated with a transient fall in 
the lipolytic response to catecholamines (Vernon and Finley, 1986), which may be 
due to a defect in growth hormone action (Vernon et al, 1987 ). Curiously despite 
there being a loss of lipid from adipocytes during lactation in the rat, the response 
and sensitivity to the lipolytic effects of catecholamines is unchanged but response 
to adenosine is increased (Aitchison et al, 1982; Vernon and Finley, 1986; Vernon 
et al, 1995). Response to adenosine decreases slowly on litter removal (Vernon 
and Finley, 1986) and this decrease is markedly accelerated by treatment with 
growth hormone, but not prolactin (Vernon et al, 1987). Effects of litter removal 
on the lipolytic response to catecholamines can be mimicked by treating rats with 
antiserum to rat growth hormone plus bromocriptine (to lower serum prolactin) 
(Vernon et al, 1987; Barber et al, 1992).
In light of the results obtained in chapter 3 (Doris et al, 1994) showing the 
inhbitory G-protein Gj as a target of growth homone action it was decided to 
investigate and identify the components involved in response to growth hormone 
treatment in lactating rats and in rats in which lactation had been prematurely 
terminated. The study was carried out to determine if changes are due to 
alterations in the amount of G-, or in the case of adenosine, receptor number and to 
see if the increased response to adenosine (PIA) seen during lactation is due to a 
change in the amount of a component of the antilipolytic signal transduction 
system.
65
4.2 Experimental procedure
Wistar rats (A. Tuck and Son, Rayleigh, Essex, UK) were fed on Labsure 
irradiated CRM diet (57% carbohydrate, 18% protein, 2.4% fat; Labsure, Poole, 
Dorset, UK) and water ad libitum. They were mated 2-3 months of age, and the 
number of pups per mother was adjusted to ten within 24 h after birth. Injections 
were begun on days 10-14 of lactation. Four groups of lactating rats were used: 
some lactating rats were injected with a y-globulin fraction of antiserum to rat 
growth hormone (220 mg/injection, equivalent to 4.5ml antiserum) plus 
bromocriptine (500 pg/injection), some were injected as mentioned and were also 
given 1.0 mg of sheep growth hormone (a gift from NIADDK, Bethesda, MD, 
USA), the third group were injected with growth hormone only and the fourth 
group of controls were injected with a carrier solution (Madon et al, 1986). For 
litter-removal rats one group were injected with growth hormone as described 
earlier and the second group of controls were injected with carrier solutions, 
starting at the time of litter removal. Control age-matched, virgin rats were 
injected with carrier solutions only. All injections were subcutaneous and were 
administered twice daily at 09:00 and 17:00 h for two days: rats were not injected 
at 09:00 h on day 3 and were anaesthetized. Immediately after induction of 
anaesthesia, samples of blood and parametrial adipose tissue were taken, after 
which rats were killed by exsanguination. There were ten rats in each treatment 
group; five were used for measurement of lipolysis and five for preparation of 
membranes to be used in receptor binding studies and G-protein concentration 
determination (Chapter 2, sections 2.3.4, 2.3.7 and 2.3.16 respectively).
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4.3 Results
4.3.1 Litter weights
To determine effectiveness of the treatments litter weights were measured 
at lO.OOh each day at time of injections. The litter weight of the lactating rats 
increased by 22.7 ±2.18 g over the 48 h, treatment of lactating rats with growth 
hormone showed a litter weight gain of 23.4 ± 1.29 g (Fig. 4.1). Treatment with 
anti-rGH plus bromocriptine resulted in a smaller (P < 0.01) increase in litter weight 
of 3.71 ± 1 .32g  and replacement therapy with ovine growth hormone resulted in an 
intermediate increase in litter weight of 12.86 ±  0.58 g (Fig. 4.1). Therefore, 
treatment of lactating rats with growth hormone appeared to have no effect on pup 
litter weights. However, growth hormone replacement partially reversed the 
effects of bromocriptine and anti-rGH indicating a positive response to the 
hormone.
4.3.2 Serum IGF-I and Insulin levels
Lactation reduced serum IGF-I concentration and this was decreased 
further by treatment of rats with anti-rGH plus bromocriptine for 2 days (Table 
4.1). In contrast, two days after litter removal, the serum IGF-I levels were 
increased although not back to levels found in vigin rats (Table 4.1). Treatment 
with growth hormone increased serum IGF-I concentrations in litter removed rats 
and in rats treated with anti-rGH plus bromocriptine (Table 4.1). Growth hormone 
treatment was less effective in lactating rats, and although a significant effect 
(P < 0.05) was apparent when log transformed values were analysed, the level 
achieved was significantly less than found in rats in which lactation had been 
terminated either by litter removal or endocrine manipulation.
Lactation had no apparent effect on serum insulin concentrations, but litter 
removal showed an increase in serum insulin levels, while treatment with anti-rGH
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plus bromocriptine resulted in an intermediate value (Table 4.1). Treatment with 
growth hormone had no effect on serum insulin concentrations (Table 4.1).
4.3.3 Basal and Maximally stimulated lipoysis
Basal lipolysis was increased by lactation (P < 0.01) but was seen to return 
to the levels seen in virgin rats upon litter removal or treatment with anti-rat growth 
hormone plus bromocriptine. Treatment with growth hormone had no effect on the 
levels of basal lipolysis (Table 4.2).
Maximal stimulation of lipolysis was achieved, as reported previously 
(Vernon et al, 1987), by including 0.8 pg/ml adenosine deaminase and 100 nM 
isoprenaline in incubations. Lactation itself had no effect on maximal lipolysis 
(Table 4.2). At maximal lipolysis, litter removal and treatment with anti-rat growth 
hormone plus bromocriptine resulted in a significant decrease in lipolysis 
(P < 0.05). ANOVA showed that growth hormone increased the maximal rate of 
lipolysis (P < 0.005) (pooled data for all states) (Table 4.2). Comparison of 
individual treatment means showed a significant effect of growth hormone with 
lactating rats treated with anti-rGH plus bromocriptine. Analysis of log 
transformed data also showed a significant (P < 0.05) effect of growth hormone in 
litter removed rats.
4.3.4 Lipolytic response to PIA
Maximum stimulation of lipolysis was achieved by including 0.8 pg/ml 
adenosine deaminase and 100 nM isoprenaline. Lipolysis was then inhibited in a 
dose-response manner using PIA (1 to 100 nM). A concentration of 100 nM was 
found previously to induce essentially maximum inhibition in adipocytes from 
lactating rats (Vernon et al, 1993) and this is apparent in the present study if results 
are expressed on a linear scale. Lactation increased the maximum response to PIA
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(P < 0.05) (Fig. 4.2), and the response was further increased by either litter removal 
or treatment with anti-rGH plus bromocriptine (P < 0.05) (Fig. 4.2). Sensitivity did 
not change with state (ED^q mean pooled values for all states = 20.4 ±3 .3  nM); 
treatment of lactating rats with anti-rGH plus bromocriptine resulted in an apparent 
decrease in sensitivity but was not significant (ED^q = 24.8 nM). Treatment with 
growth hormone had no effect on the inhibition of isoprenaline-stimulated lipolysis 
by PIA in adipocytes from lactating rats (Fig. 4.2), but growth hormone markedly 
decreased PIA induced inhibition in adipocytes from either litter-removed or anti- 
rGH plus bromocriptine treated rats (Fig. 4.2). Treatment with growth hormone 
had no apparent effect on sensitivity to PIA.
4.3.5 Lipolytic response to Prostaglandin Ej
In contrast to the effect of PIA, lactation had no effect on the ability of 
prostaglandin Ej (PGEj) to inhibit isoprenaline-stimulated lipolysis (Fig. 4.3). 
However, the inhibition was enhanced (P < 0.05) by litter-removal or treatment of 
rats with bromocriptine and anti-rGH (Fig. 4.3). As found with PIA treatment, 
treatment of lactating rats with growth hormone had no effect on inhibition of 
lipolysis by PGEj, but markedly suppressed the antilipolytic effect of PGEj in the 
litter removed and anti-rGH plus bromocriptine treated rats (Fig. 4.3); indeed after 
growth hormone treatment the degree of inhibition induced by PGEj in these 
groups of rats was less than that found in either growth hormone-treated or 
untreated lactating rats.
4.3.6 Ligand binding to adenosine receptors
Measurement of ligand binding was carried out using rat adipocyte 
membranes to ascertain if the changes in response to PIA was due to changes in 
levels of receptor numbers. Studies by Doris et al, (1994) showed that, essentially
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maximum binding is achieved with [ H]-PIA 100 nM, therefore in the present 
study the number of adenosine receptors was assessed by measuring the binding of
'I
[ HJ-PIA to adipocyte membranes using two concentrations of PIA, 20 nM and 
100 nM. Lactation, treatment of lactating rats with bromocriptine and anti-rGH or 
litter-removal had no effect on PIA binding (Table 4.3), but ANOVA showed that 
growth hormone did decrease binding to membranes from litter removed rats 
(Table 4.3). The results are the means of 5 observations.
4.3.7 Immunoblotting of a-subunits of Gj and Gs
The amounts of GTP-binding protein a-subunits were determined by 
immunoblotting following seperation by SDS gel electrophoresis. Lactation, litter 
removal and treatment with anti-rGH plus bromocriptine had no effect on the 
amount of Gjl+2 or either isoform of Gs (Table 4.4). Similarly treatment of rats 
with growth hormone had no effect on the amounts of Gjl+2 or either isoform of 
G§ (Table 4.5). These results differ from those of Doris et al (1994) that showed 
that treatment of virgin rats with antiserum to growth hormone increased the levels 
of the inhibitory G-protein Gj2.
4.4 Discussion
The present study was carried out to investigate further the effects of 
growth hormone on the Gj-based antilipolytic system in the lactating rat. In 
addition the opportunity was also taken to explore the molecular basis for the 
enhanced response to antilipolytic factors during lactating (Vernon et al, 1983) and 
premature cessation of lactation in rats (Vernon et al, 1987).
This study shows that, in the rat, the increased response to antiloplytic 
factors during lactation does not appear to be due to either an increase in the 
number of receptors in the case of adenosine or a change in the amount of Gjl plus
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G-2. As response to prostaglandin Ej is also enhanced, this would suggest a 
change in some common component of both the adenosine and prostaglandin E 
systems, probably Gj. An increased response to adenosine is also found in 
lacatating sheep (Vernon and Finley, 1985; Vernon et al, 1995) with no change in 
the number of adenosine receptors observed, however, a small increase in the 
amount of Gjl and Gj2 was found (Vernon et al, 1995). As Gj activity is known to 
be subject to phosphorylation by both protein kinase A and protein kinase C 
(Morris et al, 1994), a more subtle change such as this may account for the 
increased ability of adenosine and prostaglandin Ej to inhibit lipolysis during 
lactation in the rat.
Effects of lactation on the amount of G§ isoforms has not been described 
previously for rats, but in studies with lactating sheep (Vernon et al, 1995), a 
significant increase in the amount of the 42 kDa form was found, in omental 
adipose tissue (also an abdominal depot). However in sheep, unlike rats (Vernon 
et al, 1993), lactation increases both the lipolytic response and sensitivity to 
P-adrenergic agonists (Vernon and Finley, 1985; Vernon et al, 1995).
The decrease in maximum lipolytic response to isoprenaline on either litter 
removal or treatment with anti-rGH plus bromocriptine agrees with previous 
studies (Vernon et al, 1987; Barber et al, 1992), but the lack of effect of litter 
removal on the amounts of Gj is in contrast with the studies of Ros et al (1992) 
who reported a decrease in the amount of both Gj (isoforms 1 plus 2) and Gg upon 
litter removal. However, the latter observation at least is perhaps surprising as the 
litter removal has no effect on the ability of isoprenaline to activate protein kinase 
A, so signalling through G§ would not appear to be altered in this state (Vernon et 
al, 1993). It would appear that the diminished lipolytic effects of P-agonist is due 
to a failure of hormone sensitive lipase translocation to the lipid droplet (Vernon et 
al, 1993).
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The present study also shows that the ability of growth hormone to 
modulate signalling through the Gj-based antilipolytic system is species specific 
and depends on the physiological state of the animal.
Serum growth hormone levels were assessed indirectly by weighing litters 
and determining serum IGF-I and insulin levels. Litter weights were unaffected by 
treatment of lactating rats with growth hormone but when both growth hormone 
and prolactin are removed using antiserum to growth hormone and bromocriptine 
respectively, litter weight gain dropped dramatically, an effect that was partially 
relieved upon the addition of growth hormone and therefore indicated a response to 
growth hormone treatment. These results were also reflected in the serum 
concentrations of IGF-I and this was also evident in litter removed rats.
In contrast to a previous study in lactating cows (Lanna et al, 1995), 
chronic treatment of lactating rats with growth hormone had no effect on maximum 
response or sensitivity to PIA, thus showing clearly that there is a species difference 
in this effect of growth hormone. The reason for the difference is unclear but could 
reflect the much higher mean serum growth hormone concentration in rats than in 
cattle, even when the latter are lactating (Harvey and Daughaday, 1995).
In contrast to lactating rats, the ability of growth hormone to decrease the 
ability of both PIA and PGEj to inhibit lipolysis was markedly enhanced by 
premature termination of lactation, either by litter removal or by endocrine 
manipulation. In these rats, growth hormone treatment decreased inhibition by 
these antilipolytic agents to levels lower than that found in untreated lactating rats 
so that the levels of inhibition achieved were at least that seen in virgin rats. This 
would suggest that the ability of growth hormone to exert its effects in lactating 
rats is prevented by an unknown factor; the identity of this putative factor would 
not appear to be prolactin as neither treatment of lactating rats with bromocriptine 
alone nor treatment of litter removed rats with prolactin had any effect on the 
ability of PIA to inhibit lipolysis (Vernon el al, 1987).
72
The diminished ability of antilipolyltic agents to inhbit lipolysis after growth 
hormone treatment in rats in which lactation is prematurely terminated does not 
appear to involve a change in either the number of adenosine receptors or the 
amount of G* 1 plus Gj2 . These results are consistent with studies in castrated male 
sheep (Chapter 5; Doris et al, 1995) suggesting that a change in activity of one of 
these components is involved. However, these findings contrast with those 
outlined in Chapter 3 of this thesis that showed that lowering growth hormone with 
a specific antiserum in virgin rats markedly increased the amount of Gj2. It is 
unclear why treatment of bromocriptine-treated rats with this same antiserum to 
growth hormone should have no effect on the amount of Gjl plus G-2, but 
presumably this reflects other endocrine differences in these states.
Interestingly, it would appear that in rats, at least the amount of G- 
modulates sensitivity to PIA and prostaglandin E j, whereas a maximum response to 
these agents is under different, more subtle control involving no change in protein 
concentration but probably involving covalent modification.
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E ffect of growth hormone treatm ent on ra t litte r weights
30  -i
LG LBA LBAG
Figure  4.1 L it te rs  from  L ac ta t in g  r a t s  (L)f lac ta t in g  r a t s  t r e a t e d  fo r  
2 day s  with GH (LG), lac ta t in g  r a t s  which had b e e n  t r e a t e d  with ArGH 
plus b ro m o cr ip t in e  (LBA)fo r  t r e a t e d  with ArGH plus b ro m o c r ip t in e  plus 
s h e e p  GH (LBAG), w e re  w eighed  b e fo r e  and a f t e r  4 8 h  t r e a tm e n t s .  
R esu lts  a re  the  m eans  + SEM of 10 o b s e rv a t io n s .
Table 4.1 Effect of growth hormone treatment on serum IGF-I and Insulin 
levels
Blood samples was obtained from virgin rats, lactating rats, lactating rats which had 
been pretreated for 2 days with antiserum to rat growth hormone (ArGH) plus 
bromocriptine (Br), and lactating rats 2 days after litter removal, treated with or 
without sheep growth hormone or carrier solution. Serum IGF-I and insulin was 
measured (sections 2.3.13 and 2.3.12); results are the means of 10 observations ± 
SEM (from analysis of variance). Values within a column which do not have the 
same superscript (a, b, c, d) differ significantly (P < 0. 05).
State___________ Treatment__________ IGF-T (ng/mll_________ Insulin (ng/mlt
Virgin carrier 555° ±31 0.27a ±  .061
Lactating carrier 337ab±46 0.28ab ±  .055
Lactating GH 466a ±46 0.20a ±.054
Lactating ArGH + Br 283b ±48 0.41bc ±  .058
Lactating ArGH + Br + GH 653c ±46 0.3l ab ±  .054
Litter removed carrier 448a ± 46 0.54° ±.054
Litter removed GH 777c ±48 0.57° ±  054
Table 4.2 Effects of lactation, litter removal and varying serum GH
concentration on basal and maximal lipolysis
Adipose tissue was obtained from virgin rats, lacatating rats, lactating rats which 
had been pre-treated for 2  days with an antiserum to rat GH (ArGH) plus 
bromocriptine, and lactating rats 2  days after litter removal treated, with or without 
sheep GH. Glycerol release was measured in the presence of 0.8 pg/ml adenosine 
deaminase (basal) or adenosine deaminase plus 1 0 0  nM isoprenaline (maximal). The 
results are the means of five observations and the SEM is determined by analysis of 
variance of all values, except for virgin rat where n = 4. Values in the same column
without the same superscript a and b are significantly different (P < 0.05).
Phvsiological state Basal SEM Maximal SEM .
Lactating 0.25a 0.025 3.80a 0.41
Litter removed 0 . 1 1 b 0.025 2 .0 0 b 0.41
Lactating + ArGH + Br 0.17ab 0.025 2.28b 0.41
Virgin 0.14ab 0.028 3.1 lab 0.46
State__________________________Basal_________________ Maximal
-GH GH -GH +GH
Lactating 
Litter removed 
Lactating + AGs + Br
0.25a 
0 . 1  l b 
0.17b
0.24a 
0.14b 
0.17b
3 8 oab 
2 .0 0 b 
2.28b
4.50a 
2 .8 8 bc 
3.51ac
SEM 0.025 0.025 0.39 0.39
Effect of PIA on Isoprenaline-stimulated lipolysis 
in lactating and litter removed ra t  adipose tissue
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Figure 4.2 Adipose tissue was obtained from virgin rats, lactating rats, 
lactating rats  trea ted  with GH (LG), or with bromocriptine plus ArGH 
(LBA), or LBA rats  t rea ted  with GH (LBAG), and li t te r-rem oved  rats  (LR) 
or LR rats trea ted  with GH (LR + GH). Lipolysis was measured in the 
p resence of 0.8 ug/ml adenosine deaminase and isoprenaline 100 nM 
and the concentration of PIA indicated above. Results are the means 
+ SEM of 5 observations.
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Figure 4.3 Adipose tissue was obtained from virgin ra ts ,  lactating ra ts ,  
lactating ra ts  t r e a t e d  awith GH (LG), or with bromocriptine plus anti- rGH 
(LBA), or LBA ra ts  t r e a te d  with GH (LBAG), and l i t t e r - r e m o v ed  ra ts  (LR) 
or LR ra t s  t r e a te d  with GH (LR + GH). Lipolysis was m easured  in the 
p r e s e n c e  of 0.8 ug/ml adenosine deaminase and isoprenaline 100 nM 
and the  concentra tion  of PGE1 indicated above. Results are  the  means 
of 5 observations  and the SED for comparing values is 7.20.
Table 4.3 Effects of lactation, litter removal and varying serum GH
concentration on adenosine receptor number in the rat
Adipose tissue was obtained from virgin rats, lactating rats, lactating rats which had 
been pre-treated for 2 days with an antiserum to rat GH (ArGH) plus bromocriptine, 
and lactating rats 2 days after litter removal treated, with or without sheep GH. 
Adipocyte membranes were prepared as described in the experimental section and 
levels of adenosine receptors were determined using [ H]-PIA. The results are the 
means of 5 observations and the SEM was determined by analysis of variance of all 
values. Values without the same superscript a and b are significantly different 
(P < 0.05).
Physiological state ffmol ligand bound/
mg .of protein)
20 nM 
[3 H]PIA
100 nM 
[3 H]PIA
SEM
Lactating 36.5 62.3 10.75
Litter removed 28.4 47.6 10.75
Lactating + ArGH + Br 2 2 . 8 50.0 10.75
Virgin 28.9 50.7 10.75
State (fmoliigand bound/ -GH_____________+GH
mg-Qf protein)
Lactating 49.4a 31.9ab
Litter removed 38.0ab 2 2 .5b
Lactating + AGs + Br 36.4ab 51.3a
SEM 5.85 5.85
Table 4.4 Expression of G-protein a-subunits in adipocyte membranes
Adipocyte membranes were prepared from lactating rats, lactating rats which had 
been pre-treated for 2 days with an antiserum to rat GH (ArGH) plus bromocriptine 
(Br), and lactating rats after litter removal. Levels of a-subunits of G-proteins, 
detected by immunoblotting, were determined by counting y-radiation of excised 
bands. Results are the means ± SEM of 4 (virgin) or 5 (rest) observations.
Arbitrary units / mg protein
State G-protein.... Gjl+2 G^ (45kDa)_________(42kDa)
Litter removed
Lactating 655 ±127a 2692 ± 424a 1510 ±  318a
588 ± 127a 1907 ±424a 1494±318a
Lactating + ArGH + Br 
Virgin
428 ±  127a 1586 ±424a 1176 ±  318a
399 ± 142a 1879 ± 474a 1497±356a
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CHAPTER FIVE
STUDIES ON THE LIPOLYTIC ACTION OF GROWTH 
HORMONE IN SHEEP ADIPOSE TISSUE IN  VIVO
5.1 Introduction
Growth hormone increases lipolysis in adipose tissue, but this appears to be 
achieved via indirect mechanisms. The chronic treatment with growth hormone in 
vivo have been shown to increase the lipolytic response to catecholamines in vitro 
in rats (Vernon et al, 1987) and in vivo in cows (McCutcheon and Bauman, 1986; 
Peters, 1986; Sechen eta l, 1990). Maintaining sheep adipose tissue in culture with 
growth hormone again increased maximum response to P-agonists (Watt et al, 
1991). In contrast, chronic treatment of cattle with bovine growth hormone in vivo 
had no effect on the response of subcutaneous adipose tissue to catecholamines in 
vitro (Peters, 1986; Lanna et al, 1992). Chronic treatment with bovine growth 
hormone in vivo decreases the response to the antilipolytic effects of the adenosine 
analog N^-phenylisopropyladenosine (PIA) in rat (Vernon et al, 1987; Doris et al, 
1994) and bovine (Lanna et al, 1992) adipose tissue in vitro.
The effects of growth hormone on the lipolytic signalling system were 
explored futher by chronically treating sheep for up to 7 days with bovine growth 
hormone and then assessing the lipolytic rate in vitro in subcutaneous adipose 
tissue. To probe the mechanism of the effect of chronic growth hormone 
treatment, the numbers of P- and ot2 -adrenergic receptors and adenosine receptors 
amd the amounts of the heterotrimeric GTP-binding proteins, which transmit 
signals from the above receptors to adenylate cyclase, were determined.
5.2 Experimental
Ten female Finn x Dorset Horn sheep, mean body weight 55.2 kg (range 44 
to 64) were used. The sheep were individually housed in metabolism crates, in 
sight of other sheep, for 7 days. During this time they were injected with either 
bovine somatotropin (10 mg in 2 ml buffer i.m. daily) or vehichle (control). The 
animals were fed at 0800 and 1500 and the meals consisted of 250g of a cereal mix
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plus hay to eat for 2  to 3 hours; drinking water was always available. One control 
and one growth hormone-treated (bovine growth hormone was a gift from 
Monsanto Europe, B-1150, Brussels, Belgium) sheep were used each week of the 
expiment. On day 7, pentobarbital (20-30 ml) was injected intravenously and sheep 
killed by exsanguination. Samples of subcutaneous tissue were removed and 
placed in 0.15M NaCl at 37°C for transportation to the laboratory (less than five 
minutes), and used in lipolysis experiments and the preparation of membranes for 
receptor and G-protein analysis.
Analysis of results
Results were analysed by ANOVA with week and treatment, or treatment 
and PIA concentration and their interaction as factors when analysing data. A P 
value of less than 0.05 was considered significant.
5.3 Results
5.3.1 Basal and Maximal Lipolysis
Adenosine deaminase 0 . 8  ug/ml was added to remove any endogenously 
produced adenosine and this caused a small (P < 0.01) increase in the rate of basal 
lipolysis (Figure 5.1). Lipolysis was increased by the addition of the P-agonist 
isoprenaline (P < 0.001) (Figure 5.1). Chronic treatment of sheep with growth 
hormone increased basal, adenosine deaminase-stimulated, and isoprenaline- 
stimulated lipolysis (Figure 5.1). The increase in the rate of lipolysis induced by 
isoprenaline was determined as the rate of lipolysis in the presence of isoprenaline 
minus the rate in the absence of isoprenaline, and was increased (P < 0.05) by 
chronic growth hormone treatment (5.37 and 7.18 ± 0.43 pmol/ 3 h/10^ cells, 
respectively, for control and growth hormone-treated sheep).
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5.3.2 Lipolytic response to PIA and PGEj
Chronic treatment with growth hormone in vivo also diminished the 
response ot acutely acting antilipolytic factors. Effects of adenosine and 
prostaglandin E j were assessed by stimulating tissue with isoprenaline plus 
adenosine deaminase and adding various concentrations of either the adenosine 
analogue PIA or P G E j.
Pre-treatment in vivo with growth hormone markedly decreased 
(P < 0.01) the response to PIA (Figure 5.2) (results are the mean of 5 observations; 
SEM are 8.02 and 4.45 for comparing values between control and growth 
hormone-treated sheep respectively). With PGEj, a concentration of 10 nM had 
no effect on the rate of isoprenaline-stimulated lipolysis in either control or growth 
hormone-treated sheep. However 100 nM PGEj reduced (P < 0.01) the rate of 
lipolysis in control sheep (5.79 and 4.32 ± 0.23 pmol/ 3 h/ 10^ cells in the absence 
and presence of PGEj respectively) (Figure 5.3), but not in growth hormone- 
treated sheep (7.85 and 7.62 ± 0.40 pmol/ 3 h/ 10^ cells in the absence and 
presence of PGEj respectively) (Figure 5.3).
5.3.3 Ligand binding to adenosine, p-adrenergic and a2-adrenergic
receptors
Binding studies were carried out using a single maximum concentration of 
labelled ligand at 20 nM, as previous studies had shown that concentrations of 
ligand at this level was sufficient to achieve essentially maximum binding with each 
of the three receptors studied (Vernon et al, 1995). The amount of 
[ HJdihydroalprenolol bound to the P-adrenergic receptors was 50.4 and 70.1 
fmol/mg protein (P < 0.05) for control and growth hormone-treated sheep 
respectively (Figure 5.4), (results are means of 5 observations; SEM was 4.9 
fmol/mg protein), indicating a small increase in the number of P-receptors. The
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amount of [ HJrauwolseine bound to a2-adrenergic receptors was 10.9 and 21.5 
fmol/mg protein (P > 0.10) for control and growth hormone-treated sheep 
respectively (Figure 5.4), (results are means of 5 observations, SEM was 3.1 
fmol/mg protein) and indicated no significant effect of treatment. Similarly, no 
effect of growth hormone-treatment was seen in [ H]PIA binding to adenosine 
receptors and was 21.1 and 17.6 fmol/mg protein (P > 0.75) for control and 
growth hormone-treated sheep respectively (Figure 5.4), (results are means of 5 
observations, SEM was 7.4 fmol/mg protein).
5.3.4 Immunoblotting of a-subunits of G*l, Gj2, Gj3 and Gs
Anti-peptide antisera were used to ascertain changes in the levels of a - 
subunits of individual G-proteins in adipocyte membranes from control and growth 
hormone-treated sheep. The results are expressed as arbitrary units (Table 5.1) and 
it should be noted that, as the affinity of the different antisera are unknown, the 
absolute amounts of Ga subunits cannot be commented upon.
Immunoblotting revealed two isoforms of G§ with molecular weights of 
about 42- and 45-kDa as found previously in sheep (Vernon et al, 1995) and rat 
(Strassheim et al, 1990; Doris et al, 1994) adipocytes; sheep, however, differ from 
rats in that there is relatively more 42-kDa than 45-kDa Gg, whereas in rats both 
isoforms are present in roughly equal amounts. Treatment of growth hormone in 
vivo had no effect on the amount of either isoform of G§ (Table 5.1). 
Immunoblotting with the antiserum to G-1 and Gj2 revealed a single band as found 
previously for sheep (Vernon et al, 1995) and rat (Mitchell et al, 1989; Doris et al,
1994) adipocytes. Pretreatment of sheep with growth hormone in vivo had no 
effect on the amount of Gjl plus Gj2 (Table 5.1)
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5.4 Discussion
Catecholamines and adenosine operate via a very similar mechanism of 
binding to a receptor in the plasma membrane that activates a G-protein, which 
then interacts with adenylate cyclase causing a change in cAMP concentration. 
This in turn alters the activity of protein kinase A, an enzyme that phosphorylates a 
number of key enzymes of which hormone-sensitive lipase in adipose tissue is an 
example (Vernon and Sasaki, 1991). Catecholamines acting via the P-adrenergic 
receptor cause activation of adenylate cyclase, but via another distinct receptor, the 
a2-adrenergic receptor, they can inhibit adenylate cyclase (Vernon and Sasaki, 
1991). Depending on the tissue, adenosine can cause either activation or inhibtion 
of adenylate cyclase; in adipose tissue it causes inhibition, while in brain tissue it 
causes activation (Stiles, 1986).
Studies on the response to catecholamines in ruminants have focused on 
their well-defined effects on lipolysis in adipose tissue. Earlier studies in vitro 
suggested that the response to catecholamines in ruminant adipose tissue was less 
than that in the rat (see Vernon, 1980) but other studies have shown that 
catecholamines can elicit a considerable increase in the rate of lipolysis in vivo 
(Gooden et al, 1986; Thompson, 1986) and in vitro (Vernon and Finley, 1985; 
McNamara, 1991).
In the present studies, chronic treatment of sheep with growth hormone 
resulted in a small increase in the rate of basal and catecholamine-stimulated 
lipolysis in vitro. However, studies carried out in which cattle were chronically 
treated with bovine growth hormone, resulted in a large increase in response to 
catecholamines in vivo (McCutcheon and Bauman, 1986; Peters, 1986; Sechen et 
al, 1990) but no apparent change in response to catecholamines in subcutaneous 
adipose tissue in vitro (Peters, 1986; Lanna et al, 1992). The latter difference 
between sheep and cattle may reflect the fact that the increased response to
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catecholamines in vitro is small and may not have been detected in earlier studies in 
cattle where SEM values were relatively high.
The apparent lack of increased response of subucutaneous tissue at least to 
catecholamines in vitro following growth hormone treatment has promoted a 
search for an alternative mechanism to account for the in vivo effect, and this has 
led to a focus on the adenosine antilipolytic system (Lanna et al, 1992). Earlier 
studies have showed that growth hormone treatment decreased the response to 
PIA in rats (Vernon et al, 1987) in vitro and sheep adipose tissue in vitro (Vernon 
et al, 1991). This study shows that growth hormone treatment of sheep in vivo 
markedly diminishes the response of subcutaneous adipose tissue to adenosine 
(PIA).
Prostaglandins of the E series are known to be antilipolytic, at least in rats 
and humans, and act via Gj (Richelsen, 1992). Growth hormone treatment in 
sheep resulted in a diminished response to prostaglandin Ej but the concentrations 
needed to achieve this result were higher than those for PIA. These results then 
indicate that growth hormone modifies a post-receptor step common to both 
agents.
The increased rate of catecholamine-stimulated lipolysis could be due to an 
increased number of P-adrenergic receptors, and these results correspond to those 
of Watt et al (1991) that showed that incubation of sheep adipose tissue in vitro 
with growth hormone over 48 hours resulted in an increase in p-receptor numbers. 
Although it has been proposed that a change in receptor number is likely to change 
sensitivity rather than maximum response to the agonist (Kahn, 1978), this will 
depend on which component is limiting maximum response. In the various cell 
types examined, the number of molecules of G§ exceeds the number of molecules 
of P-adrenergic receptors by at least 100-fold (Ransas and Insel, 1988; Post et al,
1995). If G§ is in such excess in adipocytes, then the number of P-adrenergic 
receptors could be limiting and so the increase in p-receptor number could account 
for the enhanced rate of catecholamine-stimulated lipolysis in growth hormone
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treated sheep. However, studies by Vernon et al, (1993) suggest that other 
mechanisms should not be excluded, and show that the association of hormone 
sensitive lipase with the lipid droplet may play a role in the altered response to 
catecholamines.
The lack of effect of growth hormone in vivo on the number of a2- 
adrenergic receptors agrees with the previous findings of Watt et al (1991) in vitro 
in which chronic exposure to growth hormone had no effect on either the number 
of a 2 -adrenergic receptors or response to the a 2 -adrenergic effect of 
noradrenaline. Although this study showed that growth hormone treatment in vivo 
markedly diminishes the response to PIA of subcutaneous tissue, this effect did not 
seem to be due to a change in either the number of adenosine receptors or the 
amount of the GTP-binding proteins, Gj 1 and Gj2 that transmit inhibitory signals to 
adenylate cyclase. This may suggest a change in activity by one or more 
components of the system. Studies have shown that loss of Gj function occurs as a 
result of protein kinase C activation (Houslay, 1991), and this has been attributed 
to phosphorylation of Gj2 (Morris et al, 1994). In this study there was an apparent 
lack of effect of growth hormone on the amount of Gj. This contrasts with the 
previous findings, detailed in chapter 3, with rats that showed that by lowering 
serum growth hormone levels with a specific antiserum to growth hormone, the 
amount of the G-protein Gj2 was markedly increased (Doris et al, 1994) and was a 
phenomenon that could be reversed upon growth hormone replacement. This may 
reflect a species difference or may imply that growth hormone at low 
concentrations reduces Gj2 levels and at higher concentrations decreases its 
activity.
Therefore treatment of sheep in vivo alters the cyclic AMP-based signalling 
system of subcutaneous adipocytes by more than one mechanism. That is, an 
increased maximum rate of p-adrenergic-stimulated lipolysis is seen, possibly due 
to an increase in the number of P-adrenergic receptors. At the same time, a 
decrease in response to at least two antilipolytic agents, adenosine and
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prostaglandin Ej is seen. This study shows that the effect of growth hormone in 
sheep adipose tissue is likely to be by altering the responsiveness of adipocytes to 
acutely acting factors.
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E ffec t of Growth hormone trea tm ent
on basal and stimulated lipolysis in vivo
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Figure 5.1 Adipose t issue was taken from G H - t r e a t e d  and control  
sheep . Glycerol re lease  was measured,  in the p re s e n c e  of 0.8 ug/ml 
adenosine deaminase (basal) or plus 100 nM isoprenaline (maximal). 
Results are  the means + SEM of 5 observations.
Effect of GH in vivo on response to PIA
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Figure 5.2 Adipose tissue  was taken  from G H - t r e a te d  and con tro l  
sh e ep .  Glycerol r e le a s e  was m ea su re d jn  the  p re s e n c e  of 0 .8  ug/ml 
adenosine  deam inase , 100  nM isoprenaline and the  ind ica ted  conc. 
of PIA. The resu l ts  a re  the  m eans of 5 obse rva t ions .  SEM a re  8 .02  
and 4 .4 5  for com paring values b e tw e en  con tro l  and G H - t r e a t e d  
sh e ep  respec tive ly .
E ffec t  of PGE1 on isoprena line-s tim ula ted  lipolysis following 
manipulation of GH levels in sheep  in vivo
CO
</>
o
Q .
50  -i
4 0  -
30 -
20  -
10 -
0 J a ±
contro l
GH
! _
10 100 
PGE1 nM
Figure 5.3 Glycerol re lease  was m easu red  in sheep  ad ipose  tissue  in 
the  p re se n c e  of 0.8 ug/ml adenosine deam inase, 100  nM isoprenaiine 
and the indicated concen tra tion  of PGE1. Results a re  the  m eans + 
SEM of 5 observations .
E ffec t  of GH trea tm en t  on ligand binding to  b e ta  
a lp h a -2  and adenosine r e c e p to r s
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Figure 5.4 Adipose tissue was taken from control and G H - t r e a te d  
sheep , a f t e r  which adipocyte  m em branes w ere  p rep a re d ,  and their 
ability to  bind PHldihydroalprenalol, PH lrauw olscine and PH1PIA was 
a s s e s s e d .  Results a re  the  means + SEM of 5 observa tions .
Table 5.1 Expression of G-protein a-subunits in sheep adipocyte membranes
Adipocyte membranes were prepared from control or growth hormone-treated 
sheep. Levels of a-subunits of G-proteins, detected by immunoblotting, are given 
in arbitrary units. Quantification of reactive proteins was achieved by densitometric 
scanning using a Bio-Rad 620 video densitometer. Results are the means of 5 
observations.
Treatment_______G-protein... G^l +2____ G„ (45-kDa)______(42 k-Da)
Control 2.35 2.65 4.32
GH 2.47 2.93 4.46
SEM 0.10 0.21 0.31
P 0.404 0.795 0.757
CHAPTER SIX
STUDIES ON THE LIPOLYTIC ACTION OF GROWTH 
HORMONE IN SHEEP ADIPOSE TISSUE IN  VITRO
6.1 Introduction
The mechanism whereby growth hormone facilitates lipolysis is not fully 
explained, however it is possible that growth hormone exerts its effects by 
modulating the acute regulation of this process by other hormones rather than 
having a direct effect itself Initially studies focused on modulation of response of 
adipocytes to catecholamines, but more recent studies (Lanna et al, 1992; Doris et 
al, 1994) suggest that the Gj-mediated antilipolytic system is a major target of 
growth hormone action. The effect of growth hormone is of considerable 
economic importance, contributing to the galactopoetic effect of growth hormone 
(bovine somatotrophin (Bauman and Vernon, 1993)) and is being developed as a 
potential means of producing leaner meat animals (Boyd and Bauman, 1989; 
Etherton et al, 1993; Steele and Evock-Clover, 1993).
Growth hormone enhances the responsiveness of adipocytes to acutely 
acting lipolytic agents by several mechanisms. One of the more important 
mechanisms appears to be to decrease the ability of anti-lipolytic agents, for 
example adenosine and prostaglandin E, to inhibit lipolysis (Doris et al, 1994). 
Treatment of sheep in vivo with growth hormone leads to a diminished response to
/Z
the adenosine analogue N -phenylisopropyladenosine (PIA) but with no apparent 
change in the number of adenosine receptors or amounts of Gj isoforms (Doris et 
al, 1994). This suggested a more subtle change, perhaps due to phosphorylation of 
Gj, altering its ability to interact with either its receptor or adenylate cyclase. 
Further investigations were, therefore, carried out using a tissue culture system to 
explore further the possible mechanism whereby growth hormone exerts its effects.
6.2 Experimental procedure
Sheep were 6-9 month old castrated males (wethers) and were fed on a diet 
of hay and cereals for at least one month before slaughter. On the day of killing,
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sheep were anaesthetized by injection of 20-30 ml of Sagatal (May and Baker, 
Dagenham, Essex, UK) into the jugular vein, after which they were exsanguinated 
and samples of subcutaneous adipose tissue was removed asceptically from the 
flank fat-pads immediately anterior to the hind limbs. Adipose tissue was placed 
immediately in sterile 0.15 M NaCl at about 37°C.
Pieces of adipose tissue (about 20 mg) were cut with scissors and then 
either used immediately for measurement of the rate of lipolysis or preparation of 
membranes, or maintained in tissue culture for up to 48 h at 37°C under air/C02 
(19:1) in Medium 199 with Earle's salts, 25 mM Hepes (pH 7.3), 2 mM acetate and 
antibiotics (see section 2.3.3). The medium was supplemented with ovine growth 
hormone (a gift from NIAMDD, Bethesda, MD, USA). Adipose tissue explants 
were preincubate for 24 h with no hormones and then the tissue was transferred to 
fresh medium in the presence and absence of growth hormone (4.5 nM). Following 
the 48 h incubation adipose tissue was used in lipolysis experiments or in the 
preparation of plasma membranes. In the lipolysis experiments, PMA and okadaic 
acid were dissolved in dimethyl sulphoxide (DMSO) and subsequently diluted with 
Medium 199; maximum DMSO concentration in the culture medium was 1 pl/ml; 
this concentration had no effect on the variables measured in the study.
For the immunoblotting experiments, antipeptide antisera CS1 and I1C, 
which specifically recognise the a-subunits of the G-proteins Gs and Gj 
respectively, were kindly provided by Dr. G. Milligan, Dept, of Biochemistry, 
University of Glasgow. An antiserum which recognizes Gjl plus Gj2 was 
generated against the C-terminal decapeptide of the a-subunit of rod transducin and 
characterized as described by Mitchell et al (1989).
Analysis of results
Statistical significance was assessed by analysis of variance or by Student's 
t-test for paired observations. The results are given as means either ± SED 
(standard error of difference) or ± SEM.
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6.3 Results
6.3.1 Maximal Lipolysis
Sheep subcutaneous adipose tissue was cultured for 24 h in the absence of 
additons after which it was transferred to fresh medium in the presence and absence 
of growth hormone as described in section 2.3.3., after which lipolysis experiments 
were carried out as detailed in section 2.3.4. 'Do' tissue was assayed at the time 
explants were initially prepared. The maximal response to isoprenaline was 
achieved with 100 nM agonist in the presence of 0.8 pg/ml adenosine deaminase, 
and increased over the 48 h incubation period from 2.09 ±  0.29 (Do) to 3.96 ± 1.17 
pmol / 3h /lO^cells in control tissue and to 3.89 ±  0.80 in growth hormone-treated 
tissue (Fig. 6.1). Therefore, culture tended to increase maximum rate of lipolysis 
but the effect was not significant. The results are the means of 4 observations. In 
this initial experiment with 4 sheep, culture with growth hormone had no effect on 
maximum response to isoprenaline; however, analysis of pooled results from further 
experiments using tissue from 20 sheep (Table 6.1) revealed a small, but significant 
(P < 0.01) effect of growth hormone on this variable (mean rate of isoprenaline- 
stimulated lipolysis after culture with and without growth hormone was 4.96 and 
4.22 pmol glycerol release /3h /10^ cells respectively; SED = 0.22)
6.3.2 Lipolytic response to PIA
Maximum stimulation of lipolysis was achieved by including 0.8 pg/ml 
adenosine deaminase and 100 nM isoprenaline as described above. Lipolysis was 
then inhibited in a dose-response manner using PIA (1 nM - 100 nM).
Culture of adipose tissue in the absence of growth hormone had no effect 
on the response to PIA (Fig. 6.2). Treatment of sheep adipose tissue with growth 
hormone in vitro decreased (P < 0.05) the maximum response to adenosine from 
72.8% to 40.2% inhibition of isoprenaline-stimulated lipolysis. The results are the
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means of 4 observations, SED = 9.8 (Fig. 6.2). These results show that growth 
hormone supresses the anti-lipolytic effects of PIA by decreasing the response to 
maximal concentrations of this agent.
6.3.3 Ligand binding to adenosine-, a2-, and P-receptors
Measurement of ligand binding was performed with a single maximum 
concentration of ligand in each case at 20 nM, as reported by Watt et al (1991).
'i
The amount of [ H]-PIA bound to adenosine receptors was 21.1 fmol/mg protein 
in control tissue and 2 2 . 1  fmol/mg protein in growth hormone-treated tissue 
respectively (Fig. 6.3). Tissue culture in the presence of growth hormone had no 
effect on [ HJdihydroalprenalol binding to P-receptors, although a tendency toward 
an increase in P-receptor was apparent which may have been confirmed with further 
experiments. No effect of growth hormone was seen on [ HJrauwolscine binding 
to a2-receptors (Fig. 6.3) These results suggest that the changes in response to 
PIA are due to post-receptor changes.
6.3.4 Immunoblotting of a-subunits of Gj andG$
The amounts of GTP-binding protein a-subunits were determined by 
immunoblotting following separation by SDS gel electrophoresis. Sheep adipocytes 
express three forms of Gj (Gjl, Gj2 and Gj3) and two forms of G§ (42 kDa and 45 
kDa) (Vernon et al, 1995). Incubation of sheep adipose tissue with growth 
hormone had no effect on the expression of the a-subunits of Gjl plus Gj2 (Table 
6.1). The similiarity in size of the a-subunits of Gjl and Gj2 did not permit their 
seperation under the electrophoresis conditions used. Growth hormone treatment 
also had no effect on the expression of either form of Gs (Table 6.1). These results 
are consistent with those from the sheep in vivo study (Doris et al, 1994) and 
suggest a possible covalent modification of Gj.
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6.3.5 Lipolytic response to H7
As there is evidence that Gj2a can be phosphorylated by protein kinase C 
and at least one other kinase (Bushfield et al, 1990), the effects of the protein serine 
kinase inhibitor [l-(5-isoquinolinesulfonyl)-2-methyl piperazine, HC1] (H7) 
(Scientific Marketing, Barnet, Herts, UK) was tested in the tissue culture system. 
Tissue was cultured for 24 h without additions after which growth hormone and H7 
or growth hormone were added, singly or in combination, for the next 24 h. 
Lipolysis was then measured in the presence of isoprenaline at 100 nM and 
adenosine at 0.8 pg/ml and various concentrations of PIA. Addition of 100 pM H7 
completely abolished the effect of growth hormone on response to PIA (Fig. 6.4) 
while having no apparent effect on control tissue. The results are the means of 4 
observations and SED = 7.2.
6.3.6 Effect of Okadaic acid on lipolysis
To further investigate the role of protein phosphorylation in the effect of 
growth hormone on adipose tissue, the protein-serine phosphatase inhibitor, 
okadaic acid (Calbiochem-Novabiochem (UK) Ltd, Nottingham, Notts, UK) was 
used in the tissue culture system. Addition of this agent (10 nM) to the culture 
medium mimicked the effect of growth hormone and when added in combination 
with growth hormone the effects of the two agents were additive (P < 0.05) 
(Fig. 6.5). The results are the means of 4 observations and the SED = 7.3. These 
studies thus show that growth hormone can enhance lipolysis by decreasing the 
effects of agents acting via the G--based antilipolytic system, and provide further 
evidence for the effect of growth hormone to involve protein serine 
phosphorylation.
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6.3.7 Effect of PMA on lipolysis
Phorbol 12-myristate 13-acetate (PMA) has been shown to activate PKC 
isoforms in hepatocytes, leading to the phosphorylation of Gj2a (Bushfield et al, 
1991). In the short term PMA activates PKC, while at times after about 7 h PMA is 
thought to down-regulate some isoforms PKC (Hug and Sarre, 1993; Dekker and 
Parker 1994). Therefore, studies were carried out to look at the role of PMA in 
sheep adipocytes over a 48 h period.
PMA (10 |ig/ml) was added to the culture system and lipolysis assays were 
carried out at 5, 24 and 48 h. Addition of PMA or growth hormone to the culture 
system for 5 hours had no effect on the ability of PIA to inhibit lipolyis (Fig. 6 .6 ). 
Incubation of tissue in the presence of PMA for 24 h resulted in a decrease 
(P < 0.05) in inhibition of isoprenaline-stimulated lipolysis from 60.26% in control 
tissue to 44.5% (Fig. 6 .6 ). Addition of both PMA and growth hormone combined 
for 24 h resulted in the same degree of inhibition of the PIA effect as growth 
hormone alone (Fig. 6 .6 ). PMA was then added to the culture medium for the full 
48 h of incubation and growth hormone was added for the final 24 h. Although 
over the 48 h period, addition of PMA resulted in an apparent decrease in the 
inhibition of lipolysis by PIA from 60.25 to 50.75%, the effect was not significant 
(Fig. 6.7), again, the degree of inhibition of the PIA effect by growth hormone was 
the same regardless of whether the tissue had been preincubated with PMA or not 
(Fig. 6.7). The results are the means of 3 observations and SED = 7.6.
6.3.8 Effect of D609 on lipolysis
It has been proposed that growth hormone increases diacylglycerol 
production and studies (Catalioto et al, 1990) have shown that growth hormone 
increases diacylglycerol concentration in obi771 (preadipocytes) cells by increased 
phosphatidylcholine breakdown. Addition of tricyclodean-9-yl-xanthogenate
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(D609) (Calbiochem-Novabiochem (UK) Ltd, Nottingham, Notts, UK), a 
phosphatidylcholine phospholipase C inhibitor (40 pg/ml) had no effect on the 
ability of growth hormone to inhibit the actions of PIA, however, addition of D609 
to tissue culture itself tended to enhance the effects of PIA (Fig. 6 .8 ). The results 
are the means of 4 observations and SEM = 5.95. These results suggests that 
phospholipase C activation does not play a role in the effects of growth hormone on 
lipolysis.
6.3.9 Lipolysis: time course
Adipose tissue was maintained in culture for 24 h, the tissue was then 
transferred to fresh medium in the presence or absence of growth hormone for up 
to 24 hours. Lipolysis was stimulated with isoprenaline and assayed every three 
hours up to 12 hours and then at 24 hours in the presence of 100 nM PIA. 
Maintenance of sheep adipose tissue explants in culture in the absence of 
exogenous hormones for up to 24h had no effect on the ability of PIA to inhibit 
lipolysis (Fig. 6.9). The presence of growth hormone decreased the maximum 
response to PIA (P < 0.05) after a 24 h incubation. However, at all other time 
points measured, growth hormone had no effect on the response to adenosine. 
These results suggest that for sheep adipose tissue at least, the chronic effects of 
growth hormone on lipolysis require about 24 hours to become fully manifest and 
probably involve signalling to the nucleus, rather than simply causing the activation 
of a protein which then goes on to exert its effects on the lipolytic cascade.
6.3.10 Effect of Actinomycin D
Actinomycin D is an inhibitor of gene transcription and was used in the 
tissue culture system to determine if it could prevent the decreased inhibition of 
lipolysis by adenosine in the presence of growth hormone. Analysis of variance
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showed that addition of actinomycin D (100 ng/ml) to tissue after maintenance in 
culture in the absence of growth hormone decreased the ability of PIA to inhibit 
lipolysis Fig. 6.10). When actinomycin D was added in combination with growth 
hormone, the level of inhibition of lipolysis by PIA was the same as that seen in the 
presence of actinomycin D alone (Fig. 6.10), that is, the effect of growth hormone 
was no longer apparent. These results indicate a role for gene transcription for 
growth hormone effects on the lipolytic cascade.
6.3.11 ADP ribosylation of sheep adipocyte membranes
ADP ribosylation studies were carried out to look at the interaction 
between the adenosine receptor and Gj. Pertussis toxin stimulates ribosylation of 
the undissociated (heterotrimeric) form of Gj. Experiments were therefore carried 
out in the presence and absence of PIA to determine the ratio of dissociated and 
undissociated form of Gj.
Explants of sheep adipose tissue were maintained in culture for 24 h 
without hormones and then for a further 24 h plus or minus 100 ng/ml ovine 
growth hormone. Subsequently, adipocytes were isolated, disrupted and a 
membrane fraction prepared (see section 2.3.1). The ability of pertussis toxin to 
stimulate ADP-ribosylation of the membranes was assessed (see section 2.3.17). 
Incubation of membranes with 1 pM PIA decreased the amount of ADP- 
ribosylation due to receptor induced dissociation of Gj from 3154 to 1965 cpm/mg 
protein (Fig. 6 .11). Tissue culture with growth hormone had no effect on the levels 
of ADP-ribosylation or on the ability of PIA to decrease ADP-ribosylation 
(Fig. 6.11). The results are the means of 5 observations and SED = 377. Further 
studies were carried using PIA at 1 nM and 100 nM and at both these 
concentrations, growth hormone again had no effect on the ability of PIA to 
reduce levels of ADP-ribosylation (Fig. 612). This suggests that growth hormone 
does not alter the ability of Gj to interact with the adenosine receptor.
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6.3.12 Adenylate cyclase activity in sheep adipocyte membranes
That growth hormone does not affect Gj interaction with the adenosine
receptor, suggests that the attenuation of the antilipolytic effect of adenosine by
growth hormone may be due to changes in the interaction of Gj with adenylate
cyclase. Therefore, Gj function was assesssed directly using low concentrations 
19 7(10 - 10 M) of the non-hydrolysable GTP analogue 5-[Py-imido]triphosphate
(p[NH]ppG) to inhibit the forskolin-stimulated adenylyl cyclase activity.
A small increase in stimulation of adenylate cyclase by both isoprenaline and 
forskolin was seen in membraned prepared from tissue that had been cultured with 
growth hormone (Table 6.3) reflecting the results seen at maximal lipolysis 
(Table 6.1) in experiments using inhibitors. After amplifying basal adenylate 
cyclase activity using the diterpene forskolin (10"^M), low concentrations of 
p[NH]ppG were used to cause inhibition of adenylate cyclase activity through a Gj- 
mediated response. Treatment of sheep adipocyte membranes with growth 
hormone completely prevented the inhibition of adenylate cyclase activity by 
P[NH]ppG (P < 0.01) (Fig. 6.13). The results are the means of 4 observations.
Further studies were carried out using 5 x 10"^M isoprenaline to stimulate 
adenylate cyclase activity and the ability of PIA to inhibit this effect was assessed. 
The ability of PIA at 10 M to inhibit adenylate cyclase activity via Gj in tissue 
treated with growth hormone was reduced from control levels of 26.25% inhibition 
to 0% inhibition.(P < 0.005) (Fig. 6.14). Whereas at 10"^M the level of inhibition 
of adenylate cyclase acivity by PIA in growth hormone-treated tissue returned to 
that seen in the controls (Fig 6.14). The results are the means of 4 observations, 
SEM = 5.5.
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6.4 Discussion
Studies carried out by Watt et al (1991) showed that chronic endocrine 
control of the adrenergic system of sheep adipose tissue can be achieved in tissue 
culture. Therefore, in the present study the same tissue culture system was used to 
investigate the effect of chronic exposure of sheep adipose tissue to growth 
hormone. Chronic exposure of sheep adipose tissue to growth hormone resulted in 
a small increase in maximal isoprenaline-stimulated lipolysis. These results agree 
with Watt et al (1991) who reported an increase in response and sensitivity of 
sheep adipose tissue to P-agonists, and also correspond with the in vivo studies of 
Doris et al (1996) (chapter 4 of this thesis) that also showed a small increase in 
response to isoprenaline in growth hormone-treated sheep.
The present study shows, that as with sheep adipose tissue in vivo 
(Doris et al, 1996), treatment of sheep adipose with growth hormone in vitro 
results in a decrease in inhibition of isoprenaline-stimulated lipolysis by the 
adenosine analogue PIA. Adenosine receptor number was not affected by hormone 
treatment and therefore, could not account for the decreased response to 
adenosine. Similarly growth hormone treatment had no effect on either G§ or Gj 
isoforms: thus suggesting a decrease in Gj activity; these findings and this 
conclusion are in agreement with results of Chapter 5 (Doris et al, 1996).
It has been shown that a purified preparation of brain Gj, which will consist 
of multiple Gj subtypes, could be phosphorylated by protein kinase C (Katada et al, 
1985). The phosphorylation of Gj has since been shown to occur in a number of 
cell types, including intact hepatocytes (Pyne et al, 1989) and U973 cells (Daniel- 
Issakani et al, 1989), where immunoprecipitation studies are consistent with it 
being Gj2 that is modified on serine residues. As other studies have shown that Gj2 
can be phosphorylated by PKC and at least one other kinase (Bushfield et al, 1990), 
the effect of protein kinase and phosphatase inhibitors were tested in the culture 
system. Once described as a specific PKC inhibitor (Hidaka et al 1984), H7 is now
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known as a more general protein serine kinase inhibitor and in the present study, 
H7 was shown to completely abolish the effects of growth hormone. Therefore, 
these results would suggest that the effects of growth hormone on sheep adipocytes 
involves an H7-sensitive step(s), possibly an isoform of PKC.
The activity of Gj2 is thought to be controlled by a phosphorylation- 
dephosphorylation cycle (Houslay, 1994), where activation of PKC results in 
phosphorylation of Gj2 and activation of phosphatases ensures a dynamic turnover. 
Thus either protein kinase activation or phosphatase inhibition can be expected to 
drive an increase in Gj2 phosphorylation. Okadaic acid is a potent inhibitor of 
phosphatases 2A and 1 (MacKintosh and Mackintosh, 1994), and addition of this 
agent to the tissue culture system in the present study resulted in inhibition of the 
antilipolytic effects of adenosine, as seen with the addition of growth hormone; 
effects of the two agents were additive and therefore support the theory of a 
phosphorylation-dephosphorylation regulatory system for G-. These results are 
consistent with those of Morris et al (1995), who showed that treatment of 
hepatocytes with okadaic acid increased the labelling of a-G-2.
Phorbol esters initially activate certain isoforms of PKC, but prolonged 
exposure to these agents leads to down-regulation (loss) of these isoforms (Hug 
and Sarre, 1993; Dekker and Parker, 1994). The tumour-promoting phorbol esters 
bind directly to PKC, but with a far greater affinity than endogenously produced 
DAG (Nishizuka, 1988; Sando et al, 1992). However, while DAG is metabolised 
phorbol esters are only slowly removed and chronic treatment with phorbol esters 
leads to down regulation of PKC (Nishizuka, 1988; Sando et al, 1992; Stabel and 
Parker, 1992). In human platelets treated with the phorbol ester, PMA, the 
phosphorylation of Gz appeared to occur very rapidly, with maximal labelling being 
achieved within 1 minute (Carlson et al, 1989). Studies with hepatocytes also 
showed an increase in labelling of a-Gj2 after challenge of cells with PMA (Morris 
et al, 1994; Morris et al, 1995). The use of PMA, in the present study showed no 
effect in the culture system when added alone for 5 h at a time it would be expected
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to activate PKC. Under similar conditions 5h exposure to PMA increased the rate 
of lipogenesis of sheep adipose tissue (Vernon, 1996). After 24h, PMA partly 
mimicked the effect of growth hormone and the effect of these two agents was not 
additive. Whether the effect of PMA is due to a loss of an isoform of PKC which 
enhances the PIA effect or whether PMA induced phosphorylation of Gj is long 
lasting and continues after subsequent down-regulation of PKC isoforms is not 
clear, but the latter possibility is consistent with known effects of PKC on Gj and 
the H7 study. This is also consistent with the finding that culture with PMA for 
48h did not cause a significant decrease in PIA inhibition of lipolysis; over this 
longer period there could have been a gradual dephosphorylation of Gj along with a 
loss of PKC isoforms involved. That some effect of growth hormone was apparent 
after pretreatment with PMA for 24h suggests that part of the effect of growth 
hormone at least does not involve a PMA-sensitive isoform of PKC.
Effects of PMA and growth hormone on lipolysis in sheep adipose tissue 
differ from previous findings with rat adipose tissue (Gorin et al, 1990) in that they 
are slower to appear in sheep than in the rat study and they are additive in the rat 
but not in the sheep. The present results are consistent with a previous finding with 
sheep adipose tissue which showed that both PMA and growth hormone increased 
glycerol release into the culture medium over a 2 2 h period, but again effects were 
not additive (Vernon, 1996).
PKC is activated by diacylglycerol (DAG) which is produced as a 
consequence of the receptor-mediated hydrolysis of phospholipids, such a 
phosphatidylinositol 4,5-bisphosphate and phosphatidylcholine (Shears, 1990; 
Cooke and Wakelam, 1992). Such processes are initiated by the action of a diverse 
range of biologically active substances, including hormones and growth factors 
whose receptors then stimulate appropriate phospholipases (Sando et al, 1992; 
Shears, 1990; Cooke and Wakelam, 1992). The present study shows that addition 
of D609 a phosphatidylcholine phospholipase C inhibitor, failed to abolish the
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ability of growth hormone to inhibit the actions of adenosine, thereby ruling out a 
role for phospholipase C activation in growth hormone effects on lipolysis.
In the time course experiments the maximum effect of growth hormone 
was reached after 24 hours demonstrating that growth hormone is not simply 
activating a phosphorylation cascade. These results were supported by data from 
experiments with actinomycin D, which was shown to knock-out the effects of 
growth hormone. These studies then show that growth hormone can enhance 
lipolysis by decreasing the effects of agents acting via the Gj-based antilipolytic 
system by a mechanism that requires gene transcription and probably results in an 
increase in the phosphorylation status of Gj and thereby decreasing its activity.
More detailed studies have been carried out to elucidate the nature of the 
altered activity of Gj. To do this ADP-ribosylation studies were carried out in the 
presence of PIA which causes a decrease in ADP-ribosylation and is hence a 
measure of adenosine receptor binding to Gj. The results show that the ability of 
pertussis toxin to stimulate ADP-ribosylation of the adipocytes was unchanged by 
growth hormone; as pertussis toxin stimulates the ribosylation of undissociated 
(heterotrimeric) form of Gj, this suggests that the ratio of dissociated to 
undissociated was unchanged by growth hormone. Incubation of membranes with 
PIA decreased the amount of ADP-ribosylation due to receptor-induced dissocation 
of Gj but this was not altered by culture with growth hormone. This suggests that 
growth hormone does not alter the ability of Gj to interact with the adenosine 
receptor, the attentuation of the antilipolytic effect of adenosine by growth 
hormone was therefore thought to be due to changes in the interaction of Gj with 
adenylate cyclase.
Analysis of Gj interaction with adenylate cyclase was done by assessing 
receptor-mediated Gj action or by activating Gj directly with low concentrations of 
the non-hydrolysable analogue p[NH]ppG as has been described previously by 
Strassheim et al (1990). Low concentrations of p[NH]ppG were employed to 
detect functional Gj activity by inhibiting basal adenylate cyclase activity that had
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been amplified by forskolin. Using such an approach, functional Gj activity was 
detected in membranes from control adipose tissue but not in growth hormone- 
treated tissue. The experiments involving PIA showed that the magnitude of 
receptor-mediated Gj inhibition, elicited through adenosine receptors, was 
eliminated in membrane preparations from adipose tissue treated with growth 
hormone at 100 nM PIA, but was no different at 10 pM PIA. Similar results have 
been found in studies with adipocytes from obese {fa/fa) Zucker rats (Strassheim et 
al, 1991) where functional Gj was detected in membranes from lean, but not obese 
animals in experiments using p[NH]ppG in adenylate cyclase assays. However, in 
the same studies, receptor-mediated inhibition of adenylate cyclase achieved by PIA 
and PGEj was similar in membranes from both lean and obese animals 
(Strassheim et al, 1991). A further difference between the present study and that of 
Strassheim et al (1991) is seen in the stimulatory and inhibitory G-protein levels. In 
the present study, no apparent difference in levels of Gj or G§ was seen, however, 
in (fa/fa) Zucker rats, levels of both forms of Gs and those of Gjl and Gj3 were 
lower in obese animals compared to lean animals (Strassheim et al, 1991).
These studies would then suggest that the point at which growth hormone 
exerts its effects on the antilipolytic pathway in sheep adipocytes is at the point of 
interaction between Gj and adenylate cyclase; the mechanism appears to involve the 
phosphorylation of Gj possibly by a PKC isoform and also gene transcription.
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Effect of Growth hormone on maximally-stimulated lipolysis
(A
Do control GH
Figure 6.1 Sheep adipose tissue was cultured for 24h without 
additions, a fter  which GH (4.5 nM) was added for the next 24h. 
Do tissue was assayed at time tissue was taken. Lipolysis was 
m easured in the presence  of 0.8 ug/ml adenosine deaminase and 
isoprenaline (100 nM). Results are the means of 4 observations 
and SEM = 0.73.
Table 6.1 Effect of Treatments on maximal lipolysis
Sheep subcutaneous adipose tissue was cultured for 24h without additions after which 
it was transferred to fresh medium in the presence and absence of growth hormone and 
other additions as described below, as described in section 2.3.3. Lipolysis was 
measured in the presence of 0.8 pg/ml adenosine deaminase and 100 nM isoprenaline. 
Results are the means ±  SEM of 4 observations.
H7
Okadaic acid 
PMA 
D609 
Act. D
control
4.23 ±0.77
6.23 ±0.89 
3.78 ±0.30
3.61 ±0.54 
2.83 ±0.67
Glycerol pM / 1 0 j 
inhibitor
4.43 ±0.82
6.62 ±0.52 
3.67 ±0.34
3.44 + 0.45 
2.97 ±0.61
a cells / 3 hours
GH
4.96 ±0.80 
6.69 ±0.58 
4.66 ±0.41
4.63 ±0.63 
3.57 ±0.60
inhibitor + GH
5.82 ±0.73 
6.30 ±0.58 
4.54 ±0.54 
3.59 ±  0.39
2.82 ±0.58
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Figure 6.2 Tissue was cultured for 24h without addtions after  which 
GH (4.5 nM) was added for the next 24h. Lipolysis was measured in 
the presence  of 0.8 ug/ml adenosine deaminase, 100 nM isoprenaline 
and the concentration of PIA indicated. Day 0 tissue was assayed a t 
time tissue was taken. Results are means of 4 observations.SED = 9.8.
Effect of GH trea tm ent on ligand binding to beta  
a lpha-2  and adenosine recep to rs
50 -i
control
adenosine be ta
Figure 6.3 Sheep adipose tissue was cultured for 24h without 
additions a f te r  which GH (4.5 nM) was added for the  next 24h. 
Membranes were prepared and the ability of the membranes to bind 
20 nM-PH]dihydroalprenalol,20 nM-[3 H]rauwolscine and 20 nM-PH] 
PIA to be ta , a lpha-2  and adenosine rec e p to rs  respectively was 
measured as described in methods section. Results are  the means 
+ SEM of 3 observations.
Table 6.2 Expression of G-protein a-subunits in sheep adipose tissue
Tissue was cultured for 24 h without additions after which it was transferred to fresh 
medium in the presence and absence of growth hormone. Adipocyte membranes 
were prepared and immunoblotting carried out as described in the experimental 
section. Quantification of reactive proteins was achieved by y radiation counting of 
excised bands. Results are means ± SEM of 3 observations.
Arbitrary units /  mg protein 
Treatment________ O-pnoteiiL._______G^l + 2 G^ (45 kDa) G^(42 kDa)
Control 2587 ±661 11496 ±393 22873 ±548
Growth hormone 2071 ±405 12713 ±  1034 25389 ±664
Effect of Growth hormone and H7 on lipolysis
control
Figure 6.4 Sheep adipose tissue was cultured for 24h without 
additions a f te r  which GH (4.5 nM) and H7 (100  uM) w ere  added , 
singly or in combination, for the next 24h. Lipolysis was m easu red  
in the p resence  of 0.8 ug/ml adenosine deaminase and 100  nM 
isoprenaline. Results a re  the means of 4 observations , SED = 7.2
Effect of okadaic acid and growth hormone on iipolysis
con tro l  GH
Figure 6.5 Sheep  ad ipose  tissue was cu ltured  fo r  2 4 h  without 
additions a f te r  which GH (4.5 nM) and okadaic  acid (10 nM) 
w ere  a d d e d jn  combination, for th e  nex t  24h . Lipolysis was 
m easu red  in the  p re s e n c e  of 0.8 ug/m l adenosine  deam inase  
and 100  nM isoprenaline. Results a re  m eans of 4 obse rv a t io n s ,  
SED = 7.3.
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Figure 6.6 Sheep adipose tissue was incubated for 24h without 
addtions a f te r  which it was maintained in culture for 5 or 24h 
with GH (4.5 nM) or PMA (10 ug/ml) singly or in combination. 
Lipolysis was measured in the presence  of 0.8 ug/ml adenosine 
adenosine deaminase and 100 nM isoprenaline. Lipolysis was 
inhibited using 100 nM PIA. Results are means of 3 observations,
and SED = 7.6.
Effect of PMA and GH on isoprenaline-stimulated lipolysis
over 48 hours
control GH PMA PMA + GH
Figure 6.7 Tissue was incubated in the p resence  of PMA for 
48h, and for the second 24h GH was added. Lipolysis was 
m easured in the presence of 0.8 ug/ml adenosine deaminase 
and 100 nM isoprenaline. Lipolysis was inhibited using 100 nM 
PIA. Results are the means of 3 observations and SED = 7.6.
Effect of Growth hormone and D609 on lipolysis
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Figure 6.8 Sheep adipose tissue was cultured for 24h without 
additions after  which GH (4.5 nM) and D609(40ug/ml) were added, 
singly or in combination, for the next 24h. Lipolysis was measured 
ub the presence of 0.8 ug/ml adenosine deaminase and 100 nM 
isoprenaline. Results are means of 4 observations and SEM = 5.95.
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Effect of Growth hormone and Actinomysin D on lipolysis
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Figure 6.10 Sheep adipose tissue was cultured for 24h without 
additions after  which GH (4.5 nM) and actinomycin D (100 ng/ml) 
were added, singly or in combination, for the next 24h. Lipolysis 
was measured in the presence  of 0.8 ug/ml adenosine deaminase 
and 100 nM isoprenaline. Results are the means of 4 observations, 
SEM = 5.2.
Pertussis toxin stimulated ADP-ribosylation of sheep 
adipocyte membranes
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Figure 6.11 Sheep adipose tissue was cultured for 24h without 
addtions after  which GH (4.5 nM) was added for the next 24h. 
Membranes were prepared and the ability of pertussis toxin to 
stimulate ADP-ribosylation of the membranes was assessed  in 
the presence  and absence of 1 uM PIA. The results are means
of 5 observations and SED = 311.
Effect of PIA on ADP-ribosylation of Gi in sheep membranes
80 -i
control
1000
Figure 6.12 Sheep adipose tissue was cultured for 24h without 
additions after which GH (4.5 nM) was added for the next 24h. 
Membranes were prepared and levels of ADP-ribosytion were 
assessed in the presence and absence of PIA at concentrations 
indicated above. Results are means of 3 observations and SEM 
= 4.00.
Table 6.3 Effect of Growth hormone on Adenylate Cyclase activity
Adipocytes were isolated from subcutaneous sheep adipose tissue that was cultured 
for 24h without additions after which it was transferred to fresh medium in the 
presence and absence of growth hormone, and used for preparation of membranes as 
described in section 2.3.1. Membranes were assayed for adenylate cyclase activity in 
the absence of exogenous agents (basal) in the presence of 100 pM forskolin or 5 x 
10"^M isoprenaline (Isop) alone or with 10 pM GTP. Results are the means ± SEM 
of 4 observations.
pmol / min / mg protein 
zQH___________________±GH
Basal 
+ Isop 
+ Forskolin 
+ GTP
+ Isop + GTP
61.75 ±13.02 
216.25 ±45.79 
805.00 ±49.14 
87.85 ±  6.39 
358.75 ±27.26
72.00 ±10.48
225.25 ±75.87
865.00 ±85.68 
76.00 ±  2.97
401.25 ±100.96
D ose-effect experiments for p[NH]ppG on forskolin-stimulated
adenylate cyclase activity in sheep adipocyte membranes
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Figure 6.13 Sheep adipose tissue was cultured for 24h  without 
additions a f te r  which GH (4.5 nM) was added for the  next 24h. 
Membranes were p repared  and increasing concen tra tions  of 
p[NH]ppG were added to assays  employing m em branes from 
control and G H -t re a te d  tissue. Results a re  the m eans of + 
SEM of 4 observations.
Effect of PIA on isoprenaline-stimulated
Adenylate cyclase activity
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Figure 6.14 Sheep adipose tissue was maintained in tissue 
culture for 48h in the p resence  and ab sen ce  of growth 
hormone, a f te r  which mem branes were p repared . PIA was 
then added to assays employing m em branes from control 
and G H -tre a te d  tissue. Results are  the m eans of 4 
observations, SEM = 5.5
CHAPTER SEVEN 
GENERAL DISCUSSION
The aim of the studies presented in this thesis was to determine the 
mechanisms whereby growth hormone exerts its lipolytic effect in adipose tissue in 
both rat and sheep. The results presented in this thesis, show that the G--based 
antilipolytic signal transduction system is an important target of growth hormone 
action. The effects of growth hormone on this system are complex and vary with 
physiological state.
Both in vivo and in vitro approaches have been adopted to resolve the factors 
and mechanisms which regulate the adrenergic-adenosine signal transduction cascade 
in adipocytes. Studies with both sheep and rats have involved manipulation of growth 
hormone concentrations in vivo and further studies with sheep adipose tissue have 
involved exposure of adipose tissue to the hormone in a tissue culture system.
In accordance with other studies involving lactating rats (Vernon et al, 1991) 
and cows (Lanna et al, 1992), the experiments involving growth hormone treatment 
of virgin rats had no effect on the maximum response to p-agonists. However, 
growth hormone treatment of sheep in vivo, resulted in a small increase in response 
to p-agonists in vitro (Doris et al, 1996); also studies by Watt et al (1991) showed 
that incubation of sheep adipose tissue in the presence of growth hormone resulted in 
an increase in response to p-agonists. In contrast Growth hormone has a large effect 
on response to P-agonists in adipocytes from rats in which lactation is prematurely 
terminated either by litter removal or endocrine manipulation as found previously by 
Vernon et al, (1991; 1993) and Barber et al (1992) respectively. These studies 
imply that growth hormone can enhance signalling via the P-adrenergic pathway 
which stimulates lipolysis, but in most states, effects are small and may be species 
dependent. Studies by Lanna et al (1992) and the results in this thesis show that the 
major effect of growth hormone treatment is on the inhibitory system regulating 
lipolysis.
Manipulation of serum growth hormone levels in virgin rats, using an 
antiserum to rat growth hormone, resulted in an increase in the inhibition of 
isoprenaline-stimulated lipolysis by submaximal concentrations of both PIA and
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PGEj, but no effect on the maximum response to these factors was seen. The 
experiments with lactating rats in which lactation was abruptly and completely 
curtailed either by litter removal or by endocrine manipulation showed that treatment 
with growth hormone resulted in a decrease in the ability of maximal concentrations 
of PIA and PGEj to inhibit lipolysis. However, in the same experiments treatment of 
lactating rats with growth hormone showed no effect on the maximum response or 
sensitivity to PIA. While these results support the theory that growth hormone exerts 
its effects on the antilipolytic arm of the signal transduction system, it is apparent that 
the effect of growth hormone is dependent on the physiological state of the animal.
Investigations into the mechanism whereby growth hormone exerts its effects 
on these antilipolytic factors showed that changes in adenosine receptor number in 
both virgin and lactating rats was not responsible. However, treatment of virgin rats 
with anti-rGH resulted in an increase in levels of the inhibitory G-protein Gj2, and 
this effect was reversed upon replacement therapy with sheep growth hormone. 
Interestingly, this effect was not observed in the litter removed rats treated with 
anti-rGH plus bromocriptine, and indeed no change in levels of G-proteins was seen 
in either lactating or litter removed rats. In experiments carried out by Ros et al 
(1992), involving lactating rats, levels of both G* 1 plus Gj2 and G§ were shown to 
decrease upon litter removal. In these studies control animals (virgin rats) were not 
used and it is probable that the decrease in G-protein levels seen at litter removal 
restored the protein levels to that of the controls. Levels of both Gj and G§ 
however, have been shown to increase in lactating sheep, (Vernon et al, 1995), 
indicating that G-proteins are a target of regulation in this species.
Previous studies showed that sheep adipose tissue survives well in culture 
maintaining metabolic activities and response to hormones (Vernon and Sasaki, 
1991), offering an alternative to in vivo manipulations to investigate the effects of 
growth hormone on the lipolytic system. As shown in the present studies (Chapter 5 
and Chapter 6 ) culture with growth hormone for 24h does indeed mimic the effects 
of growth hormone treatment in vivo.
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Growth hormone treatment of sheep adipose tissue, both in vivo and in vitro, 
resulted in a small increase of catecholamine-stimulated lipolysis which was also 
reflected in the increase seen in number of p-adrenergic receptors. These results are 
consistent with those of Watt et al (1991) who also showed an up-regulation of the 
stimulatory arm of the lipolytic pathway upon growth hormone treatment of sheep 
adipose tissue after a 48 hour incubation in tissue culture. Treatment of sheep in vivo 
with growth hormone decreased the maximum inhibition of isoprenaline-stimulated 
lipolysis by PIA, an effect that was not accompanied by any discernable change in the 
number of adenosine receptors or amounts of the various forms of Gj. Growth 
hormone also decreased the response to PGEj, which also activates Gj but via a 
distinct receptor; the levels of which were not measured. Maintenance of sheep 
adipose tissue in culture with growth hormone again decreased the maximum 
response to adenosine with no change in either the number of adenosine receptors or 
amounts of Gj. This contrasts with the studies in the virgin rat which show that 
growth hormone in vivo decreases sensitivity to adenosine by decreasing the amount 
of Gj (Doris et al, 1994). The results are consistent with those found in the lactating 
and litter-removed rat study of this thesis, in which changes in response to PIA and 
PGEj occurred without a change in Gj levels. These studies showed that growth 
hormone can alter signalling through the Gj-based antilipolytic system by at least two 
mechanisms: a change in the amount of Gj2 and by a change in activity of some 
component. ADP-ribosylation studies involving sheep adipocyte membranes from 
cultured tissue showed that the interaction of the activated adenosine receptor with 
Gj in sheep adipose tissue is not affected by growth hormone treatment.
In the adenylate cyclase assays, using sheep adipocyte membranes, the 
results from experiments examining Gj interaction with adenylate cyclase were rather 
surprising in that at the higher concentration of 10 pM PIA the effect of growth 
hormone is diminished. Experiments to investigate the effects of growth hormone on 
lipolysis were all carried out at a maximal concentration of 100 nM PIA, and at this 
concentration in the adenylate cyclase assays, the results are consistent with those of
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the lipolysis assays which show a decrease in efficiency of signal transduction via the 
antilipolytic pathway. Initial experiments to determine the maximum concentration of 
PIA in lipolysis assays included higher concentrations of PIA up to 10 pM and no 
reversal of growth hormone effect, as seen in the adenylate cyclase assays, was 
observed. The reason for the difference between isolated membranes and intact cells 
is not clear.
It would be useful to look at the interaction between Gj and adenylate cyclase 
in the lactating rat to see if receptor-mediated inhibition of adenylate cyclase is 
achieved when using PIA, as in studies carried out with lean and obese rats by 
Strassheim et al (1991). In this way it could be determined if the results obtained 
from experiments with sheep adipose tissue, where growth hormone treatment affects 
Gj inhibition of adenylate cyclase, elicited through adenosine receptors, is species 
specific.
Thus a second mechanism whereby growth hormone alters signalling through 
the Gj-based antilipolytic signalling system is through a change in Gj activity, in 
particular, in its ability to interact with and inhibit adenylate cyclase.
Paradoxically, despite an increase in serum growth hormone, response to PIA 
is enhanced during lactation in sheep (Vernon et al, 1995). Also response to PIA is 
increased during lactation in rats despite serum growth hormone being unchanged 
(Chapter 4). These observations show that some additional factor must be 
modulating the response to PIA during lactation and may be responsible for the 
failure of exogenous growth hormone to decrease response and/or sensitivity to PIA 
during lactation in rats. Exogenous growth hormone can decrease response and 
sensitivity to PIA in lactating cows (Lanna et al, 1995); why lactating rats and cows 
differ in this respect is not clear.
A possible reason for the change in Gj activity is phosphorylation, perhaps by 
protein Kinase C. This was investigated using inhibitors in the in vitro sheep adipose 
tissue culture system. Although the specificity of all signal transduction inhibitors 
have their limitations, they provide a valuable insight into possible mechanisms.
99
Protein kinase C activity is associated with proteins of a set of monomeric 
proteins of molecular mass around 80 kDa (Houslay, 1994). These structurally 
related isoforms are encoded by a large gene family (Stabel and Parker, 1991). 
Molecular cloning and enzymological analysis have identified at least twelve 
structurally related protein kinase C isozymes, (Stabel and Parker, 1991; Nishizuka, 
1989; Nixon et al, 1992; Parker et al, 1992; Parker and Dekker, 1994) and appear to 
belong to three categories: conventional PKCs (cPKC a, pi, pil and y) that are
activated by phospholipid, diacylglycerol and calcium; those that are insensitive to
9 +Ca , novel PKCs (nPKC 5, e, 0 and rj), and atypical PKCs that require neither
Ca^+ or DAG (aPKC X, i, and p) for review see Dekker and Parker (1994). Most
isoforms are soluble and found in the cytosol, however, depending on the isoform,
94-treatment of cells with Ca , DAG or phorbol esters (Sando et al, 1992) results in 
membrane-associated activity. It is possible that individual isoforms have distinct 
functional roles in the cell which may be characterised by differences in activation; for 
example phosphorylation which seems to be particularly important for PKC-a (Pears 
e ta l , 1992).
Protein kinase C modification of Gj2 can be observed in intact cells although 
it does not appear to be a universally apparent phenomenon (see Houslay, 1994), and 
may require a specific isoform. The ability of H7 to inhibit the action of growth 
hormone on Gj activity in sheep adipose tissue suggest that a PKC isoform is 
involved. The abililty of okadaic acid to mimic the effects of growth hormone 
provides further evidence for a phosphorylation-dephosphorylation cycle as a means 
of Gj2  regulation.
The role of PKC was further investigated using PMA. Observations have 
been made in cases where treatment with phorbol esters led to the sensitization of 
adenylate cyclase activity, suggesting that this activator of PKC might be able to 
phosphorylate and thus inactivate Gj (Katada et al, 1985). More recent experiments 
with human platelets (Carlson et al, 1989) and hepatocytes (Morris et al, 1994; 
1995) have shown that treatment of cells with PMA increases labelling of Gj2.
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Effects of PMA alone over 24h on PIA inhibition of lipolysis could be due to 
activation of PKC isoforms and phosphorylation of Gj although it is surprising that 
no effect was seen after 5h of exposure to PMA. However, as pretreatment with 
PMA for 24h, which should down-regulate at least some isoforms of PKC, did not 
prevent the effect of growth hormone on PIA inhibition of lipolysis, it would appear 
that if PKC is involved, then at least part of the effect of growth hormone involves 
PMA-insensitive isoforms, or at least isoforms which are only slowly down-regulated 
by PMA. More specific approaches, for example use of antisense technologies to 
selectively eliminate specific PKC isoforms, are needed to resolve the putative role of 
PKC. Experiments involving D609 also showed that phospholipase C is not involved 
in the effects of growth hormone on Gj activity. From the time course experiments 
and those with actinomycin D showing that the full effect is not seen for 24 hours, it 
can be speculated that at least one protein required for the phosphorylation and 
deactivation of Gj may not be constitutively present but requires gene transcription.
There are a number of similarities between the effects of growth hormone on 
lipolysis and growth hormone inhibition of lipogenesis in mature sheep adipocytes. In 
general, agents preventing the lipolytic effects of growth hormone have also been 
shown to have effects on lipogenesis. The effects of growth hormone are slow to 
develop in both lipogenesis (Borland et al, 1994) and lipolysis (Chapter 6 ) and the 
effect of growth hormone on both processes is blocked by actinomycin D (Borland et 
al, 1994; Chapter 6 ). Although D609 shows no effect on growth hormones action on 
lipolysis, addition of this phospholipase C inhibitor prevented the antilipogenic effects 
of growth hormone (Vernon, 1996). As with the studies detailed in this thesis, 
treatment of sheep adipose tissue in culture with H7 also decreased the antilipogenic 
effects of growth hormone (Vernon, 1996). However, while okadaic acid has been 
shown to mimic the effects of growth hormone on lipolysis, this protein serine 
phosphatase inhibitor diminished the antilipogenic effects of growth hormone 
(Vernon, 1996). Phosphatases 2A and 1 dephosphorylate a number of proteins 
(Mumby and Walter, 1993; Walter and Mumby, 1993) so okadaic acid may influence
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growth hormone signalling at several points. Therefore, while growth hormone 
effects on both lipolysis and lipogenesis may involve one or more isoforms of PKC 
plus gene transcription, the effects of growth hormone on these systems do not occur 
via identical mechanisms.
Recent studies have provided evidence for proteins that regulate G-proteins 
known as RSG proteins (for Regulators of G-protein signalling) (see Roush, 1996). 
It is thought that RSG proteins work by binding to one of the three G-protein 
subunits and thereby prevent it from participating in signal transduction. Given that 
there is a high degree of sequence conservation between species including yeast, 
worms and mammals, it is reasonable to speculate that these proteins may be 
involved in regulating the G-proteins of the lipolytic pathway. At the moment very 
little is known about these proteins, including what regulates their own action, but 
perhaps they play a role in growth hormones actions in the modification of Gj.
In conclusion, these studies show that growth hormone can enhance lipolysis 
by decreasing the effects of agents acting via the Gj-based antilipolytic system and 
that the inhibitory G-protein Gj is a major target of growth hormone action. The 
experiments involving virgin and lactating rats also show that the effects of growth 
hormone are dependent on physiological state.
The studies involving sheep adipose tissue reveal a species specificity of 
growth hormone action, where Gj interaction with adenylate cyclase is a target for 
modification by growth hormone. It is possible that growth hormones mechanism of 
action in lactating rats and sheep adipose tissue is similar, in that Gj is a target of 
covalent modification rather than being subjected to down regulation as seen in virgin 
rats.
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